TUBERCULOSIS A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2003 by ICON Group International, Inc. Copyright 2003 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Tuberculosis: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-83644-2 1. Tuberculosis-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on tuberculosis. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes & Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON TUBERCULOSIS .......................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Tuberculosis .................................................................................. 9 E-Journals: PubMed Central ..................................................................................................... 133 The National Library of Medicine: PubMed .............................................................................. 176 CHAPTER 2. NUTRITION AND TUBERCULOSIS .............................................................................. 315 Overview.................................................................................................................................... 315 Finding Nutrition Studies on Tuberculosis............................................................................... 315 Federal Resources on Nutrition ................................................................................................. 323 Additional Web Resources ......................................................................................................... 324 CHAPTER 3. ALTERNATIVE MEDICINE AND TUBERCULOSIS ........................................................ 327 Overview.................................................................................................................................... 327 National Center for Complementary and Alternative Medicine................................................ 327 Additional Web Resources ......................................................................................................... 345 General References ..................................................................................................................... 350 CHAPTER 4. DISSERTATIONS ON TUBERCULOSIS .......................................................................... 353 Overview.................................................................................................................................... 353 Dissertations on Tuberculosis.................................................................................................... 353 Keeping Current ........................................................................................................................ 360 CHAPTER 5. CLINICAL TRIALS AND TUBERCULOSIS..................................................................... 361 Overview.................................................................................................................................... 361 Recent Trials on Tuberculosis.................................................................................................... 361 Keeping Current on Clinical Trials ........................................................................................... 377 CHAPTER 6. PATENTS ON TUBERCULOSIS ..................................................................................... 379 Overview.................................................................................................................................... 379 Patents on Tuberculosis ............................................................................................................. 379 Patent Applications on Tuberculosis ......................................................................................... 432 Keeping Current ........................................................................................................................ 465 CHAPTER 7. BOOKS ON TUBERCULOSIS ........................................................................................ 467 Overview.................................................................................................................................... 467 Book Summaries: Federal Agencies............................................................................................ 467 Book Summaries: Online Booksellers......................................................................................... 482 The National Library of Medicine Book Index ........................................................................... 496 Chapters on Tuberculosis........................................................................................................... 498 CHAPTER 8. MULTIMEDIA ON TUBERCULOSIS.............................................................................. 501 Overview.................................................................................................................................... 501 Video Recordings ....................................................................................................................... 501 Audio Recordings....................................................................................................................... 507 Bibliography: Multimedia on Tuberculosis................................................................................ 508 CHAPTER 9. PERIODICALS AND NEWS ON TUBERCULOSIS........................................................... 511 Overview.................................................................................................................................... 511 News Services and Press Releases.............................................................................................. 511 Newsletter Articles .................................................................................................................... 513 Academic Periodicals covering Tuberculosis ............................................................................. 514 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 515 Overview.................................................................................................................................... 515 U.S. Pharmacopeia..................................................................................................................... 515 Commercial Databases ............................................................................................................... 517 Researching Orphan Drugs ....................................................................................................... 517
viii Contents
APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 521 Overview.................................................................................................................................... 521 NIH Guidelines.......................................................................................................................... 521 NIH Databases........................................................................................................................... 523 Other Commercial Databases..................................................................................................... 551 The Genome Project and Tuberculosis....................................................................................... 551 APPENDIX B. PATIENT RESOURCES ............................................................................................... 555 Overview.................................................................................................................................... 555 Patient Guideline Sources.......................................................................................................... 555 Associations and Tuberculosis ................................................................................................... 590 Finding Associations.................................................................................................................. 592 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 595 Overview.................................................................................................................................... 595 Preparation................................................................................................................................. 595 Finding a Local Medical Library................................................................................................ 595 Medical Libraries in the U.S. and Canada ................................................................................. 595 ONLINE GLOSSARIES................................................................................................................ 601 Online Dictionary Directories ................................................................................................... 602 TUBERCULOSIS DICTIONARY................................................................................................ 603 INDEX .............................................................................................................................................. 691
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with tuberculosis is indexed in search engines, such as www.google.com or others, a non-systematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about tuberculosis, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to tuberculosis, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on tuberculosis. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to tuberculosis, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on tuberculosis. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON TUBERCULOSIS Overview In this chapter, we will show you how to locate peer-reviewed references and studies on tuberculosis.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and tuberculosis, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “tuberculosis” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Preventing and Controlling Tuberculosis Along the US-Mexico Border : Work Group Report Source: MMWR Morbidity and Mortality Weekly Report 2001; 50(RR-1):1-28. Contact: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, 1600 Clifton Rd NE M/S C-08, Atlanta, GA, 30333, (404) 639-2100, http://www.cdc.gov/mmwr. US Government Printing Office, PO Box 371954, Pittsburgh, PA, 15250-7954, (202) 512-1800, http://www.access.gpo.gov. Summary: This report, for health professionals, organizations, and government agencies, provides recommendations for the improvement of tuberculosis (TB) infection
4
Tuberculosis
control and prevention along the border between the United States (US) and Mexico. It addresses the challenges created by border-crossing populations, for example, Mexico's higher TB rate, low socioeconomic status and limited access to health care, frequent border crossing and travel to the United States, and a lack of coordinated care across health jurisdictions in Mexico and the US. Surveillance needs, case management and therapy completion, performance indicators and program evaluation, and research needs are discussed. •
Tuberculosis Treatment Source: City Health Information June 1999;18 (2):1-8. Contact: New York City Department of Health, Bureau of Tuberculosis Control, 125 Worth St Rm 216 Box 74, New York, NY, 10013, (212) 788-4155, http://www.ci.nyc.ny.us/nyclink/html/doh/html/tb/tb.html. Summary: This newsletter provides healthcare professionals information on tuberculosis (TB) treatment. It presents ten basics on the diagnosis, treatment, and prevention of TB and information on countries and areas with an estimated or reported high incidence of TB, a therapy timeline for previously untreated TB patients with drugsusceptible active disease, medications used in the treatment of TB, recommended antituberculosis treatment regimens for HIV-infected persons with drug-susceptible TB disease, and the use of antituberculosis medications in special situations, such as pregnancy, TB meningitis, and renal failure. The newsletter lists contact information for resources in New York City providing TB-related services.
•
Testing and Treatment for Latent Tuberculosis Infection Source: City Health Information October 2000;19(3):1-8. Contact: New York City Department of Health and Mental Hygiene, Bureau of Tuberculosis Control, PO Box 74, New York, NY, 10013-0061, (212) 788-4155, http://www.ci.nyc.ny.us/nyclink/html/doh/html/tb/tb.html. Summary: This newsletter provides healthcare professionals with information on the testing and treatment of latent tuberculosis infection (LTBI). It summarizes and synthesizes the Centers for Disease Control and Prevention's and the American Thoracic Society's treatment recommendations, offers ten basic steps in testing and treatment, and provides a pullout guide on fundamental aspects of the testing and treatment of LTBI, including when and how to administer therapy, how to interpret the tuberculin skin test in BCG-vaccinated individuals, and how to treat HIV-positive individuals who are taking antiretroviral agents. The newsletter lists contact information for resources in New York City providing TB-related services.
•
Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children Source: American Journal of Respiratory and Critical Care Medicine 1994 (May);149(5):1359-1374. Contact: American Lung Association of Maryland, 11720 Beltsville Drive 3rd FL, Beltsville, MD, 20705, (301) 572-3205. CDC National Prevention Information Network, PO Box 6003, Rockville, MD, 20849-6003, (800) 458-5231, http://cdcnpin.org. Summary: This is an official statement of the American Thoracic Society on the treatment of tuberculosis (TB) and TB infection in adults and children. This paper discusses the following topics: treatment of TB, drugs in current use, potentially
Studies
5
effective drugs, initial treatment regimens, monitoring adverse reactions, evaluation of response to treatment, management of patients whose treatment has failed or who have relapsed, management of patients who have drug-resistant disease, TB in children and adolescents, special considerations in treatment, treatment of TB infection, persons for whom preventive therapy is recommended, screening procedures, administration of isoniazid preventive therapy, monitoring preventive therapy, and alternative forms of TB prevention. •
Controlling the Resurgent Tuberculosis Epidemic: A 50 - State Survey of TB Statutes and Proposals for Reform Source: Journal of the American Medical Association; Vol. 269, No. 2. Contact: American Society of Law Medicine and Ethics, 765 Commonwealth Ave Ste 1634, Boston, MA, 02215-1401, (617) 262-4990, http://www.aslme.org. Summary: This article reports on a 50-state survey of tuberculosis (TB) laws, based on an examination of both TB-specific statutes and more general communicable disease statutes. The survey found that many statutes still in force were enacted at the turn of the century or in the early to mid-1900s, before the development of modern concepts of constitutional law and the concept of the need to protect public health. The article also recommends the development of an individualized treatment plan for all persons diagnosed with the disease, the balancing of constitutional rights against public health risk, the maintainence of confidentiality and antidiscrimination, and the bringing of communicable disease statutes into conformity with the American With Disabilities Act (ADA).
•
Return of a Plague: The Perils of Tuberculosis in the 90's Source: The Exchange; Issue 21, July 1993. Contact: National Lawyers Guild AIDS Network, 558 Capp St, San Francisco, CA, 94110, (415) 824-8884. Summary: The re-emergence of the tuberculosis (TB) epidemic with its associated medical and legal problems, especially in relation to AIDS, is examined in this journal article. TB, its treatment, and the problem of incomplete treatment are described. The definition of AIDS has been expanded to include pulmonary TB. The article suggests that social reform is required to control TB, including the restructuring of the public health and social service systems. The interdependent reforms include public funding for TB education, emphasizing Directly Observed Therapy (DOT) to use in fighting incomplete treatment, funding research in diagnostics and treatments of TB, and developing guidelines for the legal issues involved. These legal concerns include civil rights with respect to state-mandated quarantine, confidentiality, and employment practices where infection control, not discrimination, prevents disease.
•
Tuberculose et Infection par le VIH. [Tuberculosis and HIV Infection.] Contact: Agence Nationale de Recherches Sur le SIDA, 101 rue de Tolbiac, Paris. Summary: This factsheet explains epidemiology and treatment of tuberculosis (TB) in Persons with AIDS (PWA's). Since 1988, the number of French TB cases has risen, especially among PWA's. Active tuberculosis makes its appearance in one of two ways: a previous infection resurfaces, or a fresh infection is transmitted by another infected individual. Although PWA's experience more serious side effects, drugs are very effective against the tuberculosis bacterium. The drug-resistant strain of TB which has
6
Tuberculosis
been observed in the United States is very rare in France. The factsheet also outlines the stages of TB and suggests medications for each stage. A short bibliography is appended. •
An Outbreak of Tuberculosis With Accelerated Progression Among Persons Infected With the Human Immunodeficiency Virus: An Analysis Using Restriction - Fragment - Length Polymorphisms Source: New England Journal of Medicine; Vol. 326, no. 4. Contact: San Francisco General Hospital, Department of Medicine, Chest Service, Pulmonary Complications of AIDS Study, SFGH-5K1, 1001 Potrero Ave, San Francisco, CA, 94110, (415) 821-8313. Louisiana State University Medical Center, Delta Region AIDS Education and Training Center, 136 S Roman St 3rd Fl, New Orleans, LA, 70112, (504) 568-3855, http://www.lsumc.edu. Summary: This reprint of a journal article analyzes an outbreak of tuberculosis (TB) that took place among residents of a housing facility for persons with HIV infection. As background information, the article points out that TB can develop from either a reactivation of a latent infection or from a primary infection. It then reviews the outbreak, which took place between December 1990 and April 1991, during which time 12 cases of TB were diagnosed. Two patients under treatment for TB had been admitted in the previous six months. Organisms isolated from 11 culture-positive residents had similar patterns, but isolates from the two patients treated prior to the outbreak showed different strains. The article says that this implicates the first of the 12 patients to come down with TB as the source of the outbreak. It concludes that newly acquired TB infection in HIV-positive patients can spread readily and progress rapidly to active disease. There should be heightened TB surveillance in facilities where HIV-positive persons live.
•
Prevention and Control of Tuberculosis in Facilities Providing Long-Term Care to the Elderly : Recommendations of the Advisory Committee for Elimination of Tuberculosis Source: Morbidity and Mortality Weekly Report (MMWR). 39 (RR-10): 7-20; July 13, 1990. Contact: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, 1600 Clifton Rd NE M/S C-08, Atlanta, GA, 30333, (404) 332-4555, http://www.cdc.gov. US Government Printing Office, PO Box 371954, Pittsburgh, PA, 15250-7954, (202) 512-1800, http://www.access.gpo.gov. Summary: This report discusses managing and preventing tuberculosis (TB) in facilities that provide long-term care for the elderly. It provides a brief epidemiological history of TB among elderly people in the United States, including those in nursing homes. General guidelines for prevention and control of TB in the areas of surveillance, containment, assessment, and education are provided. Recommendations for surveillance include a tuberculin skin testing program for all new residents and employees to detect TB infection and active TB, case reporting, and encouraging HIV counseling and testing. Containment recommendations include information about appropriate isolation and treatment of the elderly resident, and an overview of contact investigations for residents and staff and appropriate preventive therapy. A recordkeeping system that includes specific data for annual review and assessment is recommended. The report concludes with the role of the local health department in the management and prevention of TB in long-term care facilities for the elderly.
Studies
•
7
Spinal Tuberculosis Source: Current Opinion in Orthopedics. 11(3): 196-201. June 2000. Summary: This journal article provides health professionals with information on the diagnosis and management of spinal tuberculosis. Tuberculosis of the spine is still a common disease in some endemic regions and is returning to developed countries. The diagnosis is usually made with a high index of suspicion in endemic areas in the presence of pain and appropriate clinical symptoms and signs of a systemic infection. Typical plain radiographic changes include destruction of two adjacent vertebral bodies, narrowing of the intervening disk, scalloping of the anterior vertebrae, and a fusiform paravertebral abscess shadow. The development of the polymerase chain reaction technique and magnetic resonance imaging (MRI) in the past decade has greatly improved diagnostic accuracy. MRI is useful in diagnosing early or multicentric lesions before plain radiographic changes become obvious. The aims of treatment in spinal tuberculosis are eradication of the infection, preservation or restoration of neurologic integrity, and prevention or correction of spinal deformity. Combination chemotherapy remains the most important and effective treatment, whereas surgical intervention can help in achieving earlier fusion and less late deformity. Early results of spinal instrumentation with or without fusion appear to be promising in further enhancing good outcome. 1 figure, 2 tables, and 54 references. (AA-M).
•
Primary Pancreatic Tuberculosis Source: Missouri Medicine. 88(11): 766-768. November 1991. Summary: This article describes the first reported case that fulfills the diagnostic criteria for primary pancreatic tuberculosis. After a detailed case presentation, the authors discuss extrapulmonary tuberculosis in general, the clinical presentation, and the diagnostic testing required to determine pancreatic tuberculosis. They also briefly review the literature covering this condition. Diagnostic tests considered include radiographic studies, ultrasound, CT guided needle aspiration of pancreatic masses, and exploratory laparotomy. 1 figure. 14 references.
•
Tuberculosis and the Kidney Source: JASN. Journal of the American Society of Nephrology. 12(6): 1307-1314. June 2001. Contact: Available from Lippincott Williams and Wilkins. 12107 Insurance Way, Hagerstown, MD 21740. (800) 638-6423. Website: www.jasn.org. Summary: Tuberculosis of the kidney and urinary tract is, like other forms of the disease, caused by members of the Mycobacterium tuberculosis complex. This article reviews the clinical features of classical renal (kidney) tuberculosis, tuberculous interstitial nephritis, tuberculosis and glomerular disease, end stage renal disease (ESRD) caused by tuberculosis, tuberculosis developing in patients on hemodialysis and peritoneal dialysis, tuberculosis in transplant patients, genital tuberculosis, and hypercalcemia in dialysis patients. The authors also discuss laboratory diagnosis, pathology, the role of immunodeficiency in genitourinary tuberculosis, and treatment options. In developed nations, tuberculosis is relatively uncommon, but the risk of acquiring the disease is increased in immunosuppressed individuals, including patients on dialysis and recipients of kidney transplants. The signs and symptoms of renal tuberculosis mimic those of other infections of the kidney, so diagnostic awareness may prevent unnecessary morbidity (illness or complications). Tuberculosis may involve the
8
Tuberculosis
kidney as part of generalized infection throughout the body or as localized genitourinary disease. The morphology (shape and appearance) of the lesions depends on the site of infection, the virulence of the organism, and the immune status of the patient. Modern short course antituberculosis drug regimens are effective in all forms of tuberculosis. However, special considerations apply to the treatment of tuberculosis in patients with impaired renal (kidney) function, as some drugs may not be metabolized properly. Surgical intervention is indicated in cases of advanced unilateral (involving one kidney) disease complicated by pain or hemorrhage and for bladder augmentation. 5 figures. 49 references. •
When to Consider Tuberculosis in Evaluating Hematuria Source: Consultant. 39(12): 3225. December 1999. Contact: Available from Cliggott Publishing Company. 55 Holly Hill Lane, Box 4010, Greenwich, CT 06831-0010. Summary: Tuberculosis of the urinary tract is rare enough to justify the selective use of tuberculosis cultures when evaluating hematuria. Nonpulmonary (not in the lungs) tuberculosis accounts for only about 2 percent of diagnosed cases of tuberculosis. This brief article, one from a regular column that answers clinical questions, addresses the need to consider tuberculosis when evaluating a patient with hematuria (blood in the urine). The author recommends that physicians consider obtaining tuberculosis urine cultures for patients who are at increased risk for genitourinary tuberculosis. Such patients include immunocompromised persons and those with active pulmonary tuberculosis or a history of tuberculosis. A history of travel in or immigration from an area of high tuberculosis activity should also raise the index of suspicion. Readers are also encouraged to seek the advice of an infectious diseases consultant.
•
Tuberculosis Remains an Important Factor in the Morbidity and Mortality of Hemodialysis Patients Source: Transplantation Proceedings. 30(3): 846-847. May 1998. Contact: Available from Appleton and Lange. P.O. Box 86, Congers, NY 10920-0086. (203) 406-4623. Summary: Patients with end-stage renal disease (ESRD) are considered moderately immunocompromised and are susceptible to mycobacterial infection, including tuberculosis. This article explores the incidence of tuberculosis, organ involvement, diagnostic parameters, and response to tuberculosis treatment in the hemodialysis population. Based on data from 3 years, the incidence of tuberculosis at the authors hemodialysis unit is 2 percent (23 of 1140 patients). Diagnosis of tuberculosis in these patients is difficult, and biopsy, an invasive procedure, was required for diagnosis in 14 cases in this study. Extrapulmonary involvement (in organs other than the lungs) was a frequent finding in this population. The authors stress that, in spite of treatment, the high mortality rate due to this disease underlines tuberculosis as a persistent and significant problem that cannot be underestimated for hemodialysis patients. Because of this, all possible diagnostic methods need to be used in this group, including RT-PCR studies and tissue biopsy. 1 figure. 1 table. 5 references.
•
Renal Tuberculosis Presenting as a Large Perinephric Mass Source: Infections in Urology. 10(6): 171-172, 175. November-December 1997.
Studies
9
Contact: Available from SCP Communications, Inc. 134 West 29th Street, New York, NY 10001-5399. (212) 631-1600. Fax (212) 629-3760. Website: http://www.scp.com. Summary: Tuberculosis (TB) infections most commonly affect the respiratory and genitourinary systems. In industrialized countries, between 8 and 10 percent of patients with pulmonary TB develop renal (kidney) TB, and 15 to 20 percent of the population in developing countries have Mycobacterium tuberculosis cultured from the urine. This article reports a case of a patient who exhibited an unusual case of renal TB presenting as a perinephric mass. A 56 year old man with a 3 year history of untreated hypertension presented with a 2 week history of low grade fever, 10 pound weight loss, and acute onset of right hemiparesis (muscular weakness on one side of the body). The patient had no history of TB or urinary symptoms. Muscle strength in the right arm and right leg were diminished. A 15 by 20 cm, well defined, round, nontender, mobile mass was found in the left upper quadrant and flank. Other findings on abdominal and chest exam were normal. Urinalysis revealed many white blood cells per high power field, but no bacteria. Intravenous pyelogram was performed: the upper and mid poles of the left kidney were absent on nephrogram, and delayed excretion of contrast from the lower pole was observed. The right kidney was normal. The patient underwent an uncomplicated left radical nephrectomy for suspected liposarcoma. The gross pathology revealed a hard, fibrotic mass measuring 24 by 18 by 12 cm, filled with yellow purulent material surrounding a dilated collecting system and a 2 cm calculus. The renal tissue culture grew M. tuberculosis. The patient did well postoperatively and was discharged on the fourth day after the operation. In this patient, computed tomography (CT scan) provided the first clue to the diagnosis by suggesting the inflammatory nature of the renal mass; the diagnosis was confirmed by culture. 2 figures. 12 references.
Federally Funded Research on Tuberculosis The U.S. Government supports a variety of research studies relating to tuberculosis. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions. Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to tuberculosis. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore tuberculosis. The following is typical of the type of information found when searching the CRISP database for tuberculosis:
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
10 Tuberculosis
•
Project Title: A CENTRE FOR TUBERCULOSIS RESEARCH AND EDUCATION AT THE* Principal Investigator & Institution: Beyers, Nulda; University of Stellenbosch Stellenbosch, South Africa Stellenbosch, Timing: Fiscal Year 2002; Project Start 22-SEP-2002; Project End 21-AUG-2003 Summary: (provided by applicant): Southern Africa has the highest tuberculosis incidence in the world and South Africa is one of the 22 countries in the world that account for 80% of the global TB burden. The Western Cape province of South Africa has one of the highest reported tuberculosis incidences in the world at 500/100,000 population/year. TB, particularly in association with HIV/AIDS, is one of the major problems confronting sub-Sahara Africa where TB is the leading killer of people living with HIV. The Stellenbosch University Faculty of Health Sciences recently chartered a Centre for Tuberculosis Research and Education (CENTRE) with the mission of significantly contributing to the control of tuberculosis through purposeful interdepartmental and multidisciplinary research, education and training in collaboration with other national and international institutions. The CENTRE aims among others are 1. to enhance the collaboration and communication among TB and TB/HIV/AIDS researchers within the University as well as with other research collaborators in the Western Cape, South Africa and southern Africa, and 2. to improve the structured and unstructured education and training of graduate and post-graduate (Masters, Ph.D. and post-doctorate) students and young researchers who investigate adult and pediatric TB and TB/HIV/AIDS in southern Africa. The CENTRE is expected to have a significant impact on the training of researchers with a specific focus of understanding the dynamics of the rapidly spreading HIV/AIDS epidemic in southern Africa and its effect on the TB epidemic. The grant funds are intended to fund the work of a Steering Committee consisting of members from the CENTRE, the Harvard School of Public Health, and other potential co-operating partners. The Steering Committee with the CENTRE Director as Chairman will lead the development of a 2003 Strategic Plan for Graduate & Post-graduate Education in TB/HIV/AIDS Research. By the end of one year the CENTRE Director will prepare and assemble a Phase II Comprehensive Agreement application to fund the subsequent implementation of the 2003 Strategic Plan. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: A NEW TARGET FOR ANTI-TUBERCULOSIS AGENTS, FAS 1 Principal Investigator & Institution: Welch, John T. Chemistry; State University of New York at Albany 1400 Washington Ave Albany, NY 12222 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JUL-2004 Summary: (provided by applicant): As a sentinel disease for the diagnosis of AIDS, early reports of tuberculosis complicating AIDS seemed to indicate the disease was a result of reactivation of a previous infection, however today the picture of tuberculosis as a complication of AIDS has changed dramatically. The development of multidrug resistant strains of M. tuberculosis and the prospect of nosocomial transmission make the development of new, better tolerated therapies ever more important. It is the inclusion of pyrazinamide (PZA), an agent with a unique sterilizing activity, with isoniazid and rifampin (RIF) in current treatment regimens that constitutes the basis for 6-month short course therapy for M. tuberculosis (Mtb).l Surprisingly for a clinical agent, a detailed understanding of the mechanism of action of PZA continues to elude researchers. Recently the surprising observation was made that an analog of PZA, 5-
Studies 11
chloropyrazinamide (5-CI-PZA), inhibits fatty acid synthetase I, (FAS 1) in Mycobacterium tuberculosis. This observation has been confirmed independently in other laboratories. In prokaryotes, the synthetase is typically composed of at least seven peptides that represent the individual enzyme components and are generally classified as Type II synthases. However in mammals and mycobacteria, the synthase activity is carried out by single high-molecular weight, multifunctional peptide chains which are known as Type I synthases. In cell free extracts of Saccharomyces cerevisiae not only was the activity of 5-CI PZA confirmed to be very comparable with that of the wellknown inhibitor cerulenin in blocking the activity of FAS 1 it was also found that other pyrazinamide analogs also apparently inhibit FAS 1. The hypotheses to be tested in this proposal are that characterization of the mechanism of 5-CI-PZA on the inhibition of FAS 1 can lead to the development of better anti-mycobacterial agents and, secondly, that this inhibition process will be sensitive to structural variations of the pyrazinoic or nicotinic acid structure. The utility of the observed anti FAS activity can be enhanced by developing an understanding of the nature of the FAS 1 inhibition process so that this activity can be employed in the design of novel anti-tuberculous agents. As it is known that treatment of microbes with type I FAS inhibitors increases the sensitivity of those microbes to downstream inhibitors in a synergetic fashion, the development of antimycobacterial agents that act on FAS 1 and that can be used in combination with the aforementioned downstream agents may have a profound effect on improving tuberculosis treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: A NEW TUBERCULIN FOR THE DIAGNOSIS OF TUBERCULOSIS Principal Investigator & Institution: Einck, Leo; Sequella, Inc. 9610 Medical Center Dr, Ste 200 Rockville, MD 20850 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 29-SEP-2003 Summary: (provided by applicant):Accurate diagnosis of tuberculosis (TB) infection is one of the pillars of effective TB control programs. The current tool to diagnose infection with Mycobacterium tuberculosis is the tuberculin skin test (TST). Because of the crossreactive nature of purified protein derivative (PPD) of tuberculin, TST currently does not discriminate between infection with M. tuberculosis, vaccination with M. bovis BCG and sensitization with non-tuberculous mycobacteria found in the environment. The recent achievements in the field of bacterial genomics enable us to undertake a new approach to formulate a M. tuberculosis-specific tuberculin and to overcome poor TST specificity. Comparative genomic analyses show that the M. tuberculosis genome includes regions that do not exist in M. bovis BCG (RD regions). Thus, we can tailor a new, M. tuberculosis-specific tuberculin by selecting from the pool encoded by the RD regions those antigens that elicit TB-specific, cell-mediated immune responses. Our specific aims are 1) Identification of candidate antigens. Gene selection will be based on published results of comparative genomic analyses, BLAST protein homology searches, and Southern blot analyses. 2) Antigen screening in guinea pigs. Antigens will be selected that induce skin test reactions in tuberculous guinea pigs but not in control animals sensitized with M. bovis BCG and with non-tuberculous mycobacteria. 3) Antigen evaluation in human TB. Antigens selected in guinea pig studies will be evaluated for the ability to induce in vitro lymphoproliferation and cytokine secretion by peripheral blood mononuclear cells (PBMC) of M. tuberculosis-infected persons but not by PBMC of negative control individuals (BCG vaccinees, patients having nontuberculous mycobacterioses, and healthy, PPD-negative individuals). Antigens selected in the proposed Phase I studies will be used to formulate a multi-antigen tuberculin to
12 Tuberculosis
be taken to human clinical trials during Phase II work. PROPOSED COMMERCIAL APPLICATION: 2.1 Billion people harbor a TB infection. UNICEF reports that tuberculosis poses a serious risk to Asia's sustained socioeconomic development. In a recent National Intelligence Estimate, the Central Intelligence Agency singled out drugresistant TB-and especially its incidence among immigrants-as a potential threat to national security. Salomon and Murray report that world expenditure on TB therapy and diagnosis was $4.1 Billion (USD) in 1998. Diagnosis of TB worldwide is by sputum smear, with 50% accuracy. This new diagnostic is desperately needed. Short term markets will be in developing countries where the test will replace the current skin test as an adjunct diagnostic. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VACCINE
A
PLANT-DERIVED,
MULTI-COMPONENT
TUBERCULOSIS
Principal Investigator & Institution: Walmsley, Amanda; Plant Biology; Arizona State University P.O. Box 873503 Tempe, AZ 852873503 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): Tuberculosis is the leading cause of death due to a single infectious agent among adults in the world. The HIV-AIDS pandemic has had a strong influence on the incidence of tuberculosis in the developing world, greatly increasing the annual risk of developing tuberculosis in HIV positive individuals and contributing to the spread of tuberculosis in the community. The current tuberculosis vaccine, bacillus Calmette-Guerin (BCG) has a variable protective efficacy and can cause serious, even fatal disease in immunocompromised patients. An effective, inexpensive, easily distributed and administered subunit vaccine is required for the control of tuberculosis. The goal of this project is to investigate the ability of plant-derived, tuberculosis antigens to induce immune responses appropriate for the protection of mice against tuberculosis. The success of this project will be the first step in our overall goal of developing an inexpensive, subunit vaccine that will enable control of tuberculosis (TB) in humans including immunocompromised individuals. Investigations will include the ability of plants to correctly process and express protective antigens against Mycobacterium tuberculosis; verification of the mucosal immunogenicity of the resulting plant-derived antigens; characterization of the induced immune response(s) in mice and guinea pigs and the ability of the plant-derived antigens to protect animals from challenge with M. tuberculosis. Synthetic, plant optimized coding regions have been constructed for the tuberculosis antigens Ag85B and ESAT-6. These synthetic coding regions have been fused to the B and A2 subunits of the heat labile enterotoxin (LT) of enterotoxigenic Escherichia coil (ETEC) to promote targeting to mucosal lymphoid tissues. The resulting fused coding sequences were cloned into plant expression vectors for future Agrobacterium-mediated transformation of tomato (Lycopersicon esculentum L. cv "TA234). Expression, correct folding and concentration of the antigens in plant materials will be verified through Western analysis and enzyme linked immunosorbent assays (ELISA). Plant lines displaying high antigen expression, or elite plants, will be cloned, and transferred to the TB Research Materials and Vaccine Testing Contract at Colorado State University to be tested for mucosal immunogenicity and protective ability in mice trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 13
•
Project Title: A RAPID SERODIAGNOSTIC TEST FOR TUBERCULOSIS Principal Investigator & Institution: Lyashchenko, Konstantin P.; Chembio Diagnostic Systems, Inc. 3661 Horseblock Rd Medford, NY 11763 Timing: Fiscal Year 2001; Project Start 15-JUL-1998; Project End 30-NOV-2002 Summary: (Adapted from Applicant's Abstract): Control of tuberculosis (TB), a disease that causes 3 million deaths a year worldwide, requires rapid methods for timely diagnosis. The goal of the proposed work is to develop a simple, rapid, accurate and inexpensive serodiagnostic assay for active TB using a thin-layer immunochromatography (TLIC) format and multiple recombinant antigens of Mycobacterium tuberculosis. Serodiagnostic tests for TB require multiantigen cocktails because of patient-to-patient variation in recognition of antigens by serum antibodies. Phase I studies have already identified eight antigens suitable for cocktail development and demonstrated that TLIC methodology is applicable to multiantigen-based TB serodiagnostics. Work proposed for Phase II is expected 1) to advance test development in terms of antigen composition and assay conditions, 2) to validate the diagnostic performance of selected cocktails in different TB cohorts and control groups, and 3) to establish methodologies for batch production of antigens. The goal of Phase II studies is to develop a test having a specificity close to 100% and a sensitivity of 90% in smearpositive pulmonary TB. The commercial opportunities for a rapid serodiagnostic TB test having the proposed specifications are immense. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ADJUNCT VITAMIN A THERAPY FOR TUBERCULOSIS AND HIV/AIDS Principal Investigator & Institution: Semba, Richard D. Ophthalmology; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2003; Project Start 15-SEP-1998; Project End 28-FEB-2006 Summary: (provided by applicant): Tuberculosis is one of the leading causes of mortality worldwide, accounting for an estimated three million deaths annually. Micronutrient deficiencies are common during HIV infection and during pulmonary tuberculosis, and micronutrient deficiencies are associated with impaired immunity and increased morbidity and mortality. Despite adequate chemotherapy for tuberculosis, the morbidity and mortality of HIV-infected adults with pulmonary tuberculosis remains extremely high. The goal of this ongoing Phase III randomized, double-blind, controlled clinical trial is to determine whether a daily multivitamin (vitamins and minerals) supplement can reduce morbidity and mortality of HIVinfected adults with pulmonary tuberculosis in Malawi. All participants receive standard tuberculosis chemotherapy for eight months as per the Malawi National Tuberculosis Control Programme, and the total duration of follow-up in the trial is twenty-four months. The trial has a Community Advisory Board which consists of local community members and participants. The original sample size of the trial was reduced to 500 HIV-infected adults in order to complete enrollment within the study period and deal with a budget reduction. Interim analyses conducted for the NIAID HIV Therapeutic Clinical Trials Data and Safety Monitoring Board (DSMB) at NIH show that the trial has been conducted with steady enrollment, good adherence to supplementation, and high follow-up. The DSMB has recommended that the sample size of this trial be increased to have at least 80% power to detect a 20% reduction in mortality. To meet this recommendation, we propose to increase the sample size to 840
14 Tuberculosis
HIV-infected adults with pulmonary tuberculosis. The trial also includes 300 HIVnegative adults with pulmonary tuberculosis in order to reduce stigmatization. If this study demonstrates that a multivitamin supplement can reduce morbidity and mortality of HIV-infected adults with pulmonary tuberculosis, this appropriate, low cost intervention could be integrated with tuberculosis treatment to improve health and survival of HIV-infected individuals in developing countries. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AGING AND IMMUNITY IN TUBERCULOSIS Principal Investigator & Institution: Orme, Ian M. Professor; Microbiology; Colorado State University Fort Collins, CO 80523 Timing: Fiscal Year 2001; Project Start 01-SEP-1986; Project End 30-SEP-2002 Summary: (Adapted from the applicant's abstract): Tuberculosis is still relatively common in the elderly, probably reflecting the very high incidence of skin test positivity of the population in the first third of the century, and the fact that many of these individuals are still alive and generally healthy at the present time. As they age, however, such individuals run the risk of developing recrudescence of latent tuberculosis, while nonsensitized individuals run the risk [especially if institutionalized] of contracting a primary tuberculosis infection. The basis of the susceptibility of the aged to tuberculosis infection or recrudescent disease is still poorly understood, but is believed to reflect age-associated changes in the cell-mediated immune response to the organism. Work specifically in the investigator's laboratory supports this contention by showing a series of defects in the CD4 TH1 IFN-secreting T cell pathway associated with protection and memory immunity to the disease. Hence, using a realistic low dose aerosol infection model in aging mice, the investigators have identified specific lesions such as the low expression of adhesion markers on CD4 T cells, and the absence of a pulmonary IL-12 response needed to enhance IFN secretion by such cells. In the proposed study, they intend to continue to define the cellular response in the old lung to tuberculosis, including the use of new markers such as CD49E and CD95. In addition, they intend to resolve the nature of the recrudescent event, framed on new evidence that the capacity of a given M.tuberculosis isolate to promote local TNF and chemokine production may directly correlate with the nature of the granuloma response and its potential breakdown as the mouse ages. Further issues to be addressed include the role of the predominant TH2/IL-4 environment in old mice [an environment that includes unusual IL-4 secreting CD4+NK1. 1+ and CD8+ T cell populations] in potential interference with TH1 responses, which they will investigate in part by using aging IL-4 gene disrupted mice, and the potential reversal or delay of endogenous reactivation of disease in the old lung by administration of a sub-unit vaccine preparation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ALCOHOL, TB AND AIDS Principal Investigator & Institution: Mason, Carol M. Medicine; Louisiana State Univ Hsc New Orleans New Orleans, LA 70112 Timing: Fiscal Year 2001; Project Start 25-SEP-1997; Project End 31-AUG-2003 Summary: APPLICANT'S ABSTRACT: During the late 1980's, the previous decline in tuberculosis ceased and rates began to rise, heralding a resurgence of disease. Human immunodeficiency virus infection is largely responsible for the excess number of cases. A co-factor for TB infection is alcohol consumption. Alcohol is immunosuppressive, and
Studies 15
facilitates acquisition of pulmonary infections through malnutrition, greater propensity for indulging in high risk behaviors, and alteration of normal host defenses. Defense alterations include changes in immune effector cell populations and down regulation of cytokine production and/or function, which are critical components in the containment of intracellular pathogens, such as Mycobacterium tuberculosis. We hypothesize that alcohol adversely alters pulmonary host defense mechanisms against Mycobacterium tuberculosis by disrupting early cytokine interactions [tumor necrosis factor (TNF), interleukin (IL)-12, and interferon (IFN)-gamma] which are critical in the orchestration of effective Th1 CD4+ lymphocyte cell-mediated responses to contain the mycobacteria. We will test this hypothesis in a murine model of acute and chronic alcohol consumption and M. tuberculosis infection, initially employing mycobacterial lipoarabinomannan (LAM; a cell wall component) and nonviable organisms as probes, and subsequently utilizing an in vivo model of M. tuberculosis infection. To achieve this, we propose the following: Specific Aim 1: To test the prediction that alcohol consumption suppresses the pulmonary production of early cytokines in response to mycobacterial antigens in mice. Specific Aim 2: To test the theory that alcohol, through disruption of early cytokine pathways, impairs the development of Th1-directed cellmediated immunity to viable M. tuberculosis infection. Specific Aim 3: To demonstrate that defective antimycobacterial cell-mediated host defenses can be enhanced with IFNgamma organ specific cytokine gene therapy in an animal model. Our goal is to elucidate the mechanisms by which alcohol consumption further diminishes host resistance to M. tuberculosis infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AN EFFICIENT BACTERIAL VECTOR-BASED TUBERCULOSIS VACCINE Principal Investigator & Institution: Szumanski, Maria Bw.; Veterinary Technologies Corporation 1872 Pratt Dr Blacksburg, VA 24060 Timing: Fiscal Year 2001; Project Start 01-MAY-2001; Project End 31-MAY-2002 Summary: (Adapted from Applicant's Abstract) Tuberculosis (TB) still remains a major global health threat; worldwide, it is responsible for over 3 million deaths annually. In lieu of the emerging multi-drug resistant Mycobacterium tuberculosis strains, control of TB through an effective vaccination is of a paramount importance. Although Mycobacterium bovis strain BCG is widely used for TB prophylaxis, its protective effect has recently been shown to be far below the necessary level to protect populations efficiently. A strong ThI type of cell mediated immune response is crucial for protection against M. tuberculosis infections. Several proteins of M. tuberculosis that are involved in stimulating a protective immune response have been identified and their genes have been cloned and sequenced. The overall objective of the proposed research project is to develop a highly efficacious and safe vaccine for TB. Specifically, the company proposes to prepare an effective vaccine against tuberculosis by expressing previously identified protective protein(s) of M. tuberculosis in Brucella abortus strain RB51, a bacterial vector with unique adjuvant properties and can stimulate a strong Th1 type of immune response. In the phase I part of the project, the company intends to i) construct recombinant RB51 strains that express 85A and ESAT-6 antigens of M. tuberculosis and ii) immunize mice with irradiated recombinant RB51 vaccines and characterize their antigen-specific antibody and cell-mediated immune responses to confirm that a Th1 type of immune response is induced. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
16 Tuberculosis
•
Project Title: ANTI TUBERCULOSIS CANDIDATE VACCINE TESTING IN RHESUS MONKEYS Principal Investigator & Institution: Gormus, Bobby J.; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: Eight normal RM were inoculated with MTB via fiberoptic bronchoscope. Four received the less virulent H37Rv strain and four received the highly virulent Erdman strain via fiberoptic bronchoscope. Both monkeys that received the high dosage of H37Rv (6 X 106 cfu) developed extensive multifocal expansile and coalescing granulomas with broad central zones of necrosis, neutrophilic infiltration, and mineralization in the inoculated right lobe of the lung by 5 and 11 weeks (wk) postchallenge. Monkeys receiving the low dose of H37Rv (30 cfu) had granulomatous lesions in the bronchial lymph nodes 18 wk after infection. Lesions suggest that low doses of M. tuberculosis H37Rv are controlled, at least in the short term, by natural defenses in the simian lung and that challenge with higher doses of bacteria produces significant tissue response without evidence of septicemic spread. Two high dose (150 cfu) Erdman recipient monkeys developed extensive granulomatous pneumonia, pleuritis, and bronchial node necrosis with microgranulomas in the liver, kidney, and other sites in 7-9 weeks. The appearance of pneumonia and time course were roughly comparable to disease produced by high dose (>106) H37Rv. The 2 low dose Erdmaninoculated monkeys (15 cfu) remained clinically normal 9 weeks post-challenge and at 19 wk had minimal clinical manifestations, but fibrotic granulomatous pulmonary lesions with spread to other tissues. We conclude that chronic disease can be established by low dose Erdman inoculation with a wider distribution of lesions being produced compared to the H37Rv strain. FUNDING Base Grant, Venture Research PUBLICATIONS Didier PJ, Blanchard JL and Gormus BJ. Pulmonary Tuberculosis in Normal Rhesus Monkeys Produced by M. tuberculosis H37Rv. Am J Soc Trop Med Hyg 57:156, 1997 [Abstract]. Didier PJ, Blanchard JL and Gormus BJ. Chronic Tuberculosis Produced by Low Dosage of M. tuberculosis (Erdman) in Rhesus Monkeys. Am J Soc Trop Med Hyg 59:361, 1998. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ANTIMICROBIAL PEPTIDES IN RESISTANCE TO TUBERCULOSIS Principal Investigator & Institution: Kisich, Kevin O.; National Jewish Medical & Res Ctr and Research Center Denver, CO 80206 Timing: Fiscal Year 2002; Project Start 01-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): Infections with drug resistant strains of Mycobacterium tuberculosis and most strains of Mycobacterium avium are challenging to treat chemotherapeutically. As HIV infection and the AIDS epidemic spreads, adequate treatment of mycobacterial infections in both immunocompetent and immunocompromised patients becomes increasingly difficult. Additional understanding of innate and immune mechanisms of resistance as well as new antibiotics will be important for designing new, more effective treatment regimens for mycobacterial infection. We hypothesize that small, cationic human antimicrobial peptides (AMP), defensins and cathelicidin stored in granules of human polymorphonuclear leukocytes (PMN), and secreted from epithelia play important roles in resistance to mycobacterial infection, and may be adaptable for chemotherapeutic use. Human neutrophil peptides 1,2, and 3 (HNP 1,2, and 3) have shown to be antimycobacterial for laboratory and clinical isolates of M. tuberculosis and M. avium in
Studies 17
vitro, and we have confirmed this in our laboratory. We propose to extend these observations by fully characterizing the anti-mycobacterial activity of human AMP, examining the relationship between binding of AMP to mycobacteria and antimycobacterial activity, and evaluating the relationship between resistance to human AMP and pathogenicity. We will also examine pharmacological interactions between human AMP and first-line anti-tuberculosis drugs for mycobacteria in liquid and macrophage cultures. The proposed studies are designed to fill an important gap in our knowledge of how mycobacteria evade the innate immune system. Understanding of the relative sensitivities of mycobacteria will help us understand how mycobacteria survive their first encounter with the antimicrobial peptides in pulmonary secretions and in responding neutrophils. Correlation of AMP sensitivity with binding of the peptides will help determine whether and how AMP sensitivity is related to pathogenicity. In addition, the proposed studies will define the potential of AMP to participate in the anti-mycobacterial response of human macrophages, or whether intracellular mycobacteria are protected from exposure to AMP. These studies will further our understanding of how endogenous anti-mycobacterial substances may enhance resistance to infection, and will also reveal whether these substances may be adaptable to chemotherapeutic use for treatment of mycobacterial infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BCG + HSP, A NEW TUBERCULOSIS VACCINE Principal Investigator & Institution: Nikonenko, Boris; Sequella, Inc. 9610 Medical Center Dr, Ste 200 Rockville, MD 20850 Timing: Fiscal Year 2003; Project Start 01-JUL-2003; Project End 30-JUN-2004 Summary: (provided by applicant): This proposal describes research that will examine the safety and efficacy of a novel strain of BCG in which the heat shock repressor gene has been deleted, resulting in the overexpression of a heat shock protein (hsp70). Heat shock proteins show a good deal of promise in the protection against and treatment of tuberculosis, and this novel BCG strain produces a T-cell response indicative of a more protective immune response. The Specific Aims of this Phase I proposal are: 1. In a guinea pig model of tuberculosis (TB), we will compare the efficacies of (1) intradermally administered (i.d.) BCGdeltahspR; (2) i.d. parent BCG; (3) subcutaneously administered (s.c.) BCGdeltahspR; (4) s.c. parent BCG; and (5) no vaccination (control). 2. In a mouse model of tuberculosis, we will compare the efficacies of (1) BCGdeltahspR administered subcutaneously; (2) parent BCG, administered subcutaneously; and (3) no vaccination (control). We believe it is important to test this vaccine in several different strains of mice that represent a spectrum of susceptibility to TB, as it is not known which strain might be the best model of TB in humans. Therefore, we will test the efficacy of rBCGdeltahspR in C57BI6, DBA/2, and CBA. 3. We will examine the safety of this modified BCG as compared to the parent BCG. We will infect mice and guinea pigs with each BCG strain and examine lungs for pathology, and count the CFU of BCG still present. We will also examine the antibiotic sensitivity of this rBCGdeltahspR to 10 commonly used TB drugs to ensure that the genetic manipulations performed have not made it less sensitive to drug treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BINDING AND PRESENTATION OF LIPID ANTIGENS BY CD1B Principal Investigator & Institution: Porcelli, Steven A. Associate Professor; Microbiology and Immunology; Yeshiva University 500 W 185Th St New York, NY 10033
18 Tuberculosis
Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2004 Summary: (Adapted from Investigator's Abstract): Recent studies have identified the CD1 family of cell surface glycoproteins as novel antigen presenting molecules encoded by genes located outside of the major histocompatibility complex. Identification of naturally occurring antigens presented by CD1 has revealed the surprising finding that these prominently include a range of foreign lipids and glycolipids, such as several that are known to exist in the cell walls and membranes of pathogenic mycobacteria. Among the currently known CD1-presented antigens, the best structurally characterized are the mycolic acids and their monoglucosylated analogue, glucose monomycolate (GMM). These compounds have a lipid structure that is unlike any found in mammalian tissues, and occur abundantly as a major outer cell membrane component in a variety of pathogenic bacteria, including Mycobacterium tuberculosis. Recognition of these lipids appears to be a frequent feature of CD1b-restricted M. tuberculosis-specific T cells in humans, suggesting that T cell responses to mycolic acids and GMM may play a significant role in the protective host response to this important pathogen. Studies in the current proposal will assess whether mycolic acids or GMM are among the immunodominant T cell antigens of M. tuberculosis in humans infected with this bacterium, and will seek to clarify the molecular basis for the presentation and recognition of these novel T cell antigens. A combination of preparative and synthetic chemistry will be used to generate a range of structural analogues of mycolic acids and GMM. These will be studied for their ability to be recognized by CD1b-restricted T cells, and for their ability to bind directly to CD1b proteins. In addition, the structural basis for the binding of these antigens to the CD1b protein will be analyzed by carrying out site directed mutagenesis of residues forming the predicted ligand binding groove of CD1b. These studies will lead to a detailed understanding of the fundamental rules governing the interaction of a newly recognized class of T cell antigens with their antigen presenting molecule. The identification and detailed analysis of this newly recognized pathway for T cell antigen recognition is likely to be important for understanding the human immune response to M. tuberculosis and related pathogens, and has potential implications for future vaccine development efforts. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: BIOSYNTHESIS OF THE MYCOBACTERIAL PEPTIDOGLYCAN Principal Investigator & Institution: Pavelka, Martin S. Microbiology and Immunology; University of Rochester Orpa - Rc Box 270140 Rochester, NY 14627 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-JUL-2005 Summary: (Adapted from the Applicant's Abstract): Tuberculosis is the leading cause of death in adults due to an infectious organism. By the end of this century there may be as many as 90 million new cases of tuberculosis resulting in up to 30 million deaths. The failure of antimicrobial therapy and the dangerous association between tuberculosis and AIDS have brought renewed interest in studying M. tuberculosis, the organism responsible for this disease. A better understanding of the basic biology of the organism and the development of new anti-mycobacterial drugs are important goals of mycobacterial research. The cell envelope is an outstanding characteristic if the mycobacteria, consisting of a variety of polysaccharides such as arabinogalactan, lipoarabinomannan, and peptidoglycan, along with several different types of lipids including various glycolipids and the mycolic acids. The peptidoglycan layer of the cell envelope serves as the anchor for the principal components of the cell envelope and provides shape and structural integrity to the cell. The long-term goal of this proposal is a deeper understanding of the biosynthesis and assembly of the mycobacterial cell
Studies 19
envelope. The specific goal of this proposal is to understand more about the genetics and biosynthesis of the peptidoglycan layer of the envelope. The specific aims of this proposal are: 1) Determining the significance of N-glycolylation of the mycobacterial peptidoglycan. 2) Investigating the architecture of the peptidoglycan and the role it plays in the organization of the cell envelope. 3) Using beta-lactam antibiotics as tools to probe mycobacterial peptidoglycan biosynthesis. For the aims of this proposal, the Pi will study M. tuberculosis and M. smegmatis as a model organism using the techniques of classical bacterial genetics, molecular biology and biochemistry. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACTIVATION
CATALASE-PEROXIDASE
CATALYSIS
IN
ANTIBIOTIC
Principal Investigator & Institution: Magliozzo, Richard S. Chemistry; Brooklyn College 2900 Bedford Ave New York, NY 11210 Timing: Fiscal Year 2001; Project Start 15-JUN-1998; Project End 31-MAY-2003 Summary: (adapted from applicant's abstract) The major role of the propose research is to explain the catalytic function of Mycobacterium Tuberculosis catalase-peroxidase, a heme-enzyme, in the activation of the antimycobacterial antibiotic, isoniazid (isonicotinic acid hydrazide). The specific aims include identification of the proximal ligand to heme iron in catalase-peroxidase, characterization of the spin state and coordination number of the heme iron in the resting enzyme, identification of hypervalent enzyme intermediates, and kinetic analysis of the reaction of these intermediates with isoniazid. Of special interest is the potential catalytic competence of oxy-ferrous catalase- peroxidase, and the potential for peroxynitrite to activate the enzyme. The role of selected amino acid residues in the catalytic mechanism an in isoniazid binding will be evaluated through examination of the properties of two mutant catalase-peroxidase enzymes identified from clinically isolated, isoniazid resistant M. tuberculosis strains. Inhibition of another M. tuberculosis enzyme, a fatty acyl enoyl reductase (the inhA protein) thought to be a target of drug action, by isoniazid activated catalase-peroxidase, will also be investigated. Other aims address the Mn(II)-peroxidase activity of catalase-peroxidase considered important because Mn(III) is an efficient single electron oxidant of isoniazid. The techniques of optical stoppedflow spectroscopy, resonance Raman, and electron paramagnetic resonance spectroscopies will be applied in the experimental protocols. The results of the proposed studies will advance a detailed understanding of the action of a first line antibiotic in current use to treat tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CD1-TARGETED VACCINATION AGAINST TUBERCULOSIS Principal Investigator & Institution: Modlin, Robert L. Professor; Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JAN-2008 Summary: (provided by applicant): The long-range goal of this project is to develop and validate the CD1-based vaccine technology platform to immunize humans against microbial pathogens. This approach is based on the knowledge that several of the CD1 proteins have specific targeting sequences that direct their traffic into endosomal compartments, structures also critical for antigen presentation by MHC class II molecules to CD4+ T cells. We will determine whether this novel vaccine strategy can induce protective immunity against Mycobacterium tuberculosis, a worldwide killer,
20 Tuberculosis
and now because of multi-drug resistant tuberculosis, a potential agent of a bioterrorist attack. We propose to determine the trafficking pattern of CD1 chimers in antigen presenting cells including monocytes and dendritic cells. The ability of CD1 targeting to be used in immunization in humans will be assessed by studying the immune response to an M. tuberculosis antigen ESAT-6. In addition, the ability of ESAT-6/CD1 fusion constructs to immunize human T cell responses in vitro will be investigated. To determine whether ESAT-6/CD1 chimers can induce protective immunity, ESAT6/CD1 fusion constructs will be used to immunize mice, which will be subsequently challenged with virulent M. tuberculosis. The studies proposed will help develop and test the efficacy of CD1-based DNA vaccines for the prevention of infectious disease, including those from natural pathogens and bioterrorist attacks. Specifically, it should be possible to develop a new approach to the prevention of tuberculosis, including multidrug resistant tuberculosis, in humans. Finally, the CD1-based vaccine technology should prove useful in the vaccination against microbial pathogens in which MHC class II-restricted presentation of antigen to CD4+ T cells is required for host defense. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CD8 T CELLS AND IMMUNITY TO TUBERCULOSIS IN OLD MICE Principal Investigator & Institution: Turner, Joanne; Assistant Professor; Microbiology, Immunology & Pathology; Colorado State University Fort Collins, CO 80523 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 30-JUN-2003 Summary: (provided by applicant): The elderly are more susceptible to many infectious diseases, and yet vaccinating this population is less effective when vaccines that are designed for young individuals are used. To design a vaccine that specifically targets an aging immune system it is first necessary to understand how the aging immune response differs from younger individuals when it encounters a pathogen. Using the aging mouse model of tuberculosis we have found that old mice express a transient early resistance to infection that correlates with the rapid presence of CD8 T cells within the lungs. This identifies a previously unrecognized novel immune mechanism in old mice that is clearly absent from the lungs of young mice. Using the low-dose aerosol infection model of tuberculosis we will characterize this CD8 T cell population further by determining the signals that rapidly recruit it to the lungs, and the mechanism by which it mediates early resistance to infection. Finally, we will use vaccine strategies known to elicit antigen specific CD8 T cell responses to mycobacterial antigens to see if these cells can then be detected within the CD8 cell population recruited into the lungs of old mice after infection with M. tuberculosis. Studies will be carried out in a new BSL-3 facility at Colorado State University and will use old wild type and genedisrupted mice from our existing in-house aging mouse colonies. The technical approaches in the proposed studies will use a combination of flow cytometry, FACS cell sorting, immunohistochemical staining, and real-time PCR, to address the proposed Aims. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CD8+ T CELL RESPONSE IN RESISTANCE TO TUBERCULOSIS Principal Investigator & Institution: Bushkin, Yuri; Associate Member; Public Health Research Institute 225 Warren St Newark, NJ 07103 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2003 Summary: Tuberculosis (TB) is a chronic infectious disease caused by the intracellular bacterial pathogen Mycobacterium tuberculosis. Hence, cell- mediated immunity rather
Studies 21
than antibodies is the critical protective immune response against M. tb. Studies with animal models of TB suggest that the major histocompatibility complex (MHC) class Irestricted CD8+ T-cell response complements host defenses mediated by activated macrophages and CD4+ T cells, and has an important role in successful resolution of mycobacterial infections. However, in humans the role of CD8+ T cells has not been fully addressed. We have developed an in vitro assay that is based on a novel computerdriven algorithm predicting MHC class I ligands (peptides) with a proven high accuracy. Our assay can measure the presentation of predicted peptides by proper MHC class I alleles, and thus allows for identification of the epitopes recognized by CD8+ T cells. Thus, the overall objective of these studies is the analysis of the role of CD8+ T-cell response in resistance to TB. First, secreted mycobacterial proteins with known sequences will be analyzed by the computer program for the presence of potential CD8+ T-cell epitopes. Presentation of these predicted M. tb. -derived peptides by MHC class I will be determined in our peptide-binding assay with an antigen transporter-deficient cell line expressing HLA alleles of interest. This analysis will be extended to HLA alleles predominant in populations with high incidences of TB and HIV infection. Second, this methodology will be used in quantitative and qualitative analysis of the MHC class Irestricted CD8+ T-cell immune responses to M. tb. -derived peptides in PPD+ healthy donors and TB patients. The frequencies of memory CD8+ T cells in the peripheral blood and activated cytotoxic T lymphocytes in the bronchio-alveolar lavage will be measured. Comparison of CD8+ T-cell effector functions in TB patients vs. PPD+ healthy donors, and also in PPD+/HIV-infected and active TB/HIV- infected patients will determine the correlation between the CD8+ T-cell responses and resistance to M. tb. infection in these patients. Finally, M. tb. -specific CD8+ T cell clones will be isolated and functionally characterized. These T cell clones will be used to study the requirements for MHC class I-restricted presentation of M. tb. antigens by macrophages infected in vitro with viable bacilli. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CD8+ T CELLS AND MYCOPLASMA TUBERCULOSIS Principal Investigator & Institution: Canaday, David H. Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001; Project Start 01-JUL-1999; Project End 30-JUN-2004 Summary: This application for a mentored scientist award (KO-8) seeks 5 years of funding for research training in the cellular immunology and cell biology of M. tuberculosis infection for David H. Canaday, M.D. Research training will be provided by W. Henry Boom, M.D. and Clifford V. Harding, M.D.-Ph.D. in the Division of Infectious Diseases and the Department of Medicine at Case Western Reserve University. The research proposal which will provide the focus for Dr. Canaday's training is outlined below. M. tuberculosis is spread from person to person by inhalation of aerosolized mycobacteria. Most healthy people do not develop clinical tuberculosis. Instead, cellular immune responses become activated and are able to successfully control the active infection. T cells play a crucial role in regulating the cellular immune response. T cell subsets(CD4+, CD8+, gammadelta+), are activated by mycobacterial antigens, yet little is known about the roles and function of the different T cell subsets in the protective immune response to M. tuberculosis. While CD4+ T cells have been the focus of many studies, CD8+ T cells are an important accessory T cell subset in the protective immune response to M. tuberculosis. Recent studies by us and others have demonstrated that human CD8+ T cells serve as CTL for M. tuberculosis infected macrophages, produce IFN-gamma and are activated by mycobacterial
22 Tuberculosis
antigens. The broad goal of the current studies is to determine the repertoire of mycobacterial proteins which stimulate human CD8+ T cells, to examine the antigen processing mechanism the macrophages use to present M. tuberculosis antigens on MHC class I molecules, and to determine the function of CD8+ T cells in patients with active tuberculosis. The Aims are: Aim 1. To determine the mycobacterial proteins and peptides recognized by human alphabeta TCR+ CD8+ T cells. Aim 2. To determine the mechanism(s) used by M. tuberculosis infected macrophages to process and present mycobacterial proteins by MHC class I molecules. Aim 3. To characterize the functional CD8+ T cell responses to specific proteins and peptides from in patients with active M. tuberculosis infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL ENVELOPE BIOSYNTHESIS IN M TUBERCULOSIS Principal Investigator & Institution: Glickman, Michael S. Medicine; Yeshiva University 500 W 185Th St New York, NY 10033 Timing: Fiscal Year 2001; Project Start 01-JUL-1998; Project End 07-DEC-2001 Summary: This proposal outlines a career development plan that consists of intensive research experience and didactic training in bacterial pathogenesis. The institutional environment is scientifically rich and well suited for the training of young physicianscientists. The ultimate goal of this period of intensive research training is to train the candidate as an independent investigator on a medical school faculty. Tuberculosis, caused by Mycobacterium tuberculosis, is the single leading cause of death from an infectious disease in the world today. Three million die each year from Tuberculosis and one third of the world's population is infected with M. tuberculosis MTB. The cell envelope of MTB is a complex structure composed of hydrophobic lipids, mycolic acids, cord factors, and Lipoarabinomannan and is thought to contribute to the virulence of the organism. Despite substantial investigation into the ultrastructure and chemical composition of the mycobacterial cell envelope, the contribution of specific cell walls constituents to mycobacterial virulence remains poorly defined. The importance of the cell envelope to the viability of the mycobacterial cell is emphasized by the observation that several antimycobacterial drugs including Isoniazid are thought to exert their bacteriacidal effect through inhibition of cell envelope biosynthesis. This proposal outlines a series of experiments designed to investigate the role of the cell envelope of MTB in pathogenesis through the generation and characterization of mycobacterial mutants deficient in the synthesis of cell envelope constituents. Using a recently developed transposon mutagenesis system, a series of insertional mutants will be generated and screened for alterations in their cell envelope composition. Morphologic, immunologic, and functional approaches to the isolation and characterization of cell envelope altered mutants will be used. Isolation and characterization of such mutants will likely yield important insights into the role of the mycobacterial cell envelope in the pathogenesis of Tuberculosis and the interaction of the tubercle bacillus with host cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CELL MIGRATION IN TUBERCULOSIS INFECTION Principal Investigator & Institution: Chan, John R. Associate Professor; Medicine; Yeshiva University 500 W 185Th St New York, NY 10033 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-MAY-2007 Summary: (provided by applicant): The granuloma plays an important role in host defense against M. tuberculosis. The mechanisms that regulate the formation and
Studies 23
maintenance of the tuberculous granuloma are, however, poorly understood. Chemokines and chemokine receptors play an essential role in cell migration in both physiological and pathophysiological states. Emerging evidence suggests a role for chemokine and chemokine receptors in regulating the granulomatous response during infection. M. tuberculosis has the ability to modulate chemokine and chemokine receptor expression in both in vitro and in vivo systems. Tumor necrosis factor-alpha (TNF-alpha) is essential for the control of tuberculosis, and is a potent regulator of chemokine expression and leukocyte trafficking. We have shown that neutralizing TNFalpha in mice with persistent tuberculosis results in disease recrudescence associated with granuloma disorganization and diffuse cellular infiltration in the lungs. Based on these observations, we propose to test the hypotheses that: i) chemokines and chemokine receptors play an important role in orchestrating cell migration and granuloma formation in tuberculosis; and ii) TNF-alpha regulates the granulomatous response by directing the trafficking of immune cells at the site of infection via regulation of specific chemokines and chemokine receptors. Because of the importance of Type 1 T cells in host defense against M. tuberculosis, efforts will be focused on examining a subset of chemokines and receptors that can modulate migration of these T lymphocytes. Murine tuberculosis models, as well as immunohistochemical, laser microdissection, and realtime PCR techniques will be used to characterize the expression of these specific chemokines and receptors during tuberculous infection. Mice with disruption of specific chemokine receptor genes and ligand neutralizing reagents will be exploited to dissect specific chemokine network. Similar techniques, in conjunction with in vitro cell migration assays and the TNF-alpha neutralization model of murine reactivation tuberculosis, will be employed to evaluate the effects of TNFalpha on the expression of specific chemokines and receptors, as well as on migration of T cells and monocytes during tuberculous infection. These studies should yield valuable information that will shed light on the roles of chemokines and receptors on cell migration, granuloma formation, and host defense in tuberculous infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELL WALL BIOGENESIS-TARGET FOR NEW ANTI-TB DRUGS Principal Investigator & Institution: Mcneil, Michael R. Professor; Microbiology; Colorado State University Fort Collins, CO 80523 Timing: Fiscal Year 2002; Project Start 30-SEP-1992; Project End 31-AUG-2007 Summary: (Provided by applicant): In this competing continuation, mycobacterial cell wall metabolism is targeted as a route to new tuberculosis drugs. In one approach, essential cell wall biosynthetic enzymes are targetted. It is proposed to prepare M. tuberculosis luciferase reporter strains that respond specifically to inhibitors of the following essential enzymes: rhamnosyl transferase (WbbL), galactofuranosyl transferase (GlfT), dTDP-Rha formation enzymes (RmIB-D), and the UDP-Galf formation enzyme (Glf). In addition, direct enzyme assays amenable to screening for inhibitors will be developed for WbbL and GlfT (such assays are already in place for RmIB-D and Glf). It is further proposed to identify the genes encoding the three enzymes that form the arabinosyl donor, decaprenylphosphoryl-D-arabinose, show that their corresponding enzymes are essential, and prepare M. tuberculosis luciferase reporter strains and enzyme assays for use in finding inhibitors of them. In the second approach it is hypothesized that compounds that activate or deregulate the cell wall degrading arabinases and peptidoglycan hydrolyases can act more quickly than inhibition based drugs and thereby shorten tuberculosis therapy. Thus newly discovered M. tuberculosis endogenous arabinanases (of unknown function) that cleave
24 Tuberculosis
cell wall arabinan will be purified and their genes identified. The effect of overexpressing these enzymes in M. tuberculosis will be tested; it is hoped the effect will be lethal. Reporter strains of M. tuberculosis to detect small molecules that up regulate the expression of the arabinanases will be prepared. The presence of a cell wall metabolic enzyme complex containing these arabinases (which can potentially be disrupted for therapy) will be searched for using a novel cross-linking reagent, cyanogen complexes of peptidoglycan synthetic and degradative enzymes, after covalent crosslinking with cyanogen, will be isolated. The identity of all proteins present in the complex will be determined by LC/MS and how individual proteins interact in the complex will be determined for the long-term goal of disrupting the complex to release the peptidoglycan cleaving enzymes. We will test M. tuberculosis for increased arabinase activity after exposure to novel highly active ethambutol like compounds (the presence of endogenous arabinase was first recognized during ethambutol treatment). Finally, large numbers of novel Betalactams will be tested for their action against M. tuberculosis with and without ethambutol like compounds anticipating that some will strongly stimulate cell wail degradation and bacterial death. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CELLULAR TUBERCULOSIS
NECROSIS
INDUCED
BY
MYCOBACTERIUM
Principal Investigator & Institution: King, C Harold. Medicine; Emory University 1784 North Decatur Road Atlanta, GA 30322 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 14-SEP-2003 Summary: (provided by applicant): A key step in the pathogenesis of M tuberculosis is its ability to cause caseating necrosis, parenchymal lung destruction, and cavity formation, which develop into the characteristic necrotizing bronchointerstitial pneumonia and bronchiolitis of tuberculosis. M tuberculosis is cytotoxic to epithelial cells in vitro, and we have shown that this cytotoxicity is associated with cell membrane permeation to lactose dehydrogenase and is mediated by necrosis of lung epithelial cells after infection with virulent mycobacteria (Dobos, K. M., Quinn, F. D. and King, C. H. 2000, Infect. Immun. 68:6300-6310). Interestingly, the attenuated M bovis BCG does not induce necrosis in this epithelial cell model suggesting that necrosis is related to the virulence of mycobacteria. Our working hypothesis is that M tuberculosis possesses factors that cause necrosis. We intend to identify the genes that encode or synthesize such factors and determine their functions. Towards this goal, we have been successful in isolating two such (necrosis-deficient) mutants with insertions into genes that have no known function by screening a transposon library of the Erdman strain of M tuberculosis (TN5370) for mutants that have lost their ability to cause cell membrane permeation and necrosis. Both nec mutants possess extremely interesting phenotypes when grown in mice. The first mutant (necA) appears to be highly attenuated for growth and virulence in SCID mice. This is an important result as it suggests that we have identified a gene whose product either directly causes necrosis or induces necrosis and thus should enhance our understanding of tuberculosis pathogenesis. Interestingly, the second mutant (necB) appears to kill SCID mice more rapidly than the parental strain. We intend to characterize these mutants, characterize the functions of the gene products, and extend this mutant isolation strategy to identify a large battery of mutants defective for necrosis of host cells. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 25
•
Project Title: CHARACTERIZATION OF ACID INDUCED PROMOTERS OF M. TB Principal Investigator & Institution: Saviola, Beatrice J. Basic Sciences; Western University of Health Sciences Health Sciences Pomona, CA 91766 Timing: Fiscal Year 2003; Project Start 15-MAY-2003; Project End 30-APR-2005 Summary: (provided by applicant): Tuberculosis exacts an enormous burden in morbidity and mortality on the global population. With the advent of the HIV epidemic and multiple drug resistances, disease due to tuberculosis has increased leading to a need for research into the basic mechanisms of pathogenesis. The long-range goal of this proposal is to understand how Mycobacterium tuberculosis, the causative agent of tuberculosis, can sense environmental stresses, up regulate critical genes, and survive in the hostile environment of the host. When M. tuberculosis invades a host it infects human macrophages. M. tuberculosis can also be found within host granulomas that have been shown to have an acidic pH. The putative promoter regions of the M. tuberculosis genes lipF and Rv0834c have been identified to be upregulated in response to acidic pH. The specific aims of this proposal are to: 1) characterize the putative promoter regions of lipF and Rv0834c to better understand how acid induced promoters are regulated 2) determine if lipF and Rv0834c are required for mycobacteria to resist acidic stress and identify additional stresses which may upregulate these genes. The expectation is that this work will result in the characterization of acid responsive promoter regions and provide the groundwork for the eventual identification of a general mechanism by which M. tuberculosis can resist environmental stresses such as acidic stress. This work is significant because it will contribute to a greater understanding of mycobacterial stress response and ultimately survival and persistence in the host during infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHARACTERIZATION OF MYCOBACTERIAL AUTOLYSINS Principal Investigator & Institution: Deng, Lingyi; Medicine; Boston University Medical Campus 715 Albany St, 560 Boston, MA 02118 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2002 Summary: (Adapted from the Applicant's Abstract): Mycobacterium tuberculosis remains the bacterial leading cause of death worldwide and multidrug-resistant strains have emerged as a new problem in both developed and developing countries. The cell wall of M. tuberculosis has a unique, complex structure and is extraordinarily thick, rigid, and hydrophobic. Because of these characteristics, it is highly impermeable to ordinary antimicrobial agents. Bacterial autolysins are enzymes which are capable of hydrolyzing the bacterial cell wall and are associated with normal bacterial cell division, growth, and autolysis. Little is known about the autolysins of mycobacteria. The central hypothesis of this proposal is that mycobacterial cell wall autolysins are essential for the growth and survival of the organisms and can be exploited as new targets for antimycobacterial agents. In preliminary studies, the investigators have (i) prepared a mycobacterial cell lysate that hydrolyzed the cell wall polysaccharide; (ii) observed that ethambutol treated mycobacteria have increased cell wall hydrolysis; and (iii) identified an open reading frame (ORF) in the M. tuberculosis genome that is highly homologous to a Bacillus subtilis cell wall hydrolases, i.e., an N-acetylmuranoyl-L-alanine amidase. The investigators now propose the following: AIM1. The putative M. tuberculosis amidase gene noted above will be amplified by PCR, cloned and expressed. If the protein is confirmed to have the predicted enzymatic activity, then its functional and biochemical characteristics will be determined and the expression properties of the gene
26 Tuberculosis
will be analyzed. AIM 2. (a) Develop rapid and sensitive in situ phenotypic assays and apply these to screening for cloned mycobacterial autolysins expressed in E. coli. (b) Develop improved zymography and cell-free enzymatic assays and apply these to the isolation and purification of putative hydrolases. Purified enzymes will be analyzed for structural information (e.g. N-terminal sequence, quantitative protein mass as determined by MALDI/TOF mass spectroscopy), which will be used to identify the encoding gene in the published M. tuberculosis genome sequences. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CHARACTERIZATION OF MYCOBACTERIAL SIGMA FACTORS Principal Investigator & Institution: Husson, Robert N.; Children's Hospital (Boston) Boston, MA 021155737 Timing: Fiscal Year 2001; Project Start 01-JUN-1995; Project End 28-FEB-2005 Summary: (provided by the applicant): The long-term goal of this research is to investigate the role of the alternative sigma factors SigD, SigE, SigH and SigM in the regulation of Mycobacterium tuberculosis gene expression and virulence. The underlying hypothesis of this research is that extracytoplasmic function (ECF) sigma factors of M tuberculosis play an important role in the regulation of gene expression during the interaction of this organism with the host during infection, and that this regulation is important for the virulence of this organism. This proposal has four complementary specific aims. The first aim is to complete construction of sigma factor mutant strains of M tuberculosis and to compare the survival of these mutants vs. the parental strain H37Rv following in vitro oxidative and nitrosative stresses that may be relevant to infection. The second aim is to compare the virulence of these mutants vs. H37Rv in macrophage and mouse models of infection. Mutant strains will be complemented to verify that any phenotypes observed in these experiments result from the disruption of the sigma factor gene that was mutated. The third aim is to investigate the role of these sigma factors in regulating M tuberculosis gene expression, focusing on the use of microarray technology, supplemented with bioinformatic and traditional molecular genetic methods. The fourth aim is to investigate the role of specific sigma factor-regulated genes in M tuberculosis virulence, by examining their expression and by constructing and testing M tuberculosis strains with mutations in these genes. These investigations are expected to identify regulatory networks and specific genes that are important in M tuberculosis virulence. This research thus has the potential to generate new insights into the pathogenesis of M tuberculosis infection, and may provide the basis for new approaches to the control of tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CHARACTERIZATION TUBERCULOSIS
OF
THE
SIGE
REGULON
OF
M
Principal Investigator & Institution: Posey, James E.; U.S. Centers for Disease Control & Prev Control and Prevention Atlanta, GA 30333 Timing: Fiscal Year 2001; Project Start 01-APR-2001 Summary: (provided by the applicant): The experiments outlined in this proposal are designed to elucidate the sigE regulon of M. tuberculosis and the role it plays in the infection process. Recent data demonstrate the induction of sigE when M. tuberculosis is phagocytized by the macrophage. The in vivo signal and the genes regulated by SigE are not known. The objectives of this proposal are to: (1) determine if SigE is required for intracellular survival in macrophage, (2) identify genes regulated by SigE, and (3)
Studies 27
characterize the regulation of sigE at the transcriptional and post-translational level. A delta sigE strain of M. tuberculosis will be constructed, and its ability to survive and replicate in the macrophage will be assessed. This strain will also be used to identify genes that are regulated by SigE. The expression of sigE will be controlled in the strain by cloning this gene downstream of an acetamide inducible promoter located in a shuttle vector. The protein expression profiles of strains harboring this plasmid in the presence and absence of acetamide will be compared to identify genes regulated by SigE. To assess the regulation of sigE, a delta orf1 strain of M. tuberculosis will be constructed, and the levels of SigE in wild type and this strain will be compared by western blot. The transcript levels of sigE in both strains also will be examined. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CLINICAL INVESTIGATIONS IN LUNG HOST DEFENSES Principal Investigator & Institution: Schluger, Neil W. Associate Professor of Medicine & Public; Medicine; Columbia University Health Sciences New York, NY 10032 Timing: Fiscal Year 2001; Project Start 20-SEP-1999; Project End 31-JUL-2004 Summary: Tuberculosis remains the world's leading infectious cause of death, and the rise of multidrug resistant tuberculosis and the interaction of the TB and AIDS epidemics worldwide are creating a public health threat of massive proportions. In recent years, we have pursued studies aimed at elucidating ways in which the host immune response to tuberculosis may offer protection from the disease, as well as ways in which inflammatory responses can be modified to improve outcomes in patients with multidrug resistant tuberculosis. We have demonstrated that the cytokine interferon (IFN) gamma plays a major role in human host defense against tuberculosis; a detailed understanding of immune mechanisms upstream and downstream from IFN's action in patients should provide significant insight into protection against tuberculosis infection and disease. To that end, three specific aims are planned: Specific aim 1: To assess, by determining the types and levels of chemokine present in bronchoalveolar lavage fluid of patients with tuberculosis, the signals in the lung which may cause recruitment of immune effector cells associated with an effective host response. Specific aim 2: To assess the state of activation of antigen presenting cell as well as immune effector cells in the lungs of patients with tuberculosis compared to controls. Specific aim 3: To assess changes in the pulmonary host response after administration of interferon gamma by aerosol to clearly define the mechanisms by which IFN causes clinical improvement in tuberculosis patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CLINICAL RESEARCH IN TUBERCULOSIS Principal Investigator & Institution: Chaisson, Richard E. Professor; Medicine; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-SEP-1999; Project End 31-AUG-2004 Summary: This application for a Midcareer Investigator Award in Patient-Oriented Research is submitted by Richard E. Chaisson, M.D, Professor of Medicine, Epidemiology and International Health at the Johns Hopkins University. The applicant completed subspecialty training in infectious diseases and clinical epidemiology in 1987. Since that time, he has built a successful and productive research program within the Johns Hopkins AIDS Service, a multidisciplinary clinical care enterprise for adults with HIV infection. In addition, he has organized and led the clinical and research efforts of the Baltimore City Health Department Tuberculosis Clinic, and has undertaken field
28 Tuberculosis
trials in HIV-related tuberculosis in Haiti and South Africa. In 1998 Dr. Chaisson was promoted to Professor and began a refocusing of his academic activities and commitments. This application is intended to support this effort. Dr. Chaisson has relinquished the directorship of the AIDS Service and has appointed a replacement director of the Tuberculosis Clinic in order to devote his full attention to clinical research in tuberculosis and HIV infection. Dr. Chaisson has founded the Johns Hopkins University Center for Tuberculosis Research, an interdivisional, multidisciplinary program dedicated to improving global tuberculosis control through innovations in diagnosis, treatment and prevention. The centerpiece of this initiative is field trial comparing alternative tuberculosis control strategies in communities within high-incidence countries, funded under the US Agency for International Development's Infectious Disease Initiative. This trial will be conducted in several countries and will randomly assign communities to one of three tuberculosis control strategies: i) directly observed therapy (DOT) for active cases; ii) DOT plus screening of household contacts for active disease; and iii) DOT plus screening and preventive therapy for household contacts. This trial will provide important insight into effective strategies for global tuberculosis control. The applicant is also Principal Investigator of the Baltimore Tuberculosis Trials Consortium site, and a funded investigator in other studies of tuberculosis epidemiology and control. With support under this award, he will develop an integrate program in tuberculosis research utilizing the clinical and laboratory resources of the Baltimore Tuberculosis Clinic, the Johns Hopkins University and sites in developing countries with high tuberculosis incidence. Moreover, he will serve as mentor to junior faculty in infectious diseases and related fields who are beginning academic careers in patient-oriented research. A mentoring program organized to enhance professional development and independent scholarly activity will be undertaken with two recent faculty recruits. An award under this program will substantially enhance the research and mentoring capabilities of the applicant, and will contribute to the generation of new knowledge essential for the control of tuberculosis worldwide. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONJUGATION AND RECOMBINATION IN MYCOBACTERIA Principal Investigator & Institution: Derbyshire, Keith M.; Wadsworth Center Empire State Plaza Albany, NY 12237 Timing: Fiscal Year 2001; Project Start 01-FEB-1999; Project End 31-JAN-2004 Summary: Mycobacterium tuberculosis accounts for more deaths worldwide than any other infectious agent. Recent increases in the number of cases have been associated with the spread of the AIDS virus and the appearance of drug-resistant strains of M. tuberculosis. The development of new treatments for mycobacteria requires an understanding of the biology of these bacteria and the ability to manipulate their genomes to determine the genetic basis of pathogenesis and drug resistance. In M. tuberculosis, studies have been hindered by inefficient methods for the introduction of DNA into and between strains, and by the low frequency of targeted recombination. In particular, the ability to make site-directed changes within the M. tuberculosis genome is crucial for understanding the role of particular genes in virulence. We propose to characterize a novel conjugation system that can transfer chromosomal DNA between strains of Mycobacterium smegmatis and use it as a tool for the analysis and transfer of DNA between mycobacteria. This naturally occurring system could offer an efficient method for the introduction of DNA into the slow-growing pathogenic mycobacteria. Furthermore, by examining conjugation between different species of mycobacteria we
Studies 29
will assess its promiscuity and possible role in the spread of drug resistance. Finally, we have identified three M. tuberculosis genes that are highly homologous to those encoding the RecBCD pathway of recombination in Escherichia coli, which is the major pathway for conjugal recombination and double-strand break repair. We intend to characterize these genes to facilitate the development of a defined homologous recombination system in M. tuberculosis. These goals will be achieved by: 1. Cloning and characterizing the cis-acting sequences necessary for conjugal DNA transfer. 2. Identifying the trans-acting protein functions necessary for transfer. 3. Monitoring conjugal transfer from M. smegmatis into other mycobacterial species including the slow-growing pathogenic species. 4. Developing a defined allele-exchange system by characterizing the RecBCD pathway of M. tuberculosis Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CONTACT-MEDIATED HOST RESISTANCE TO M TUBERCULOSIS Principal Investigator & Institution: Silver, Richard F. Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2003 Summary: Tuberculosis remains an international health problem of immense proportions, as one-third of the world's population is currently infected with the causative organism, Mycobacterium tuberculosis. Cell-mediated immunity, involving the interaction of sensitized lymphocytes with M. tuberculosis-infected mononuclear phagocytes, can contain the organism, resulting in the finding that the great majority of otherwise healthy individuals do not develop active tuberculosis following infection. HIV-positive individuals have greatly increased susceptibility to the development of active disease following infection with M. tuberculosis. Furthermore, tuberculosis is often an early complication of HIV infection which precedes marked declines in CD4+ T-cell counts. In contrast to studies of other intracellular pathogens, in vitro addition of activating cytokines does not mediate significant reduction in the intracellular growth of M. tuberculosis. Utilizing a method of quantitative infection of human mononuclear phagocytes with virulent M. tuberculosis in which the interactions of lymphocytes with these infected cells can be characterized, preliminary studies indicate that addition of lymphocytes to cultures of M. tuberculosis-infected monocytes is more effective at limiting intracellular growth than is transfer of the supernatants of those cultures. It is hypothesized that cell-to-cell contact involving the interactions of specific cell surface molecules is necessary to maximally activate human mononuclear phagocytes to contain intracellular growth of M. tuberculosis. This hypothesis will be addressed in the following Specific Aims: 1) To determine the contact-dependent mechanisms by which antigen-specific CD4+ T-cells activate bactericidal functions of M. tuberculosis-infected mononuclear phagocytes; 2) To determine whether maximal CD4+ T cell-mediated activation of M. tuberculosis-infected mononuclear phagocytes requires sequential or interactive effects of cell contact and cytokine production; and 3) To determine whether CD8+ T-cells, gammadelta T-cells, and NK cells mediate contact-dependent activation of M. tuberculosis-infected mononuclear phagocytes, to compare the mechanisms used by these effector populations to those of CD4+ T cells, and to determine the role of Fas/FasL-mediated cytotoxic effector mechanisms on killing of M. tuberculosis within human mononuclear phagocytes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
30 Tuberculosis
•
Project Title: CONTROL OF BACTERIAL TOXINS BY VIRUSES AND PLASMIDS Principal Investigator & Institution: Holmes, Randall K. Professor and Chair; Microbiology; University of Colorado Hlth Sciences Ctr Uchsc at Fitzsimons Aurora, CO 800450508 Timing: Fiscal Year 2001; Project Start 30-SEP-1976; Project End 31-MAR-2005 Summary: (Adapted from the Applicant's Abstract): The long term goals of this project are to determine molecular mechanisms for virulence regulation in pathogenic bacteria and to develop new methods to treat bacterial infections. The investigators will study Corynebacterium diphtheriae, a paradigm for toxin-mediated bacterial infections, and Mycobacterium tuberculosis, a prototype for intracellular bacterial infections. These very different bacterial pathogens produce closely related, iron-activated, global regulatory proteins that govern virulence: the diphtheria toxin repressor (DtxR) and the iron-dependent regulator (IdeR), respectively. The investigators will determine the molecular basis for function of DtxR, IdeR and the homologous regulator SirR from Staphylococcus epidermidis. The investigators will use structure-based design to develop new antimicrobial drugs called "super-activators" that will target DtxR, IdeR or their homologs; activate them by iron-independent mechanisms; and inhibit production of virulence factors that are negatively regulated by iron- and DtxR-related repressors. The development of IdeR as a novel target for antimicrobial therapy could address the urgent global need for improved treatment of tuberculosis. The investigators will characterize the genes and gene products that are iron-regulated and under control of DtxR and IdeR, both to provide new insights into the pathogenesis of diphtheria and tuberculosis and for development of additional classes of antimicrobial agents. Specific Aim I will analyze structure and function of DtxR, IdeR and SirR. The investigators will investigate the molecular basis for repressor-operator interactions, for iron-independent super-repressor activity, and for domain function in biological activity of these regulatory proteins. Specific Aim 2 will characterize the DtxR and IdeR regulons in C. diphtheriae and M. tuberculosis. The investigators will develop an allelic exchange system for C. diphtheriae, characterize the DtxR and IdeR regulons by proteomic and molecular genetic methods, assess physiological functions of DtxR and IdeR domain 3, and investigate atypical phenotypes among clinical isolates of C. diphtheriae. Specific Aim 3 will develop super-activators of DtxR and IdeR by structure-based design. The investigators will design combinatorial peptide libraries, test them for super-activator function, identify individual peptides with activity, determine the structural basis for that activity, and develop better super-activators by iterative application of these methods. The investigators will also use molecular genetic methods to identify novel mechanisms for super-repressor activity and new lead compounds for development as tools against these bacterial infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CORE--INTERNATIONAL Principal Investigator & Institution: Remick, Scot; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001 Summary: Since 1988, an interactive and multi-disciplinary team of investigators at the Case Western Reserve University and the Tuberculosis Research Unit have effectively and creatively fostered the development of scientific, clinical, laboratory, and education programs in the area of infectious disease (tuberculosis, HIV-AIDS) with investigators at the Makerere University (MU) in Kampala, Uganda and the AIDS Control Program of
Studies 31
the Ugandan Ministry of Health. The intent of this application is to continue to build on this program by expanding expertise within the center for AIDS research at CWRU and create an International Clinical Coordinating Center (ICCC). The core facility will provide an administrative structure with which to coordinate and considerably expand upon the international collaborative endeavors of CWRU and to foster realistic and meaningful clinical advances to clinicians, scientists, and other healthcare providers in Uganda with the emphasis on certain aspects of the HIV/AIDS pandemic. The creation of the ICCC core facility represents an unprecedented and exciting opportunity to join basic and clinical researchers from six-NIH designated centers at CWRU inclusive of: The Tuberculosis Research Unit, Dr. J.J. Ellner, Director; University Hospitals Ireland Cancer Center (UHICC), Dr. James Wilson, Director; Skin Disease Research Center (SDRC), Dr. Craig Elmets, Director; AIDS Clinical Trials Unit (ACTU), Dr. Michael Lederman, Director; Fogarty AIDS International Training and Research Program, Dr. Christopher Whalen, Director; and the Center for AIDS Research (CFAR), Dr. Stuart Le Grice, Director. The specific aims of this proposal arena to enhance interaction between Ugandan and CWRU clinicians and scientists in the HIV/AIDS are inclusive of tuberculosis, medical mycology, AIDS- related malignancies, and primary HIV vaccine development; to coordinate research activities in the field, clinic, and hospital settings in Kampala, Uganda and research programs/laboratories at CWRU; and to create an environment in Uganda for collaborative research suitable for realistic and meaningful technology transfer. Key research projects that would be funded by the International Core are DNA metabolizing enzyme targeted therapy (CA62502, J. Wilson), Viral etiology and cellular signals in AAKS (CA43703, J. Wilson), preparation for AIDS vaccine evaluation AI35173/CPV1, J.J. Ellner); Preventative therapy for TB in Uganda(CCU50671605, J.J. Ellner); Tuberculosis prevention and control unit (AI45244, J.J. Ellner); Impact of TB on HIV infection in Uganda (AI32414, C. Whalen). Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COST EFFECTIVE CONTROL OF TUBERCULOSIS IN THE US Principal Investigator & Institution: Brewer, Timothy F. Assistant Professor of Medicine; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-JUN-2003 Summary: In the mid-1980's, the long-standing historical decline in tuberculosis cases in the United States reversed itself and case rates began to rise. With the tuberculosis epidemic came the recognition that this disease was becoming increasingly concentrated in defined segments of the overall population. Though total case rates are falling again, groups in the US at significantly higher risk for tuberculosis than the general population exist. It is unknown whether the current recommendations for the control of tuberculosis in the US general population are as effective for these groups. To address this issue, a desktop Computer based mathematical model has been developed to simultaneously project tuberculosis cases and deaths over a l 0 year period using the best available epidemiological data. By adapting this model for US groups at increased risk for tuberculosis, this project will evaluate tuberculosis control strategies for four high risk groups. The groups are persons infected with human immunodeficiency virus, health care workers, immigrants, and the homeless. For each group, a database of inputs based on the epidemiology of tuberculosis within that group will be created. These databases will draw on the published literature and available government information such as that provided by the Centers for Disease Control and Prevention revised report of verified case of tuberculosis. The following tuberculosis control strategies will be evaluated singly and in combinations: increased coverage and improved efficacy of
32 Tuberculosis
preventive therapy, increased coverage and improved efficacy of treatment, increased effectiveness of contact tracing, and the introduction of bacille Calmette-Guerin vaccination. The robustness of the model results will be assessed in sensitivity analyses by simultaneously varying all inputs using Latin hypercube sampling. The combination of mathematical modeling and epidemiology provides the most complete evaluation of TB control measures among these high risk groups to date, and forms a basis for improving approaches to control this epidemic among these populations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CRYSTALLIZATION OF THE GALACTOSYLTRANSFERASE FROM MTB Principal Investigator & Institution: Reynolds, Robert C.; Southern Research Institute Birmingham, AL 35205 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 31-AUG-2004 Summary: (provided by applicant): This application is in response to PAS-02-031 for a supplement to our current NIAID-funded program AI45317 entitled Glycosyltransferases as Drug Targets in Mycobacteria. This supplemental program will involve the expression, purification, and crystallization of the galactosyltransferase (Rv3808c) from Mycobacterium tuberculosis. The galactosyltransferase adds galactofuranose units to the growing galactan, a polysaccharide that anchors the mycolylarabinan superstructure and is critical to mycobacterial cell wall integrity in the harsh environment of the human macrophage. This effort is responsive to the announcement in that it supplements our current program by applying modern structural biology techniques to obtain a structure of a protein targeted for drug development under our current grant. This protein was not available at the time of our application, and the information provided through the application of the requested supplemental funds will give us a specific picture of the protein active site allowing more rapid development of drugs to target this critical mycobacterial enzyme. As well, this grant is responsive to the PA in that it addresses a new drug target in tuberculosis, and may have implications in the treatment of multi-drug resistant tuberculosis (MDRTB), a critical health problem worldwide. Tuberculosis and its drug resistant forms are the focus of two active NIAID Program Announcements (PA-99-124 & PA-01-113) and is considered a potential biological weapon by the Department of Defense. This application involves modern structural biology that may not be considered as innovative as recent techniques in bioinformatics, genomics, and microarray technology. This effort, however, is innovative in the choice of target and the impact that structural biology can have on our funded program. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: CYTOTOXIC RESPONSE TO HISTOCOMPATIBILITY ANTIGENS Principal Investigator & Institution: Bevan, Michael J. Professor; Immunology; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2003; Project Start 01-JUN-1990; Project End 31-DEC-2007 Summary: provided by applicant): Our goal is to investigate the CD4 and CD8 T cell response to pathogenic infectious agents to uncover basic principles of T cell biology in controlling these infections. Two contrasting models of intracellular bacterial pathogens are chosen to ask fundamental questions about how the immune system perceives, responds, contains and eliminates these pathogens. One model to be studied is virulent Mycobacterium tuberculosis delivered via aerosol to the lungs of mice. This organism
Studies 33
can survive inside vacuoles within macrophages and set up a chronic infection which can be contained, but not eliminated, by adaptive CD4+T cell immunity. The role of CD8+ T cells in controlling tuberculosis is controversial. Recombinant organisms producing a model antigen containing well-studied epitopes for CD4 and CD8 T cells will allow a study of the tempo of the T cell response, and provide new information on protection against what has been called the world's most successful pathogen. M. tuberculosis may infect one third of the world's population. The second intracellular pathogen we plan to use is a common food-borne pathogen, Listeria monocytogenes. Excellent mouse models exist already for the study of this Gram positive pathogen, where it appears that adaptive CD8+ T cell immunity is the critical force in eliminating the infection. L. monocytogenes is a candidate vaccine vector for the induction of CD8 immunity, for example, against tumor antigens. The massive response of CD8+ T cells to acute infection with Listeria and the generation of long-lived protective immunity may also require CD4+ T cell help. The proposed studies are aimed at a greater understanding of the development of long-lived, protective immunity induced by this pathogen. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT AND TESTING OF NEW TUBERCULOSIS VACCINES Principal Investigator & Institution: Horwitz, Marcus A. Medicine; University of California Los Angeles 10920 Wilshire Blvd., Suite 1200 Los Angeles, CA 90024 Timing: Fiscal Year 2001; Project Start 01-APR-1991; Project End 31-AUG-2005 Summary: (Adapted from Applicant's Abstract) Mycobacterium tuberculosis, the primary agent of tuberculosis, infects one-third of the world's population and kills 3 million people annually, making it the world's leading cause of death from a single infectious agent. It is a leading cause of disease and death in AIDS patients, particularly in the developing nations of the world. The rapid global emergence of strains resistant to the major antibiotics used to treat tuberculosis poses a serious threat to public health. The highest priority in the fight against tuberculosis is the development of a vaccine that is more efficacious than the current vaccine - BCG. A vaccine more potent than BCG would have an impact on human health greater than virtually any other conceivable development in the fight against infectious diseases. Studies from this laboratory completed under the current grant established the importance of major extracellular proteins of M. tuberculosis in inducing both cell-mediated and protective immunity in the guinea pig model of pulmonary tuberculosis, a highly susceptible species that develops disease remarkably similar to human tuberculosis. Studies under the current grant also succeeded in developing technology for high level expression and secretion in native form of major M. tuberculosis extracellular proteins in a nonpathogenic rapidly growing heterologous host, allowing isolation and purification of 100 mg quantities of recombinant M. tuberculosis extracellular proteins for vaccine studies. In this grant application, we seek to build on the knowledge and experience gained in previous studies to develop a vaccine more potent than BCG in the highly relevant guinea pig model. We seek to develop and test live recombinant vaccines including recombinant BCG expressing major M. tuberculosis extracellular and cell-associated proteins and new non-live particulate vaccines formulated as liposomes and microspheres. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
34 Tuberculosis
•
Project Title: DEVELOPMENT OF A TUBERCULOSIS CURRICULUM Principal Investigator & Institution: Jones, Brenda E. Medicine; University of Southern California 2250 Alcazar Street, Csc-219 Los Angeles, CA 90033 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-SEP-2003 Summary: The goal of this proposal is to develop and implement comprehensive, interdisciplinary curricula on tuberculosis for health care providers in academic and community settings. We will first establish interdisciplinary curricula at a Health Sciences campus, train faculty to disseminate these curricula, and adapt the curricula for use in the community. Our specific aims are: 1) Establishment of comprehensive, interdisciplinary tuberculosis curricula at a Health Sciences campus. The target audience will include physicians, physician assistants and nurses who care for most tuberculosis cases in urban areas, and primary care providers who evaluate most patients for tuberculosis infection. As part of this aim, we will use a Telemedicine system that allows transmission of high-quality images and interactive videoconferencing between faculty at a central location and trainees at geographically separate sites. The effectiveness of the tuberculosis curricula will be measured by: (1) objective tests of factual knowledge and clinical decision-making skills, using written tests and structured clinical examinations; (2) evaluation of changes in clinical practice patterns, using focused chart reviews. 2)Training Health Sciences faculty to provide instruction in tuberculosis. Faculty will be trained to disseminate the curricula developed in aim 1. Regularly scheduled forums will be established to provide ongoing education and discussion among trainees and faculty, and the quality of faculty teaching will be assessed and improved through evaluations by trainees, peers and experts. 3) Expansion of educational efforts to the community. Using the educational infrastructure of Tuberculosis Control of Los Angeles county, we will adapt the tuberculosis curricula developed in aim 1 for delivery to community health care providers, including those who work with populations in which special problems are encountered, including the homeless, immigrants, HIV-infected persons and inmates of correctional institutions. Computer-based interactive programs using CD-ROM technology and/or the Internet will be used for some target audiences. Supervisory physicians and nurses at Tuberculosis Control will be trained to disseminate these curricula. The efficacy of these curricula will be assessed by objective measures of clinical decision- making skills and clinical practice patterns. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DEVELOPMENT OF AN IMPROVED MYCOBACTERIA CULTURE MEDIUM Principal Investigator & Institution: Somoskovi, Akos L.; Life Biomed, Llc 2800 Millers Way Dr Ellicott City, MD 21043 Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 14-SEP-2004 Summary: (provided by applicant): The clinical signs and symptoms of tuberculosis are not specific. Therefore, laboratory methods play a crucial role in establishing the diagnosis, monitoring the therapy and preventing transmission of the disease. Laboratory results must be not only accurate, but also rapidly available. However, the culture techniques most commonly employed world-wide for the diagnosis of tuberculosis are time-consuming. Recently it has been shown that the spent culture supernatant of Mycobacterium tuberculosis and active components (phopholipids and peptides) derived from it can enhance the growth of tubercle bacilli and allow small inocula to initiate growth in liquid culture. The aims of the proposed study are: (1) To
Studies 35
evaluate the growth enhancing/resuscitating factors as additives to current liquid and solid medium culture systems using lab strains of M. tuberculosis. Experiments will be carried out in both liquid media (7H9, 7H12B Bactec and MGIT) and solid medium (7H1 1 agar), with different inoculum sizes on both fresh and 01 cultures. Serial dilutions of a fresh culture representing the varying bacterial load of smear positive and smear negative clinical specimens can provide information about the growth enhancing effect of the examined agents, while inocula from old cultures will enable investigation of the resuscitation effect of the agents. (2) To evaluate the effect of opitmal growth enhancing factors on drug susceptible and drug-resistant clinical isolates of M. tuberculosis. The effect of selected phospholipids and peptides (based on the results of the above-detailed experiments) will also be studied both on 50 drug susceptible and drug-resistant clinical isolates. (3) To evaluate the effect of growth enhancing factors on drug susceptibility testing. Drug susceptibility testing will be performed on media containing the growth enhancing factors to rule out any interference and to determine the appropriate MIC values. At the end of the Phase I study the optimal components will be selected for formulation of a new culturel medium with commercial potential for improved diagnosis of tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT OF IMMUNE EVASION IN TUBERCULOSIS Principal Investigator & Institution: Ernst, Joel D. Professor; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2001 Summary: Acquired immunity to intracellular pathogens depends on T cell recognition of HLA-bound microbial peptides. Pathogens that occupy phagosomes are controlled by CD4+ cells that recognized microbial peptides bound to HLA class II. While these interactions occur in response to Mycobacterium tuberculosis, they are only partially efficacious: the human immune system is unable to completely resolve infection with M. tuberculosis. M. tuberculosis has been found to inhibit class II antigen presentation, but the mechanisms has not been determined. The goal of this project is to define the mechanism of inhibition of class II antigen present in human macrophages infected with M. tuberculosis. We have found that M. tuberculosis causes a decrease of cell surface class II (HLA-DR) in macrophages, without a decreased in the total cellular HLA-DR pool. This suggests that M. tuberculosis alters trafficking of class II. We will further characterize the decreased surface expression of class II by determining whether it is directly related to the number of intracellular M. tuberculosis and by comparing expression of HLA-DR on infected macrophages and dendritic cells. We will test the hypothesis that HLA-DR is sequestered in M. tuberculosis phagosomes, and will determine whether HLA-DR is sequestered due to failure of exchange of exogenous peptides for CLIP. We will also further characterize the functional effects of M. tuberculosis down-regulation of HLA-DR. We will determine whether down-regulation of class II inhibits CD4+ cell recognition of extracellularly loaded M. tuberculosis antigens and whether M. tuberculosis antigens and whether M. tuberculosis inhibits allogeneic responses. Finally, we will test the hypothesis that inhibition of class II antigen presentation is an inherent property of mycobacteria by comparing the response of CD4+ T cell lines that recognize a DR3-restricted epitope of M. tuberculosis hsp65 when it is expressed by mycobacteria or by an alternative vehicle. We anticipate that our results will provide new information on the pathogenesis of tuberculosis, and may identify alternative means of delivering M. tuberculosis antigens for vaccination. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
36 Tuberculosis
•
Project Title: DEVELOPMENT OF SYSTEM FOR TREATMENT OF TUBERCULOSIS Principal Investigator & Institution: Tsukamoto, Takuji; Chemica Technologies, Inc. 325 Sw Cyber Dr Bend, OR 97702 Timing: Fiscal Year 2001; Project Start 05-SEP-2001; Project End 28-FEB-2003 Summary: Tuberculosis causes a staggering burden of mortality world-wide, killing 2 million people annually. To cure tuberculosis, prolonged therapy of at least 6 months is required, because antituberculosis drugs do not penetrate well into macrophages, which are a major reservoir of M. tuberculosis. To devise antituberculosis medications that will shorten the duration of therapy, we will use microparticles to target the delivery of enzyme-cleavable lipophilic derivatives of isoniazid and rifampin to infected macrophages. Once inside the macrophage, the microparticles degrade and release the lipophilic drugs, which are then transported across the M. tuberculosis cell envelope. Our specific aims are: 1. To synthesize and characterize palmitic acid derivatives of isoniazid and rifampin. 2. To determine the rates of esterase or amidase hydrolysis of these derivatives. 3. To evaluate the capacity of these derivatives to kill M. tuberculosis. If this proposal is successful, a phase II proposal will be submitted to perform additional studies to evaluate these agents combined with microparticles in cell culture systems in vitro and in animals. This project will explore the feasibility of a strategy that can be applied to the treatment of infection caused by many intracellular organisms, including viruses, fungi and parasites. PROPOSED COMMERCIAL APPLICATIONS: The technology we will develop in this program has the potential to significantly improve the treatment of diseases due to pathogens that reside in macrophages, such as tuberculosis and HIV infection. In the treatment of tuberculosis, targeted-delivery systems of enzyme- cleavable lipophilic drugs are presently not available. This strategy has the potential to increase the efficacy of treatment, reduce the dosage of drugs required, reduce side effects of treatment, improve patient compliance, and minimize development of drug resistance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DIABETES AND TUBERCULOSIS PILOT Principal Investigator & Institution: Perez, Adriana; Assistant Professor; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, TX 77225 Timing: Fiscal Year 2003; Project Start 03-MAR-2003; Project End 29-FEB-2008 Summary: Screening for Mycobacterium tuberculosis infection in those at high risk for developing clinical tuberculosis (TB) is a key strategy of the Centers for Disease Control and Prevention (CDC) to control the spread of TB in the US. This is particularly important at the US/Mexico border, where converging socioeconomic and demographic factors contribute to the higher burden of TB when compared to the US national average. This region also has high prevalence of type II diabetes (DB), which has long been known to predispose to active tuberculosis. Based on this information, we hypothesize that DB contributes to the burden of TB in the Hispanic population from four Texan counties along the Mexican-American border. Four counties in the Lower Rio Grande Valley (LRGV) will be analyzed in this pilot project: Hidalgo, Cameron, WilIacy and Starr. A secondary analysis of the Texas hospital discharges during 2001 will be implemented using ICD 9 codes for case and control selection. Unconditional multiple logistic regression analysis will be used to evaluate the relationship between tuberculosis and tentative associated factors. Health production functions will be estimated, using unconditional multiple logistic regression as well. The specific aims of the project are: Aim 1: Determine the degree of association of DB and TB in Hispanics in
Studies 37
the LRGV Aim 2: Determine the strength of the association between TB and its associated risk factors (besides DB), with emphasis on underlying medical conditions. Aim 3: Estimate health production function that will identify relevant socio-economic indicators of TB and DB. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIAGNOSIS & PATHOGENESIS OF TUBERCULOSIS: AIDS OPPORTUNISTIC INFECTION Principal Investigator & Institution: Didier, Peter J.; Tulane University of Louisiana New Orleans, LA 70118 Timing: Fiscal Year 2001 Summary: The objective of this pilot project is to continue the characterization of the tuberculosis model in rhesus monkeys. We previously found that high dose inoculation (six million bacteria) of Mycobacterium tuberculosis H37Rv and Erdman strains produced lethal lung disease within five to ten weeks. Monkeys developed clinical signs of dyspnea, coughing, anorexia, and weight loss 4-6 weeks after inoculation. Skin testing with Old tuberculin became mildly positive after 5 weeks while PPD skin tests remained negative. Animals developed extensive necrotizing granulomatous lesions in the inoculated half of the lung with spread to the contralateral lung and bronchial lymph node in animals with H37Rv, and to the liver and kidney in animals with the Erdman strain. Animals vaccinated with culture filtrate from H37Rv and challenged with two million bacteria developed the same clinical disease as unvaccinated controls. However, low dosage inoculation of a pair of animals with each strain (<300 Erdma n, <30 H37Rv) failed to produce clinical disease within 18 weeks. Lesions in three of four animals were confined to the bronchial lymph node. To confirm this finding, four more animals per strain have been inoculated with low dosages of bacteria. All animals have strongly positive skin tests but remain clinically normal four weeks after inoculation. Characterization of this model by culture, blastogenesis, flow cytometry, and cytokine detection continues. Results contradict old literature and indicate that tuberculosis in rhesus monkeys may present as a chronic disease based on the dose of the inoculum. This suggests that future studies using low dose inoculation will be feasible in SIVinfected monkeys to study tuberculosis as an opportunistic infection. FUNDING Venture Research PUBLICATIONS Scollard DM, Didier PJ, Dietrich MA, Bohm Jr RP. Selective increases in CD45RO(+) CD38(+) T cells in 1? and 2? responses to BCG in rhesus macaques. [Abstract]. Proceedings of the 9th International Immunology Congress, San Francisco, CA, July 23-29, 1995. Scollard DL, Didier PJ, Bohm Jr RP. A method to assess changes in rhesus lymphatic T cells in vivo during local immune responses. [Abstract]. Second Annual Molecular Biology and Biotechnology Conference, Baton Rouge, LA, February 9-10, 1996. Didier PJ, Blanchard JL, Gormus BJ. Pulmonary tuberculosis in normal rhesus monkeys infected with Mycobacterium tuberculosis H37Rv. [Abstract #159]. Amer Soc Trop Med Hygiene, 57(3):156, 1997. Didier PJ, Blanchard JL. Chronic tuberculosis produced by low dosage of M. tuberculosis (Erdman) in rhesus monkeys. [Abstract #734]. Amer Soc Trop Med Hygiene 59(3):361, 1998. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DIAGNOSTICS FOR AIDS-RELATED PEDIATRIC TB, PERU Principal Investigator & Institution: Oberhelman, Richard A. Professor; Tropical Med & Parasitology; Tulane University of Louisiana New Orleans, LA 70118
38 Tuberculosis
Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2005 Summary: (provided by applicant)Tuberculosis is the major infectious cause of mortality among AIDS patients in the developing world, and HIV infection has been shown to increase mortality from tuberculosis five-fold in parts of Subsaharan Africa. Increasingly, HI V-infected children in developing countries are becoming infected with Mycobacterium tuberculosis (Mtb) and dying at an early age, presenting new dilemmas that differ from those facing adults with HIV-Mtb coinfection. The diagnosis of pediatric TB is complicated by inefficient and expensive methods to recover Mtb and vague diagnostic criteria. This project will evaluate novel approaches to the diagnosis of AIDSrelated pediatric TB in a hyperendemic setting using 1) rapid, cost-effective Mtb culture and susceptibility methods based on direct microscopic observation techniques and 2) alternative non-invasive specimens such as nasopharyngeal aspirates (NPA) and stool to detect Mtb. An optional component will assess improved rapid detection of Mtb by a semi-nested polymerase chain reaction assay (N2 PCR), a technique appropriate for regional reference laboratories in developing countries. Our preliminary data show a high correlation between culture results and N2 PCR results in adults (sputum PCR) and children (stool and NPA PCR) with tuberculosis, and mean time to detection of Mtb by our microscopic observation method was 9 days (at a fraction of the cost of rapid methods used in the U.S.). This is a collaborative effort between PRISMA, a Peruvian private voluntary organization, two U.S. universities (Tulane and Johns Hopkins), and a Peruvian university (Cayetano Heredia). Two hundred-sixty children with pulmonary disease meeting clinical criteria for TB disease (including at least 100 HIV-infected) from the Hospital del Nino, Lima, Peru, and 260 age-matched controls from both high- and low-risk communities will be enrolled. Mtb will be detected in gastric aspirates (cases only), NPAs, and stool by new and traditional culture methods and by N2 PCR. Children with a positive N2 PCR but without clinical evidence of TB requiring antituberculous therapy will be followed longitudinally. These new diagnostic methods have tremendous potential to improve and simplify the diagnosis of pediatric tuberculosis in low-income countries with limited laboratory resources. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFICIENCY
DIETARY
DEFICIENCIES
AND
TUBERCULOSIS
VACCINE
Principal Investigator & Institution: Mcmurray, David N. Professor; Medical Microbiol & Immunology; Texas A&M University Health Science Ctr College Station, TX 77843 Timing: Fiscal Year 2001; Project Start 30-SEP-1982; Project End 31-JAN-2005 Summary: The ultimate aim of this project is to elucidate the mechanisms by which protein deficiency interferes with vaccine-induced resistance to pulmonary tuberculosis. New tuberculosis vaccines will be tested, ultimately, in malnourished humans. Thus, the focus of this project has never been a more urgent research priority. Previous work with a highly relevant guinea pig model, employing low-dose aerosol exposure to virulent Mycobacterium tuberculosis, has revealed diet-induced defects in trafficking, activation, and interactions of immune cells. The recent acquisition of cDNA clones for guinea pig chemokines (MCP-1, IL- 8, RANTES) and cytokines (IFNgamma, TNFalpha, TGFbeta, and IL- 1beta) provides a unique opportunity to apply molecular biological approaches to test four hypotheses: (a) protein deficiency affects trafficking of immune cells into inflammatory exudates by interfering with the production/function of chemokines; (b) abnormal granuloma formation in protein-deficient guinea pigs results from alterations in the production/function of TNFalpha; (c) failure of immune lymphocytes from protein- deficient guinea pigs to activate macrophages to suppress
Studies 39
intracellular M. tuberculosis is due to decreased production/function of paracrine (IFNgamma) or autocrine (IL- 1beta, TNFalpha) cytokine signals; and (d) TGFbetamediated suppression of T lymphocytes and/or deactivation of macrophages leads to loss of control of intracellular mycobacteria in protein deficiency. Recombinant proteins and polyclonal antibodies will be produced for each of the chemokines and cytokines. Protein- deficient and well-nourished, BCG-vaccinated or nonvaccinated guinea pigs will be challenged by the pulmonary route and levels of these molecules assessed in freshly isolated or cultured cells by Northern blot and RT-PCR (for mRNA), or by bioassay (TNFalpha, TGFbeta) or ELISA. A tuberculous pleuritis model, previously established in the laboratory, and bronchoalveolar lavage will be used to assess the role of chemokines by instillation of recombinant chemokines or specific anti-chemokine antibodies. The effects of recombinant TNFalpha or anti-TNFalpha on granuloma formation will be determined. TGFbeta activity will be blocked in vivo by the injection of anti-TGFbeta antibodies or recombinant decorin. These experiments will provide important new insights into the contributions of these molecules to loss of tuberculosis vaccine efficacy observed in malnourished subjects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DIRECT DETECTION OF DRUG RESISTANT MTB WITHOUT PCR Principal Investigator & Institution: Wu, Whei K.; Applied Gene Technologies, Inc. 6190 Cornerstone Ct E, #101 San Diego, CA 921214701 Timing: Fiscal Year 2002; Project Start 01-AUG-2002; Project End 31-JAN-2003 Summary: (provided by applicant): Drug resistance is a significant problem in the fight against the bacterial pathogen Mycobacterium tuberculosis. Resistance to rifampin, a first-line antituberculosis drug, is almost always the result of mutations in the rpoB gene of the pathogen. In order to speed the diagnosis of drug resistant tuberculosis, it is possible to detect these mutations by a variety of available methods. However, all such methods require the PCR reaction, which is too expensive for routine use in most countries. There is a critical need for new diagnostic methods that detect genetic markers of rifampin resistance at a fraction of the cost of current methods. Our Tessera Array Technology detects single-copy chromosomal genes of M. tuberculosis without the need for PCR amplification. The method involves high-affinity labeling of pathogen DNA in crude or partially purified lysates, hybridization of the labeled DNA to sequence-specific probes, and detection of the labeled, hybridized DNA. A test for detecting M. tuberculosis has been developed by AGTI and is currently in pre-clinical trials. We propose to expand the test for simultaneous taxonomic detection of M. tuberculosis and genotypic detection of mutations that cause rifampin resistance. The specific aims of Phase I of the project are to adapt the Tessera platform to accommodate probes for rpoB; to enhance test sensitivity by optimizing cell lysis methods; and to conduct a non-clinical trial on known rifampin-sensitive and rifampin-resistant clinical isolates of M. tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DISSEMINATED TUBERCULOSIS IN HIV INFECTION Principal Investigator & Institution: Von Reyn, C Fordham. Medicine; Dartmouth College 11 Rope Ferry Rd. #6210 Hanover, NH 03755 Timing: Fiscal Year 2001; Project Start 01-AUG-2000; Project End 31-JUL-2005 Summary: Disseminated infection (mycobacteremia) with Mycobacterium tuberculosis (dMTB) has been documented by our group in 10-25 percent of patients with HIV
40 Tuberculosis
infection in Africa using lysis- centrifugation blood cultures. Unlike pulmonary tuberculosis (pMTB), most cases of dMTB are not recognized and death ensues rapidly. Thus, in developing countries dMTB may be a more important cause of HIV-associated mortality than pMTB. Risk factors for dMTB have not been identified and it is not known if most cases are due to primary infection, reactivation or re- infection. We hypothesize that most cases of dMTB are due to primary MTB infection in patients without prior infection with MTB or non-tuberculous mycobacteria (NTM). Mycobacterial immunization in early HIV infection is a potential strategy to prevent dMTB. Mycobacterium vaccae (MV) is an investigational vaccine prepared by heat inactivation of an NTM, and has been shown to be protective against MTB in several animal models. Studies conducted by our group indicate that a 5-dose series of MV is safe in patients with HIV infection and induces a durable cellular immune response to MTB antigens in persons with prior BCG immunization. Our hypothesis is that MV immunization will reduce the risk of HIV-associated dMTB by 50 percent. Our specific aims are: (1) to define risk factors for HIV-associated disseminated tuberculosis and to assess the relative contributions of primary infection, reactivation and re-infection in the pathogenesis of disseminated tuberculosis, and (2) to assess the safety and efficacy of a 5-dose schedule of inactivated MV vaccine for the prevention of HIV-associated pulmonary and disseminated tuberculosis in persons with prior BCG immunization. 2274 HIV-positive patients with prior BCG immunization and 100 HIV-negative controls will be entered in a 5-year study in Zambia. Baseline evaluation will include history, chest x-ray, dual skin tests with purified protein derivative (PPD) and Mycobacterium avium sensitin (MAS), and whole blood assay for interferon-gamma production in response to MV sonicate, PPD, ESAT-6 (a protein antigen unique to MTB) and MTB antigen 85. Subjects with PPD reactions greater than or equal to 5 mm will receive 6 months of prophylaxis with isoniazid. All subjects will be randomized 1:1 to receive a 5dose series of MV or placebo over 12 months with repeat skin test and in vitro studies at 14 months. Subjects will be followed every 3 months for 3-5 years to assess new pMTB (microbiologic or clinical diagnosis) or dMTB (microbiologic diagnosis). All isolates will have susceptibility tests and IS6110 DNA fingerprinting performed. Potential risk factors for dMTB, including baseline PPD test results, will be assessed in placebo and vaccine groups. Vaccine efficacy against dMTB and pMTB in HIV-positive subjects will be determined, and post immunization interferon gamma responses used to identify a surrogate marker of efficacy. The proposed study has important implications for the reduction in mortality from HIV-associated tuberculosis and for design of future trials of new vaccines against tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DNA GYRASE AND QUINOLONE RESISTANCE IN TUBERCULOSIS Principal Investigator & Institution: Drlica, Karl A. Associate Professor; Public Health Research Institute 225 Warren St Newark, NJ 07103 Timing: Fiscal Year 2001; Project Start 30-SEP-1993; Project End 30-JUN-2003 Summary: (Adapted from the applicant's abstract): Drug resistance is a major problem for anti-tuberculous chemotherapy and is one of the main reasons why compounds such as fluoroquinolones are not first line agents. Two recent advances, using a variety of bacteria, encourage refinements of fluoroquinolones. First, resistance arises stepwise from mutations in two independent targets, DNA gyrase and DNA topoisomerase IV. Thus a first step resistant gyrase mutant can be used to screen new fluoroquinolones for derivatives that require two mutations to confer resistance. Since double mutations occur less frequently that single mutations by many orders of magnitude, resistance to
Studies 41
the new compounds should arise very rarely. Second, the double mutant concept was experimentally validated: a C8-methoxyl group reduced the acquisition of resistance by at least three orders of magnitude. Two approaches are proposed to define how these principles apply to fluoroquinolone resistance in Mycobacterium tuberculosis. In one, fluoroquinolone structural variants will be examined for their ability to prevent resistance. Prevention of resistance will be correlated with avid killing of moderately resistant strains 1) in pure culture under growing and non-growing conditions, and 2) inside cultured human macrophages. The generality of the conclusions will be tested using a wide variety of clinical isolates of M. tuberculosis. In the other approach, resistance will be studied by examining nucleotide sequences of genes encoding gyrase and topoisomerase IV. Mutants will be selected for resistance to various fluoroquinolone congeners, some of which are already known to elicit different alleles. Selected mutants will be tested for 1)cross-resistance, 2) adaptation to changing environment, and 3) invasion of human macrophages. Already available are many new compounds, two novel assays (killing resistant mutants and prevention of resistance), a human macrophage infection system, and a large collection of clinical isolates of M. tuberculosis. Significant progress is expected toward finding fluoroquinolones that will prevent resistance from arising in M. tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DRUG DEVELOPMENT FOR MDR-M TUBERCULOSIS Principal Investigator & Institution: Dick, James D. Pathology; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2003; Project Start 15-MAR-2003; Project End 28-FEB-2008 Summary: (provided by applicant): Tuberculosis is one of the oldest and most common infectious diseases of man. The disease is epidemic with approximately 1.8 billion people or one third of the world's population currently infected. The HIV epidemic and the emergence of multi-drug resistant M. tuberculosis (MDR-TB) has led to a critical need for the discovery and development of new and effective therapeutic agents for the treatment and control of tuberculosis. The b-sulfonylcarboxamides are a novel class of compounds which have potent in vitro activity against pathogenic mycobacteria with minimal inhibitory concentrations (MICs) ranging from 0.78 micrograms per ml to 12.5 micrograms per ml for M. tuberculosis, including MDR-TB. In addition, these compounds are highly specific for pathogenic mycobacteria, maintain activity in the presence of human serum, and are not cytotoxic for mammalian cells at 40 times their MIC for M. tuberculosis. Recent studies in our laboratories have demonstrated the antimycobacterial activity of the b-sulfonylcarboxamides to be the result of inhibition of a potentially unique pathway/target involved in central energy metabolism. The longterm objectives of this grant proposal are to determine the molecular target and mechanism of action of this novel class of compounds, with subsequent optimization of drug structure, synthesis, and preclinical drug development. This will be accomplished through: (1) characterization and identification of the target/pathway using available genomic and proteomic technologies, (2) confirmation and validation of candidate target(s) through microbiologic, biochemical, and genetic comparisons between resistant and susceptible mycobacteria, (3) determination of the three dimensional structure of the identified target, (4) design and synthesis of optimum small molecule inhibitors of the identified target/pathway (5) in vitro and in vivo toxicity and efficacy testing in a murine model of tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
42 Tuberculosis
•
Project Title: DRUG DISCOVERY FOR PERSISTENT TUBERCULOSIS Principal Investigator & Institution: Sacchettini, James C. Professor & Wolfe-Welch Chair; Biochemistry and Biophysics; Texas A&M University System College Station, TX 778433578 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Tuberculosis (TB) is the leading cause of death by an infectious disease in the world. The synergy between TB and AIDS is also very apparent. TB is the primary cause of death for individuals co-infected with the human immunodeficiency virus (HIV). HIV infection is the greatest single risk factor known for progression from TB infection to active TB disease in developing nations, where as many as 40-80% of individuals with the acquired immunodeficiency syndrome (AIDS) will also develop TB. Conversely, coinfected patients with active TB show enhanced viral replication and accelerated progression of AIDS. Although Tb is a treatable disease, current chemotherapy regimens require a complex strategy of 3 drugs for at least six months. Such prolonged therapy is necessary because conventional drugs are poorly effective against a sub-population of latent and drug-tolerant bacterial 'persisters'. Most patients will not adhere to this treatment regimen. Patients who default suffer increased rates of treatment failure, relapse, and drug resistance. New drugs against persisting mycobacteria are urgently needed to counter the problem of patient non-compliance. The development of new drugs would be greatly facilitated by the identification of bacterial 'persistence factors' as candidate drug targets. A significant step towards this goal was our recent demonstration that the glyxoylate shunt enzyme isocitrate lyase, ICL, is essential for persistence of Mycobacterium tuberculosis, in vivo. In addition, we have demonstrated that ICL is expressed at high levels in M. tuberculosis living in murine macrophages. Building on these observations, we will take a multi-discipline approach to define the role of the glyoxylate shunt and fatty acid catabolism in persistence. Enzymes found essential to persistent organisms will be characterized and used in high throughput drug screening and structure based drug-design. Promising lead compounds will be tested for safety and efficacy in a mouse model of chemotherapy, latency, and relapse. Indeed, the primary goal of this proposal is to develop new chemotherapeutics for the treatment of persistent M. tuberculosis infections. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: DRUG RESISTANT TUBERCULOSIS Principal Investigator & Institution: Montellano, Paul; University of California San Francisco 500 Parnassus Ave San Francisco, CA 94122 Timing: Fiscal Year 2002; Project Start 01-SEP-1997; Project End 31-AUG-2007 Summary: Drug resistant tuberculosis is a major opportunistic infection in AIDS patients and resistance to the available drugs is growing. Tuberculosis infection both increases the infectivity of the HIV virus and is a major cause of death in AIDS patients. This project focuses on the role of selected oxidation-reduction processes in the development of Mycobacterium tuberculosis drug resistance and the use of this information for the design of new antitubercular agents. Isoniazid, a first line drug, is activated by the KatG catalase peroxidase to a reactive intermediate. This intermediate, or one of its further reaction products, is responsible for interaction with the cell wall biosynthetic enzymes InhA and KasA-AcpM, the ultimate targets of the drug. Resistance to isoniazid is largely caused by mutations that disable KatG and is associated with the enhanced expression of AhpC and AhpD, two unrelated non-heme alkylhydroperoxidases (peroxiredoxins) that compensate for the loss of KatG. Inhibition
Studies 43
of AhpC/AhpD in conjunction with isoniazid treatment is a potentially useful mechanism for counteracting isoniazid resistance. In the expiring grant period, AhpC and AhpD were cloned, expressed, and partially characterized and the crystal structure of AhpD was determined. Building on these results, further structural and mechanistic studies are to be carried out with AhpC/AhpD, and this information is to be used to develop potent and selective inhibitors of these two proteins. Ethionamide is another antitubercular prodrug. It is activated by the enzyme EtaA rather than by KaG but the activated species also appears to act at the level of InhA andor KasA-AcpM. Ethionamide resistance is due to impairment of EtaA activity and is associated with elevations in AhpC/AhpD similar to those observed with isoniazid. We have cloned and expressed EtaA and shown it to be a flavoprotein that catalyzes two sequential step in the activation of ethionamide and other thioamide drugs. We propose to complete characterization of EtaA, including the nature of the reactive intermediate, the mechanisms of its interactions with InhA and KasA-AcpM, and its biological importance. The information is to be used to synthesize agents that inhibit one of these two target proteins and, if warranted, EtaA. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DRUG TRANSFERASES
TARGETING
M.
TUBERCULOSIS
ARABINOSYL
Principal Investigator & Institution: Lee, Richard Edward. Assistant Professor; Pharmaceutical Sciences; University of Tennessee Health Sci Ctr Health Science Center Memphis, TN 38163 Timing: Fiscal Year 2001; Project Start 30-SEP-2000; Project End 31-MAY-2003 Summary: (adapted from applicant's abstract): Tuberculosis is still a major cause of morbidity and mortality worldwide with the number of cases rising due to the HIV pandemic and the emergence of drug resistant strains. To combat these problems more effective antibiotics must be developed with better pharmacokinetics and lower toxicity than the drugs currently used. It is the aim of this proposal to study the chemistry, biochemistry and genomics of arabinose metabolism in M. tuberculosis and the effects of the front line drug ethambutol on the important mycoloylarabinogalactan (MAG) biosynthetic cascade. MAG is a unique lipidated polysaccharide surrounding and protecting the tubercular bacilli from the host immune system where it has found its evolutionary niche. The proteins involved in MAG biosynthesis are excellent drug targets because they are essential for growth of the organism and are unique to mycobacteria. However, a fundamental lack of knowledge of the genes involved prevents these targets from being developed. This proposal initiates the synthesis of advanced cell wall mimetic acceptors and the development of new arabinosyl transferase assays. Using these assays the relationship between the alpha (1-3) arabinosyl transferase activity and the frontline drug ethambutol will be defined. These assays will also allow detailed analysis of the mechanism of beta (1-2) arabinosyl transfer and aid in identification of the beta (1-2) transferase. The role of the protein encoded embCAB operon in arabinan biosynthesis will be explored, and its sensitivity to ethambutol and novel antimycobacterials examined. Most importantly the knowledge gained from these studies will initiate a thorough medicinal chemistry effort involving these targets for the development of new, more effective and less toxic treatments against tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
44 Tuberculosis
•
Project Title: EARLY PULMONARY HOST DEFENSE IN M. TUBERCULOSIS INFECTIO Principal Investigator & Institution: Sherman, David R. Senior Scientist; Pediatrics; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2003; Project Start 30-SEP-1999; Project End 31-JUL-2004 Summary: Although a lung is a portal of entry for this M. tuberculosis and chronic pneumonia is the most common disease caused by M. tuberculosis infection, the specific nature of the pulmonary host response to this pathogen is relatively unknown. The central goal of the studies outlined in this proposal is to determine whether components of the early pulmonary immune response are critical determinants for resistance or susceptibility to disease caused by M. tuberculosis. The specific aims will address the role of TNF-alpha, beta chemokines and the B7/CD28/CTLA4 costimulation pathway in the initiation and amplification of the pulmonary host response to aerosol infection with M. tuberculosis. Preliminary studies using transgenic mice with a local inhibition of TNF-alpha in the lung (SPCTNFRIIFc mice) indicate that blockade of TNF-alpha selectively in the lung results in early deaths, severe lung pathology and an alteration of antigen specific immunity. These studies also indicate that transgenic mice with local inhibition of the immune response in the lung are a useful model to study pulmonary host defense. Further studies are proposed to compare the response that develops in the lung vs. regional lymph nodes in wildtype and SPCTNFRIIFc mice. To investigate the role of beta chemokines in the pulmonary host defense, transgenic mice that secrete a virally encoded inhibitor of all chemokines has been generated. The phenotype of these mice will be determined then used to investigate the role of beta chemokines in the initiation of the pulmonary host response to M. tuberculosis. To investigate the role of the B7/CD28/CTLA4 costimulation pathway in the initiation and amplification of the pulmonary host response to M. tuberculosis, transgenic mice that secrete an inhibitor of the B7/CD28/CTLA4 co stimulation pathway will be generated, characterized then used in experiments examining the immune response to M. tuberculosis. To determine the relative importance of the intrapulmonary component of the immune response vs the systemic immune response, in each of the project specific aims, mice will be included with both local inhibition of the immune response and systemic inhibition. In the studies examining the pulmonary host response to M. tuberculosis, infections will occur via the aerosol route because inhalation is the usual route of infection in humans. The primary endpoints will include bacterial burden, lung histology, survival and the phenotypic and functional characteristics of the immune response. The proposed studies should advance the existing knowledge of the specific nature of the pulmonary immune response to M. tuberculosis, will directly test the role of these mediators in host defense against M. tuberculosis, suggest important targets for novel therapies and elucidate role of specific mediators of the host immune response that are critical for the induction of an antigen specific immune response by candidate vaccines. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EDUCATION IN TUBERCULOSIS--A NEED IN PUERTO RICO Principal Investigator & Institution: Rodriguez, William; U.S. Dept/Vets Affairs Medical Center Affairs Medical Center San Juan, PR 00933 Timing: Fiscal Year 2001; Project Start 01-JUL-1997; Project End 30-JUN-2002 Summary: During the last seven years we have seen dramatic changes in the epidemiology and incidence of tuberculosis in the United States. Despite improved
Studies 45
methods of diagnosis and treatment, tuberculosis is increasing. Likewise, in Puerto Rico, tuberculosis cases have increased and occur disproportionately in certain high risk groups as HIV-infected persons. Over the last 3 decades as tuberculosis cases diminished, so did tuberculosis education. Medical students at the University of Puerto Rico School of Medicine, as well as housestaff, postgraduate fellows, and faculty receive an inadequate amount of training in tuberculosis and tuberculosis control. Moreover, the Puerto Rican community has little means of learning about this increasing public health threat. The primary goals of the curriculum development program in this application are the following: 1) to provide an integrated curriculum in tuberculosis that emphasizes principles and practices relevant to tuberculosis control at all levels of medical education; 2) to improve tuberculosis education in Puerto Rican community focusing on the providers caring for ("high risk" clients; 3) to develop a faculty capable of providing high quality tuberculosis instruction. The proposed curriculum development plan involves the following major components; a) creation of a multidisciplinary advisory committee; b) development of instructional materials that emphasize the importance of tuberculosis and tuberculosis control in case-based problem solving sessions; c) increased didactic and case-based teaching during the clinical rotation of medical students as well as housestaff postgraduate fellows; d) training of faculty responsible for tuberculosis education; e) improved continuing education in tuberculosis for community physicians and health care workers through a number of innovative courses and collaborations with the Department of Public Health and other community organizations. Research related to tuberculosis control will be fostered by support of student research projects as well as the continuation of the candidate's research program and the many collaborations that will result from this award. Evaluation of the curriculum development program will be conducted by an experienced group of physician and health educators through a stepwise and analytical manner. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFLUX INHIBITORS FOR MYCOBACTERIUM THERAPIES Principal Investigator & Institution: Markham, Penelope N. Director of Research; Influx, Inc. 2201 W Campbell Park Dr Chicago, IL 60612 Timing: Fiscal Year 2001; Project Start 01-MAR-2001; Project End 31-DEC-2001 Summary: (Verbatim from Applicant's Abstract): New drugs are desperately needed for tuberculosis both to reduce the long duration of treatment and to cure and stop transmission of multiple-drug-resistant Mycobacterium tuberculosis. Recent studies, including the completion of the TB genome sequence, suggest that efflux pump inhibitors may play a significant role in the intrinsic resistance of M. tuberculosis to most common antibiotics. Influx has identified several low molecular weight inhibitors of the NorA efflux pump in Staphylococcus aureus which demonstrated synergistic activity with ciprofloxacin and which dramatically reduced the frequency of emergence of ciprofloxacin-resistant mutants. In preliminary in vitro experiments with M. tuberculosis, two of these compounds demonstrated marked synergy when combined with two tetracyclines and a macrolide. We propose to a) test additional congeners of these inhibitors to determine structure-activity relationships with respect to M. tuberculosis, b) determine the substrate specificity of the effected efflux pump by testing for synergy with a wide variety of antimicrobials, c) determine the effect of the inhibitors on the frequency of emergence of drug-resistant mutants and d) with a variety of TB drug-susceptible and resistant clinical isolates, and e) assess synergistic activity of inhibitors with antimicrobial agents in a macrophage model of TB infection. It is
46 Tuberculosis
anticipated that these studies will result in the identification of one or more lead compounds that would be assessed for activity in animal models of acute and chronic TB in a phase II project. In addition these compounds would serve as starting points for synthesis of additional congeners. PROPOSED COMMERCIAL APPLICATION: The envisioned commercial product is a combination of tetracycline, a macrolide, or possibly another antibiotic with an efflux pump inhibitor. This combination can form a powerful anti-TB agent which can be effective against resistant strains and prevent further emergence of resistance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EMERGING MDR TUBERCULOSIS ACROSS THE US/MEXICO BORDER Principal Investigator & Institution: Mccormick, Joseph B. None; University of Texas Hlth Sci Ctr Houston Box 20036 Houston, TX 77225 Timing: Fiscal Year 2003; Project Start 15-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant) Our application will create dynamic databases to analyze and generate preliminary data on the precise patterns of transmission of tuberculosis (TB), especially multidrug resistant tuberculosis (MDR-TB), across South Texas and North Eastern Mexico. This will be achieved through a binational consortium that will share social, demographic, and geographic data on tuberculosis cases from each of their respective areas. The aims of the consortium are 1) aggregate existing sociodemographic, drug resistance and molecular fingerprinting databases currently held separately by consortium members 2) merge, geocode and analyze the aggregated database 3) establish common protocols and procedures for testing of drug resistance, extraction of M. tuberculosis DNA, and molecular characterization of isolates 4) evaluate social network analysis as a method for improving the tracking of MDR-TB transmission. These analyses link individual cases over 3-5 years with molecular fingerprints, drug susceptibility patterns, sociodemographic characteristics and geographic location, allowing regional understanding of the distribution and dynamics of DR and MDR-TB transmission across the border. These data will be used to improve control techniques and become the basis of hypotheses that will be tested in future, more elaborate research applications. These applications will include epidemiologic and translational research studies using common protocols for binational projects in emerging diseases, specifically MDR-TB. The geographic area of the consortium encompasses 5 counties of the Lower Rio Grande Valley (LRGV) from the Gulf of Mexico to Laredo, and the Mexican border states of Tamaulipas and Nuevo Leon. The consortium will be led by the Dean and faculty of the University of Texas School of Public Health Regional Campus at Brownsville, less than a mile from the border and contributing expertise in molecular microbiology, epidemiology, biostatistics, social network studies and spatial-temporal analyses. Leading tuberculosis researchers in Houston, San Antonio and Monterrey will play key roles in strengthening the capacity to conduct specialized public health, epidemiologic, and molecular based research on MDR-TB in the study area. Border consortium participants are from all the public health investigatorities responsible for TB elimination in both countries. An important defense of MDR introduction by bioterrorism is understanding how transmission of these organisms may differ from non resistant TB (if at all) and detailed knowledge of local strains of MDR that will allow quick distinction between known circulating strains of MDR TB and newly introduced strains. This application will be instrumental in addressing all of these issues. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 47
•
Project Title: ENHANCEMENT OF TUBERCULOSIS VACCINE BY THYMOSIN Principal Investigator & Institution: Tuthill, Cynthia W.; Sciclone Pharmaceuticals, Inc. 901 Mariner's Island Blvd San Mateo, CA 94404 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2004 Summary: (provided by applicant): Tuberculosis (TB) is a chronic infectious disease. Although most of the earths' 5.7 billion inhabitants have received the attenuated M. bovis BCG vaccine, many have still become infected and are at risk for developing clinical disease. The difficulty of compliance with lengthy and costly treatment regimens, coupled with the emergence of multi-drug resistant strains and the global AIDS crisis, have contributed to an emerging tuberculosis pandemic. An effective prophylactic vaccine is desperately needed. Most recent vaccines use non-viable bacterial proteins, lipids, or DNA; these require added adjuvants to generate a T helper 1 cellular response. We propose to evaluate the effects of thymosin, a synthetic 28 amino acid peptide with demonstrated Th1 immunomodulator properties, as an adjuvant. A well-characterized murine aerosol model of infection will be used with viable, virulent M. tuberculosis. We will evaluate the effect of thymosin on the level of antigen-specific IFNg production by circulating T cell populations; the reduction of bacterial load in lung and spleen; and conduct histopathological analyses of lung tissues to determine immune responsiveness and protective granuloma formation. Findings that indicate superior performance to BCG vaccinated controls will provide the basis for further evaluations in the more sensitive guinea pig model of infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EXPRESSION OF TUBERCULOSIS IN THE LUNG Principal Investigator & Institution: Ellner, Jerrold J. Professor and Executive Vice President; Medicine; Univ of Med/Dent Nj Newark Newark, NJ 07103 Timing: Fiscal Year 2001; Project Start 30-SEP-1993; Project End 31-JUL-2005 Summary: (Adapted from the Applicant's Abstract): Mycobacterium tuberculosis infects a third of the worlds' population and TB is the leading cause of morbidity and mortality due a single infectious agent. However, only 5-10% of M. tuberculosis-infected subjects without an underlying immunodeficiency develop disease during their lifetimes. Therefore protective immunity is induced in the majority of subjects. Understanding correlates of protection against M. tuberculosis in humans is needed to better direct efforts in the development of antituberculosis vaccines. The PI suggests that increased susceptibility to M. tuberculosis infection by patients with IFNgamma receptor I deficiency and successful therapeutic use of IFNgamma in refractory mycobacterial infections indicates the importance of IFNgamma in immunity against mycobacteria. However, during the previous funding period the PI found increased levels of IFNgamma in the lungs of patients with TB. Thus, the question is raised as to the effectiveness of IFNgamma and/or involvement of other factors in protective immunity. In the present competitive renewal application, the PI proposes to define pulmonary correlates of protective immunity by comparing several immunological parameters in TB patients, healthy household contacts of TB patients (tuberculin skin test positive), and community control subjects. Bronchoalveolar and blood mononuclear cells obtained from each study subject will be utilized to characterize antigen-specific cytokine induction, killing of M. tuberculosis, CTL activity against M. tuberculosisinfected targets and mediators involved in these effector functions (iNOS, granzyme, perforin, granulysin, FasL) (specific aim 1). According to the PI, this first part of the work should identify correlates of protective immunity as differences between
48 Tuberculosis
protective immune responses (in skin-test-positive, healthy household contacts) and failed immune responses (patients with TB). Correlates of protection identified in aim #1 should then be used to assess induction of protective immunity and chemokine expression by vaccination of humans with BCG. Two strains of BCG having different efficacy and reactogenicity, and two routes of vaccine administration (oral and intracutaneous) will be compared (specific aim 2). The PI states that this proposal attempts to define new parameters of immunological protection in humans and to rationally assess the impact of BCG strain variation and the route of BCG administration on the induction of protective immunity. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: FUNCTION OF CD8 T CELLS IN TUBERCULOSIS Principal Investigator & Institution: Flynn, Joanne L. Associate Professor; Molecular Genetics & Biochem; University of Pittsburgh at Pittsburgh 350 Thackeray Hall Pittsburgh, PA 15260 Timing: Fiscal Year 2002; Project Start 30-SEP-1997; Project End 31-MAR-2007 Summary: (provided by the applicant): The immune response against Mycobacterium tuberculosis results in control, but not elimination, of infection. T cells are a crucial component of this response. This proposal extends our current work on examining the CD8 T cell subset and the effect of these cells in tuberculosis. It is clear that the naturally induced immune response is insufficient to resolve a M. tuberculosis infection. Understanding how the CD8 T cell response develops and is modulated over the course of infection may provide clues to augmenting this response to provide better control of infection. In this proposal, we will focus on following CD8 T cell responses to specific antigens, focusing on the function of the CD8 T cells at various times post-infection. Specifically, cytokine production and cytotoxic ability will be tested during acute, chronic, memory and reactivation states. Our hypothesis is that the CD8 T cell response and function wane during a chronic infection, and boosting this response would result in improved control of the infection. In addition, preliminary data indicates a role for CD4 T cells in maintaining CD8 CTL function, and the mechanisms responsible for this will be investigated. Our long term goal is to have a clear picture of the CD8 T cell response in tuberculosis, including antigen specificity, function, evolution, and maintenance. This information will impact directly on vaccine development, since it appears that stimulation of both CD4 and CD8 T cells will be necessary to provide adequate protection against tuberculosis. To this end, our specific aims are: Aim 1. To examine evolution in the antigen specific CD8 T cell responses during M. tuberculosis infection. Aim 2: To investigate the function of CD8 T cells in M. tuberculosis infection. Aim 3: To assess the development, maintenance and function of memory and recall CD8 T cell responses in tuberculosis. Aim 4: To determine the effects of CD4 T cells on CD8 T cell maintenance and function in tuberculosis. Animal models will be used in these studies, and we have adapted a variety of functional assays for CD8 T cells for use with lung cells. These complementary aims will provide a definitive picture of the CD8 T cell response in tuberculosis, and contribute to a greater understanding of the challenges facing vaccine development and design against this disease. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: FUNTIONAL GENOMICS OF INTERFERON FOR TUBERCULOSIS Principal Investigator & Institution: Pine, Richard I. Assistant Member; Public Health Research Institute 225 Warren St Newark, NJ 07103
Studies 49
Timing: Fiscal Year 2001; Project Start 10-SEP-2001; Project End 31-JUL-2006 Summary: Interferon-gamma (IFNgamma) is a cytokine released by TH1 lymphocytes in tuberculosis and is an essential mediator of the cellular immune response, producing macrophage activation. Signaling is transduced through activation of STAT-1, a latent transcription factor, and leads to induced expression of other transcription factors. STAT-1 and the other transcription factors like IRF-1 together increase expression of effector genes such as iNOS. We have been conducting a clinical trial of aerosolized IFNgamma as treatment for pulmonary tuberculosis and have reported that patients with multi-drug resistant tuberculosis improved on this regimen. We now report that aerosolized IFNgamma induces STAT-1 and IRF transcription factors in lung cells. Treatment also markedly reduces HIV-1 levels in the lungs of AIDS patients with tuberculosis, providing further evidence of enhanced lung immunity produced by pharmacological doses of IFNgamma. THP-1 macrophages and alveolar macrophages are similar with regard to induction of STAT-1, IRF-1 or IFR-9 (also called p48 and ISGF3-gamma) after infection with M. tuberculosis (M.tb) or IFNgamma treatment. THP-1 macrophages respond to IFNgamma with increased IRF-9 mRNA but do not change its transcription, demonstrating that IRF-9 is up-regulated by posttranscriptional mechanisms such as splicing or message stability. We used functional genomics to identify other IFNgamma responsive genes. Of 4375 genes present on a high density filter array, 48 were induced and 13 were repressed after 4 hours of IFNgamma stimulation. Only 15 of these 61 genes have been reported to be responsive to IFNgamma Finally, with the goal of assaying genome wide transcription rates, we have developed a novel assay for transcription using Br-UTP labeled nascent RNA. Our goal is to identify genes unique to the cellular immune response during tuberculosis in vivo and genes induced or repressed by IFNgamma and/or M.tb. ex vivo and in vivo. We propose to use functional genomics to identify the genes induced and repressed in: 1) THP-1 macrophages infected with M.tb and/or treated with IFN-gamma in vitro 2) Alveolar macrophages infected with M.tb and/or treated with IFNgamma ex vivo and 3) Bronchoalveolar lavage cells from tuberculosis patients before and after aerosolized IFNgamma. We will then assay transcription rates of the genes that are IFN responsive to define the contribution of transcriptional and post transcriptional regulation to mRNA abundance. We hypothesize that like IRF-9, other genes important to the IFNgamma response are post-transcriptionally regulated in macrophages. This analysis will further the understanding of cellular immunity in tuberculosis and gene expression regulated by IFNgamma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENE EXPRESSION IN MYCOBACTERIUM TUBERCULOSIS Principal Investigator & Institution: Clark-Curtiss, Josephine E. Research Associate Professor; Biology; Washington University Lindell and Skinker Blvd St. Louis, MO 63130 Timing: Fiscal Year 2001; Project Start 01-FEB-2000; Project End 31-JAN-2004 Summary: Tuberculosis, one of the great scourges of humankind, is the leading cause of death worldwide from a single infectious disease. Although the incidence of TB has again begun to decline in the U.S., TB remains a significant health problem in this country, most frequently affecting the elderly, the homeless, individuals with AIDS and immigrants from nations where TB is endemic. Although the causative agent of TB, Mycobacterium tuberculosis, was identified a century ago, knowledge about fundamental physiological capabilities, the genetics and the mechanisms of pathogenicity of M. tuberculosis is only now beginning to emerge. We have identified
50 Tuberculosis
several genes which are expressed by M. tuberculosis H37Rv when the bacilli are growing in human macrophages in culture, but which are not expressed by the bacilli when they are growing in laboratory broth culture. We hypothesize that these genes and their products may be important in the survival and growth of M. tuberculosis in macrophages and may contribute to the pathogenicity of the tubercle bacilli. We propose to (1) determine the contribution of specific macrophage-expressed gene products to survival and growth of M. tuberculosis in macrophages by molecular and genetic characterization of genes on a cosmid that appear to be coordinately expressed, a putative response regulator gene, and mceD, a gene that has been shown to enhance survival of E. coli in cultured macrophages; and (2) to identify and characterize genes and gene products of M. tuberculosis that are expressed at early times after phagocytosis, at late times, and throughout growth in human macrophages in culture. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENE MACROPHAGES
EXPRESSION
OF
M.TUBERCULOSIS
WITHIN
Principal Investigator & Institution: Mcdonough, Kathleen A. Research Scientist; Wadsworth Center Empire State Plaza Albany, NY 12237 Timing: Fiscal Year 2001; Project Start 01-JUL-2000; Project End 30-JUN-2005 Summary: (Adapted from the Applicant's Abstract): The long term objective of this proposal is to gain a better understanding of how Mycobacterium tuberculosis establishes infection so that effective strategies can be developed to prevent it. A multidisciplinary approach will focus on the interaction of tubercle bacilli with macrophages at the molecular, genetic and cellular levels, with an emphasis on M. tuberculosis gene expression within macrophages. The specific aims are: 1) Identifying M. tuberculosis genes that are induced when bacteria are within macrophages by 2D gel electrophoresis coupled with mass spectrometry. 2) Identifying class-specific regulatory motifs among intracellular induced promoters using a combination of molecular and computational techniques. 3) Characterizing the roles in the M. tuberculosismacrophage interaction of selected intracellular induced M. tuberculosis genes. Assays will include bacterial survival, replication and trafficking in macrophages. 4) Assessing the role of cAMP signaling in M. tuberculosis within macrophages by defining the distribution and expression among mycobacteria of genes encoding novel cyclase and cyclic NMP binding proteins; estimating the minimum number of cAMP-responsive proteins using 2D gels; and determining the effects of a novel adenylate cyclase gene knock-out on M. tuberculosis interaction with macrophages using tissue culture, microscopy, and 2D gel analyses. This work will contribute to our understanding of the factors needed for the establishment of tuberculosis infection and disease and will identify potential targets for tuberculosis vaccines, therapeutics, and diagnostic purposes. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENES TUBERCULOSIS
FOR
METHY1-BRANCHED
WALL
LIPIDS
AND
Principal Investigator & Institution: Kolattukudy, Pappachan E. Professor and Directpr; Neurobiotechnology Center; Ohio State University 1800 Cannon Dr, Rm 1210 Columbus, OH 43210 Timing: Fiscal Year 2001; Project Start 15-JAN-2000; Project End 31-DEC-2003
Studies 51
Summary: Resurgence of tuberculosis (TB) and other mycobacterial infections associated with AIDS threaten human health world-wide. Emergence of drug resistant TB makes it critical to discover new drug targets. Cell walls of Mycobacterium tuberculosis contain a variety of unusual lipids with many types of multiple methylbranched fatty acids that are unique to pathogenic mycobacteria. These lipids are thought to play important roles in the ability of the pathogens to resist antimicrobial agents and evade the defense reactions of the host. Biosynthesis of these unique lipids containing multiple methyl-branched fatty acids could offer ideal targets for new anti mycobacterial drugs. Genomic sequencing revealed that a remarkably unique feature of the mycobacterial genome is that it contains an unusually large number of genes involved in lipid metabolism. Based on the homology to mycocerosic acid synthase (mas) we have identified two classes of polyketide synthase (pks)-like genes which contain a full complement of active site domains that should be involved in the catalysis of all of the steps required for the synthesis of multimethyl- branched fatty acids: Class 1 mas-like genes mas-like genes (msl1, msl2 and msl3) that are highly homologous to mas and Class 2 (msl4m msl5, msl6 and msl7) which show a lesser degree of homology to mas. These open reading frames (ORFs) most probably encode the more than eight classes of methyl-branched fatty acids found in M. tuberculosis. To elucidate the function of these genes and to examine their possible role in the host-pathogen interaction, we propose to pursue the following specific aims: 1) Determine the functions of Class 1 mas-like genes, ms1, msl2 and msl3 of M. tuberculosis by characterization of their products expressed in M. smegmatis, and by determination of the biochemical and functional consequences of their disruption. 2) Determine the functions of Class 2 (msl4, msl5, msl6 and msl7) mas-like genes in M. tuberculosis genome, by characterization of their products expressed in M. smegmatis, and by determination of the biochemical and functional consequences of their disruption. 3) Determine whether lack of specific lipids caused by the above gene-disruptions affects host-pathogen interaction and virulence. The results will help identify cell wall lipids critical for pathogenesis that might be suitable targets for new anti-mycobacterial drugs. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC DISSECTION OF MYCOBACTERIAL INFECTION Principal Investigator & Institution: Schurr, Erwin; Associate Professor; Mc Gill University James Admin. Bldg., Room 429 Montreal, PQ H3A 2T5 Timing: Fiscal Year 2001; Project Start 14-SEP-2001; Project End 31-JUL-2006 Summary: (provided by applicant) The objective of the studies proposed in this application is to identify genotypic combinations of mice and mycobacteria that result in significant alterations of host responses to experimental mycobacterial infection. Susceptibility or resistance to experimental infection will be defined by determination of median survival time, weight loss, mycobacterial load in the lung and spleen, and in addition various immunological parameters in lung and other tissues. In these experiments, the host genome will be varied by use of 37 recombinant congenic strains (RCS), which are derived from inbred progenitors that are either susceptible to tuberculosis (A/J, abbreviated A) or resistant to tuberculosis (C57BL/6J, abbreviated B). The AcB/BcA RCS are now fully inbred and genotyped with a dense set of genomewide microsatellite markers. These strains will be infected with a panel of Mycobacterium tuberculosis and M. bovis strains that have been deleted for genome regions associated with attenuation of BCG vaccines. The infection protocol in the RCS will reveal informative, significant deviations from the "expected" or "parental" disease phenotypes which signify the presence of quantitative trait loci (QTL) with strong effect
52 Tuberculosis
on phenotype expression and possibly specific gene(s) interaction between the host and pathogen. In RCS carrying QTL with strong effect on phenotype expression, changes in gene expression level in both lung macrophages and intracellular mycobacteria will be revealed by microarray analysis. The knowledge to what extent host responses in mycobacterial infections are a reflection of specific host pathogen combinations will be crucial for our understanding of the epidemiological flow of M. tuberculosis through an exposed population. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC FACTORS AND SUSCEPTIBILITY TO TUBERCULOSIS Principal Investigator & Institution: Goldfeld, Anne E.; Cbr Institute for Biomedical Research 800 Huntington Ave Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 30-JUN-2004 Summary: The host factors and mechanisms involved in the pathogenesis of pulmonary tuberculosis in the setting of AIDS as well as in the normal host are poorly understood. The long term objective of this project is to further identify and to characterize host factors that predispose individuals to develop pulmonary tuberculosis. Preliminary data indicate an association of an HLA allele, the HLA-DQB1*0503 class II allele, with susceptibility to pulmonary tuberculosis in Cambodia. Specific Aim 1 will determine whether the same or different HLA alleles are associated with TB progression in a genetically distinct population from South Africa. The TNF-alpha gene occurs in the class III region of the major histocompatibility complex (MHC) and its protein product plays a critical role in the containment of tuberculosis infection. Studies will include the identification of polymorphisms and microsatellites in the tumor necrosis factor-alpha (TNF-alpha) gene, and their association to tuberculosis susceptibility. Specific Aim 2 will characterize the mechanisms of activation of the TNF-alpha gene by mycobacteria. By using the TNF-alpha gene promoter as a target, these studies could define the molecular mechanisms of the activation of this important gene by mycobacteria. Specific Aim 3 proposes to investigate the genetic and molecular determinants of anergy in the setting of pulmonary tuberculosis. This aim will investigate whether there is an HLA association with anergy or lack of DTH, and will characterize the cytokine profiles and T cell proliferative responses in anergic pulmonary tuberculosis patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETIC TUBERCULOSIS
STUDIES
OF
HUMAN
SUSCEPTIBILITY
TO
Principal Investigator & Institution: Scott, William K. Associate Research Professor in Medicine; Medicine; Duke University Durham, NC 27706 Timing: Fiscal Year 2001; Project Start 10-SEP-2001; Project End 31-JUL-2006 Summary: (provided by applicant) Tuberculosis (TB) is currently and historically an enormous public health problem. Approximately one-third of the world's population are currently infected with Mycobacterium tuberculosis (M. tuberculosis) and TB accounts for over 25% of preventable adult deaths world-wide. Despite the high infection rate, only about 10% of people infected with M.tb ever become sick with active TB. Evidence suggests that progression to active TB is influenced by host genetic factors. For example, the epidemiology of TB suggests that genetic selection takes place after introduction of M. tuberculosis to the population; genetically susceptible individuals succumb to the infection and relatively resistant individuals survive to reproduce. As well, twin studies demonstrate higher concordance rates for TB among identical twins,
Studies 53
compared to fraternal twins. Mouse models of mycobacterial infection have identified several potential susceptibility loci, such as the gene named Nramp1, as well as several cytokine and cytokine receptor genes. Family-based linkage studies and case-control studies of candidate genes in humans suggest roles for these and other genes associated with development of TB in humans. In light of these observations, we propose a familybased association study of candidate genes for TB susceptibility. To accomplish the goal of identifying genes influencing susceptibility to TB we specifically propose to: 1) Ascertain 1,000 parent- child triads (500 Caucasian, 500 African-American) from North and South Carolina for genetic studies of TB susceptibility genes. 2) Test candidate genes in the first 500 parent-child triads. Multiple single nucleotide polymorphisms (SNPs) will be genotyped in each gene and analyzed using family- based tests of association; significant results will be followed-up in the remaining 500 triads. 3) Examine the relationship between candidate genes and other clinical variables such as PPD skin test results, disease severity, treatment relapse and failure, and presence of extrapulmonary disease. 4) Evaluate gene-gene and gene-environment interactions using multivariable models and data reduction techniques such as the multifactor dimensionality reduction (MDR) method. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC SUSCEPTIBILITY TO MYCOBACTERIUM TUBERCULOSIS Principal Investigator & Institution: Kramnik, Igor; Assistant Professor of Immunology & Infe; Immunology/Infections Diseases; Harvard University (Sch of Public Hlth) Public Health Campus Boston, MA 02460 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 30-JUN-2006 Summary: (provided by the applicant): It is projected that a total of 225 million new cases of tuberculosis will occur between 1998 and 2030. The outcome of primary infection with Mycobacterium tuberculosis (MTB) varies and, in immunocompetent hosts, imparts only a 10 percent lifetime risk of developing clinical disease. The significant variation in tuberculosis susceptibility among immunocompetent individuals remains unexplained. Differences in the outcome of tuberculosis infection in the setting of similar risk factors support a significant role of the host genetic background in predisposition to progression towards clinical disease. Therefore, identification of genetic factors associated with susceptibility to tuberculosis will have important implications for controlling the disease. We use a mouse experimental model of infection with virulent strain of MTB to characterize genes that are responsible for control of tuberculosis infection in immunocompetent hosts. We have identified and mapped to a 2 cM interval on mouse chromosome 1 a novel locus (sst1) that significantly contributes to control of growth of virulent MTB primarily in the lungs. Observations on its phenotypic expression demonstrate that genetic mechanisms controlling infection with virulent MTB are distinct from those that control an avirulent vaccine strain of M bovis BCG. Having generated a set of sst1-congenic inbred strains of mice, we propose to use them (1) to isolate the sst1-candidate genes by positional cloning; (2) to identify genetic polymorphism responsible for tuberculosis susceptibility; (3) to identify cells and functional pathways affected by the sst1 polymorphism. The proposed project will identify the nature and mechanism of action of the sst1 in mice, which in the future should permit isolation of its human homologue and the analysis of its role in tuberculosis susceptibility in humans. The understanding of genetically determined mechanisms that operate during the course of tuberculosis infection in the lung will provide new insights into the pathogenesis of tuberculosis and suggest improved strategies for treatment and prevention of the disease.
54 Tuberculosis
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GENETIC/IMMUNOLOGICAL BASIS OF TUBERCULOSIS AND ANERGY Principal Investigator & Institution: Delgado, Julio C.; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-2001; Project End 31-JUL-2006 Summary: (provided by applicant): The purpose of this Clinical Investigator Development Award is to prepare the candidate, Dr. Julio C. Delgado, MD, for a career as an independent investigator in infectious diseases with a special emphasis on the genetic and immunological mechanisms associated with susceptibility to tuberculosis infection. The applicant proposes a 5-year training and research program that will prospectively identify novel host factors that predispose individuals to develop pulmonary tuberculosis in a population from Cambodia and characterize the events associated with the anergic state induced by tuberculosis infection in the intact human host. In Specific Aim 1, he will test the hypothesis that HLA molecules are functionally associated with tuberculosis progression and differential immune response to PPD and whether polymorphisms of the promoter region of certain cytokines are associated with impaired immune response against tuberculosis infection. In Specific Aim 2 and 3, he will characterize immunological and chromatin structural mechanisms associated with anergy to PPD in a cohort of tuberculosis patients from Cambodia with persistent and specific lack of response to PPD. Tuberculosis infection and pathogenesis are the result of a balance between the virulence of a particular invading organism and the host immune response. Susceptibility to tuberculosis in human populations is likely to be due to a complex interaction between several genetic, immunological and environmental factors. The experiments proposed in this application would attempt to identify host genetic factors and unveil abnormal immunological mechanisms leading to increase risk of clinical tuberculosis disease. It is anticipated that these results will be useful in the development of genetic and immune therapeutic strategies to combat tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GENETICS OF M TUBERCULOSIS PERSISTENCE & DRUG TOLERANCE Principal Investigator & Institution: Gomez, James E. Lab/Infection Biology; Rockefeller University New York, NY 100216399 Timing: Fiscal Year 2001; Project Start 01-APR-2001 Summary: (provided by the applicant): One of the primary reasons that our arsenal of drugs has failed to lead to the successful control of tuberculosis is the ability of the etiologic agent, Mycobacterium tuberculosis (Mtb), to persist within the host tissues, where the drugs that readily kill this bacterium in vitro require prolonged periods of time to achieve similar effects. The extended duration of chemotherapy required to cure a human (6-12 months) is one of the greatest barriers to effective TB control. Poor patient compliance may lead to chronic infection, either active or latent, and the emergence of drug resistant Mtb. The underlying biology of persistent Mtb infection is poorly understood, and therefore, the objectives of this study are as follows: I) to better characterize the "persistent state" by examining drug efficacy and bacterial division at a variety of stages of infection in the mouse model; 2) to identify Mtb genes required for persistence in a mouse model using signature-tagged mutagenesis (STM); and 3) to identify Mtb genes that are required for the increased tolerance of Mtb to
Studies 55
chemotherapeutic agents in vivo, again using STM in the mouse model. Achievement of these aims will provide a basis for the rational development of novel therapeutics that target persistent bacilli, thereby shortening the time required to achieve a cure. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GLUTAMINE SYNTHETASE INHIBITORS FOR TUBERCULOSIS THERAPY Principal Investigator & Institution: Atkins, William M. Medicinal Chemistry; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2005 Summary: (Provided by the applicant:) Infection by Mycobacterium tuberculosis (MBT) is a significant complication experienced by many AIDS patients. Recently, the enzyme glutamine synthetase (GS) has become a new therapeutic target for MTB, due to the demonstration that secretion of enzymatically active MBT GS is required for survival and pathogenecity of the organism. The long-term goal of the proposed research is to develop inhibitors of MBT GS with potential therapeutic use. Many in vitro inhibitors of bacterial GS's have been documented, but none are useful clinically. In order to initiate MBT GS inhibitor design, a portion of this proposal is aimed at understanding its molecular properties, in comparison to the well studied E. coli GS. If comparable to the E. coli GS, then a new strategy will be pursued to obtain inhibitors that are more potent and selective than any previously described compounds. Specifically, the highly symmetrical ring structure of GS will be exploited to design a library of multivalent inhibitors which bind to the flexible loop on several subunits, in contrast to the monovalent inhibitors previously targeted individually to the active sites. The specific aims are: 1) To determine whether structural modification of the central loop on each subunit results in loss of enzyme activity. Because the modification of the central loop of the E. coli GS does lead to loss of activity, it is anticipated that this will be the case for MBT GS; 2) To design, synthesize and screen libraries of multivalent inhibitors targeted to the central loops of MBT GS, and to E. coli GS, for 'proof-of-principle.' Demonstration of the utility of multivalent inhibitors targeted to the central loops of MBT GS would provide a new rationale for GS inhibition and possibly for tuberculosis therapy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: GLYCOPROTEINS OF MYCOBACTERIUM TUBERCULOSIS Principal Investigator & Institution: Belisle, John T. Associate Professor; Microbiology, Immunology & Pathology; Colorado State University Fort Collins, CO 80523 Timing: Fiscal Year 2001; Project Start 01-FEB-1999; Project End 31-JAN-2004 Summary: (Adapted from the Applicant's Abstract): In response to the NIH Program Announcement calling for more basic information regarding the biology, immunology and pathogenesis of this disease, the investigators present the hypothesis that past failures in vaccine development against tuberculosis have been due to the inability to emulate the immunogenicity of the whole bacillus due to failure to recognize the importance of appendages that covalently modify key protective protein antigens. The differential immunological reactivity of native and E. coli recombinant forms of mycobacterial proteins as well as our own preliminary data support this principle. Recently, the investigators provided definitive chemical proof that some M tuberculosis proteins are glycosylated. They have now extended these studies to demonstrate that the M tuberculosis proteome possesses a number of such structures and that glycosylation plays a direct role in immunological recognition of M tuberculosis
56 Tuberculosis
proteins, facts which now portend new approaches to vaccine and serodiagnostic antigen development. To address the issue of the contribution of aprotein components to immunological recognition of protein antigens, they will (i) exploit their proven strengths in protein chemistry to demonstrate the relative abundance of glycoproteins in the M tuberculosis proteome and provide a precise chemical characterization for a large number of these molecules; (ii) apply this structural information, some of which is already in hand, to immunological assays in both the human and murine systems, to provide a detailed understanding of how the host's acquired immune system responds to M tuberculosis glycoproteins; and (iii) initiate studies of the biosynthesis of the posttranslationally modified, and specifically mannosylated, proteins, which will yield information and new tools for full evaluation of the general biological, particularly immunological, significance of protein glycosylation and lipidation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: GROWTH ACTIVATING FACTOR FOR MYCOBACTERIUM TUBERCULOSIS Principal Investigator & Institution: Griffin, John P.; Mycos Research, Llc 217 Racquette Dr, #6 Ft. Collins, CO 80524 Timing: Fiscal Year 2001; Project Start 01-JUL-2001; Project End 30-JUN-2002 Summary: (provided by applicant): In this proposal we are requesting funding for proof of principle research into Mycobacterial Growth Activating Factors (GAFs). The longterm objective of these studies is the production of a commercial product that would significantly reduce the time required for diagnosis and drug susceptibility screening of tuberculosis. The aims of this proposal are to: (1) establish the growth promoting characteristics of GAFs using both clinical and laboratory isolates of M tuberculosis. (2) Evaluate the potential use of GAFs in drug susceptibility testing. (3) Determine the effects of GAFs in a clinical setting. And (4) Evaluate derivatives of our defined peptides for potential activity and test for synergistic combinations. If successful, these products could lead to multiple innovative uses that range from the improvement of diagnoses in developing nations to significantly faster identification of efficacious therapeutic drug regimens. PROPOSED COMMERCIAL APPLICATION: MycoQuick Growth Media: A culture medium supplement that reduces the time required for the culture of slow growing mycobacteria species. This in turn will significantly reduce the lengthy time required for laboratory diagnosis of infection with M. tuberculosis. Rapid diagnosis will also permit the timely initiation of drug therapy in these patients and permit rapid drug resistance profiling. MycoQuice Diagnostic Kit: A diagnostic kit for M- tuberculosis, specifically targeted for use under laboratory conditions commonly encountered in developing nations. This product will incorporate the MycoQuick growth medium in pre-prepared assemblies with or without drugs commonly prescribed and antituberculosis therapy. MycoQuick Kit will facilitate both rapid diagnosis and drug susceptibility profiling in a format conducive for use under the less stringent conditions found in distant third world sites. This product may have a significant impact in these regions where tuberculosis is endemic. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HEAT SHOCK PROTEIN BASED VACCINE FOR TUBERCULOSIS Principal Investigator & Institution: Mo, Annie Xy.; Antigenics, Inc. 34 Commerce Way Woburn, MA 01801 Timing: Fiscal Year 2003; Project Start 01-JUN-2003; Project End 30-NOV-2003
Studies 57
Summary: (provided by applicant): Mycobacterium tuberculosis is a continuing health threat both in the United States and the rest of the world with an estimated two billion people currently infected worldwide. Antibiotic regimens requiring lengthy direct observation of patients and the emergence of drug resistant strains create a pressing need for novel therapies. One such novel therapy is the use of heat shock protein to adjuvant a tuberculosis peptide vaccine for optimal generation of cell-mediated immune response. Heat shock protein-peptide complexes are recognized by HSP receptors on antigen presenting cells. Peptides chaperoned by HSP are then represented by MHC Class I and II molecules leading to cell mediated immunity including stimulation of antigen-specific CD4+ and CD8+ T cells. Cell mediated immunity is an important major protective mechanism in tuberculosis. The ability of heat shock protein-peptide complexes to elicit T cell responses may address a shortcoming of traditional tuberculosis vaccines that primarily elicit antibody responses. The proposed product will consist of Mycobacterium tuberculosis antigens complexed in vitro to mammalian heat shock protein 70. Total cytosolic and culture filtrate fractions from M tuberculosis will be obtained and subjected to proteolysis with highly selective proteases to generate a large array of peptides containing T cell epitopes. Murine heat shock protein 70 will be complexed to the TB peptide extract and utilized as a vaccine. The product will be evaluated in mice for induction of cellular immune responses, assessed by antigen-specific cytotoxicity, cytokine response, and proliferation. The ultimate purpose of the research funded by this grant is to ascertain whether it will be possible to utilize the heat shock protein technology to generate a novel and efficacious therapeutic vaccine. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HETEROGENEITY OF T CELLS IN M TUBERCULOSIS INFECTION Principal Investigator & Institution: Boom, W Henry. Professor of Medicine; Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001; Project Start 01-FEB-1989; Project End 31-MAR-2002 Summary: (Adapted from the applicant's abstract): T cells have a critical role in regulating the protective immune response to Mycobacterium tuberculosis. As a result of studies supported by AI-27243, our understanding of the interaction between human T cells and macrophages in response to M. Tuberculosis has increased substantially during the last five years. First, M. Tuberculosis antigens activate three major T cell subsets from healthy tuberculin positive donors: V delta2 + gamma delta TCR bearing T cells (gamma delta T cells and CD8+ alpha beta (ab) TCR+ T cells (CD 8 T cells) in addition to CD4+ ab T cell receptor (TCR) bearing T cells (CD 4 T cells. Second, all three T cell subsets produce IFN-gamma and can serve as cytotoxic effector cells (CTL) against M. Tuberculosis infected macrophages, fitting into a Th-1 like pattern. These findings allow refinement of the model in which control of mycobacterial growth and maintenance of immunity requires the activation not only of CD4+ T cells and gamma delta T cells, but also of CD8+ T cells. This model postulates that there is a defined sequence of T cell subset recruitment and that the antigen processing mechanisms used by M. Tuberculosis infected mononuclear phagocytes are critical in the recruitment of T cell subsets and in determining the antigen repertoire recognized by CD4+, CD8+ and gamma delta T cells. In addition, the model postulates that both secretion of macrophage activating cytokines and CTL effector function are necessary for protective immune responses to M. Tuberculosis. There are three specific aims to test the postulates of this model: 1. To further characterize a 10-14KD M. tuberculosis antigen for V delta2+ gamma delta T cells, to determine if the antigen can be detected on the
58 Tuberculosis
surface of mononuclear phagocytes for presentation to V delta2+ gamma delta T cells and to determine if gamma delta T cells activated by this antigen enhance the production by mononuclear phagocytes of chemokines (MIP-1alpha/beta, RANTES) and cytokines (IL-12, IL-15) that promote T cell recruitment and differentiation into CTL. 2. To characterize the antigen processing pathways of M. tuberculosis antigens for class II MHC presentation to CD4+ T cells, using the 30kD 85B antigen as model antigen. 3. To characterize the repertoire of antigens, the antigen-processing pathway and CTL function of CD8+ T cells reactive to M. tuberculosis in comparison to CD4+ and gamma delta T cells. These studies will provide insight into the regulation of human T cell subsets involved in protective immunity to M. tuberculosis, which is necessary for the design of improved vaccines, and immunotherapies for tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HIV PREVENTION/ALCOHOL TREATMENT IN A RUSSIAN TB SAMPLE Principal Investigator & Institution: Fleming, Michael F. Professor; Family Medicine; University of Wisconsin Madison 750 University Ave Madison, WI 53706 Timing: Fiscal Year 2001; Project Start 28-SEP-2001; Project End 31-AUG-2003 Summary: (provided by applicant): HIV infection, tuberculosis, and hazardous drinking are of increasing concern in Russia. While the number of officially registered cases of HIV infection as of October 31, 2000 was 69,120, experts expect an exponential increase in the number of Russian people infected with the human immunodeficiency virus in the next 10 years. Incident cases of TB and multi drug resistant tuberculosis in Russia are among the highest in the world. Mortality rates exceed 10% with over 125,000 persons receiving medical treatment for active TB in 1999. Hazardous drinking is common and a major source of morbidity and mortality in Russia. Alcohol use also complicates prevention and treatment programs for HIV infection and TB. Russia shares borders with 13 countries. The global health implications of a large reservoir of HIV infection and tuberculosis in a country that crosses 8 time zones is enormous. Now is the time to prevent the spread of HIV infection and tuberculosis in Russia and neighboring countries. Potential strategies include testing of HIV prevention programs (i.e., Project RESPECT) and treatment programs to reduce rates of hazardous drinking. This proposal is designed to increase our understanding of HIV risk factors, and to increase the role and treatment of alcohol use disorders in the prevention of HIV infection in the context of a TB treatment population. This proposal will conduct the following 3 studies in St. Petersburg and Ivanovo, Russia: a) a prevalence study designed to assess the frequency of HIV risk factors and alcohol use in a patient population being treated for tuberculosis (n=600); b) a naturalistic study designed to assess the effects of alcohol use on HIV risk behaviors and TB treatment outcomes (n=200); c) a combined day-treatment program for HIV risk reduction and alcohol treatment (n=80). The data from these studies will provide new information. The findings are expected to facilitate the development, testing and implementation of HIV prevention and alcohol treatment programs. It is hoped that these programs can reduce the spread of HIV infection and TB in Russia and neighboring countries. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HIV/TB INTERACTION IN THE LUNG Principal Investigator & Institution: Weiden, Michael D. Medicine; New York University School of Medicine 550 1St Ave New York, NY 10016
Studies 59
Timing: Fiscal Year 2001; Project Start 01-APR-1999; Project End 30-MAR-2004 Summary: We have shown that HIV-1 replication is suppressed in uninflamed lung and increased during tuberculosis. In vitro, we recently showed that monocytes increase HIV-1 replication after infection with M. tb. but, surprisingly, we now show M. tb infection inhibits HIV-1 replication in macrophages. Suppression of HIV-1 replication is associated with repression of the HIV-1 LTR and induction of ISGF-3, an interferonalpha/beta (IFN)-specific transcription-factor complex. Monocytes do not induce ISGF-3 after IFN treatment or infection with M. tb. Intact C/EBP sites in the HIV-1 LTR negative regulatory element (NRE) are required for promoter repression. Macrophages but not monocytes induce an inhibitory 16-kDa C/EBP-Beta isoform coincident with the HIV-1 LTR repression. Low-dose IFN-Beta represses the HIV-1 LTR and induces the 16kDa inhibitory C/EBP-Beta. During LTR repression, C/EBP-Beta is present in over 95 percent of the NRE/protein complexes. Mouse bone- marrow macrophages deficient in an IFN receptor do not produce the C/EBP-Beta repressor after an inflammatory stimulus. Taken together, these data suggest that, in vitro, proinflammatory stimulation of macrophages produces an antiviral IFN response that induces a C/EBP-Beta transcriptional repressor and inhibits LTR-mediated transcription. In vivo, alveolar macrophages from uninflamed lung are like macrophages treated with IFN-Beta in vitro; both strongly express inhibitory 16-kDa C/EBP-Beta and inhibit HIV-1 replication. Pulmonary tuberculosis abolishes C/EBP-Beta expression and induces a novel C/EBP DNA binding protein in involved lung segments of both HIV-1- infected and immunocompetent patients. Stat-1 homodimer (an IFN-gamma-specific transcription factor) is also induced, but only in immunocompetent tuberculosis patients. A plausible hypothesis for these observations is as follows: In the absence of inflammation, alveolar macrophages are primed by low doses of IFN-Beta. The cellular immune response in pulmonary tuberculosis disrupts this innate immunity, switching C/EBP expression in both HIV-1-infected and immunocompetent patients. The failure to produce IFNgamma in AIDS patients allows high-level viral replication. This proposal will investigate the regulation of IFN-mediated immunity in uninflamed lung and in tuberculosis. It will also model stimulation of viral replication in tuberculosis and assess how HIV-1 infection alters IFN response. It will investigate the mechanism and effects of inhibitory C/EBP-Beta induction. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST & PATHOGEN DETERMINANTS OF M TUBERCULOSIS LATENCY Principal Investigator & Institution: Kaplan, Gilla; Full Member; Public Health Research Institute 225 Warren St Newark, NJ 07103 Timing: Fiscal Year 2002; Project Start 15-SEP-2002; Project End 30-JUN-2007 Summary: (provided by applicant): Our aim is to define the host and bacterial factors that characterize the clinical and microbiologic latency which distinguish human tuberculosis. We hypothesize that in human tuberculosis, persistent/latent infection is associated with a different immune response than active chronic disease. For Mycobacterium tuberculosis to survive in the face of these varying host immune responses, it must alter its physiology through differential changes in gene expression. Thus a particular clinical state associated with a specific state of immunity will elicit a corresponding profile of genes expressed by the infecting organism ("molecular mirror"). We will utilize M. tuberculosis infected lung tissue obtained from surgical resection of TB patients with active disease, or asymptomatic persistent infection, or recurrent disease. These tuberculous lung specimens will be used to characterize the
60 Tuberculosis
host immune response by histology and immunohistology combined with real time RTPCR with molecular beacons to quantitate leukocyte gene expression in the lung. Our collaborator, Dr. John McKinney, will use the same tissues to identify the patterns of M. tuberculosis gene expression in each type of disease. In addition, we will use the rabbit model of M. tuberculosis infection to generate animals with either active disease or persistent asymptomatic infection (latency). Rabbits will be infected with clinical strains of M. tuberculosis of differing degrees of virulence to recreate the range of human disease. Tissues from rabbits with each form of the disease will be used to characterize the cellular response to infection in the lung and to elucidate the patterns of M. tuberculosis gene expression associated with either active disease or persistent asymptomatic infection (latency). We will also infect rabbits with M. tuberculosis mutants selected to be defective for persistence in murine models and establish whether these mutants retain their persistence defect in the rabbit model. By combining the results obtained from the rabbit studies and the human studies, we will validate our experimental animal model as a mirror of human disease and use the model to identify the molecular correlates of M. tuberculosis latency. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST DEFENSE FUNCTIONS OF M. TUBERCULOSIS LIPOGLYCAN Principal Investigator & Institution: Chan, Edward D. Associate Professor; National Jewish Medical & Res Ctr and Research Center Denver, CO 80206 Timing: Fiscal Year 2001; Project Start 15-JUL-2001; Project End 31-MAY-2006 Summary: (Adapted from the Applicant's Abstract): Tuberculosis (TB) is the leading cause of death by an infectious agent. Macrophages play a pivotal role in the control of Mycobacterium tuberculosis through the expression of nitric oxide (NO.) and TNFalpha. NO plays an important mycobactericidal role in murine TB and is increasingly recognized to be important in humans. The overall hypothesis of this proposal is that macrophages, by specific surface receptor(s), recognize mycobacterial cell wall products to initiate iNOS- and TNFa-induction. Hence, the focus of this proposal is to: i) determine the receptor and signaling mechanisms which regulate iNOS and TNFa following exposure to the mycobacterial cell wall component lipoarabinomannan (ManLAM) and ii) to determine the significance of each of these components in an in vitro model of infection. Based on experiments showing that macrophages from the Toll-like receptor 4 (TLR4)-mutant C3H/HeJ mice produced significantly lower levels of NO than TLR4-intact C3H/HeN macrophages in response to IFNg + ManLAM, we hypothesize that ManLAM engages a TLR to induce iNOSNO*/ TNFa expression. Since non-mannose capped LAM (AraLAM) from M. smegmatis induced greater NO about expression than ManLAM, we hypothesize that ii) the exposed arabinose residues on ManLAM or AraLAM are the components of ManLAM that bind to its putative TLR. Since initial studies show that the mitogenactivated protein kinases (MAPKs) and NFkB signaling pathways regulate iNOS and TNFa expression, we hypothesize that the proximal kinase MAP/ERK kinase kinase (MEKK) is a pivotal regulator for ManLAM-induction of iNOS and TNFa. Lastly, because TLRs recognize pathogen-derived molecules and enhance host-defenses, we hypothesize that blocking one or more of the TLRs will enhance the growth of M. tuberculosis and inhibit NO* and TNFa expression. These hypotheses will be addressed by three specific aims: 1. To determine the ManLAM structures that mediate the induction of iNOS-NO*/TNFa and the receptor that mediates these ManLAM effects. 2. To investigate the role of the MAPK and NFkB signaling pathways in ManLAM- and other lipoglycan-induced iNOS-NO* and TNFa. 3. To elucidate the role of the TLRs,
Studies 61
MAPK and NFkB signaling pathways, and ManLAM in controlling the growth of M. tuberculosis in mouse and human macrophages and to correlate effects on growth with NO* and TNFa expression. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST DETERMINANTS OF INFECTIOUSNESS IN TUBERCULOSIS Principal Investigator & Institution: Fennelly, Kevin P. Assistant Professor; Medicine; Univ of Med/Dent Nj Newark Newark, NJ 07103 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: Both experimental and epidemiological data suggest that there is a wide range of infectiousness among patients with tuberculosis. Although much research has focused on the virulence of the organism, little is known of the host determinants of infectiousness. A novel Cough Aerosol Sampling System (CASS) can isolate and quantify (viable airborne Mycobacterium tuberculosis from individual patients with pulmonary tuberculosis. We hypothesize that the production of viable aerosols of M. tuberculosis determined by this method is correlated with infectiousness. Our central hypothesis is that most of the variability of infectiousness in tuberculosis is explained by non-immunological host factors including the duration of antimycobacterial therapy with drugs to which the organism is susceptible, the strength and frequency of coughing, and the physicochemical properties of the sputum. The first specific aim is to correlate viability assessed by the air sampling method used in the CASS and infectiousness using the mouse and guinea pig models. The second aim is to determine if the infectiousness of tuberculosis decreases rapidly with appropriate antimycobacterial therapy. The third aim is to assess whether cough strength and frequency are associated with the quantity of viable aerosol. The fourth aim is to determine if infectiousness is associated with physicochemical properties of sputum. These data may alter clinical practice and public health control measures. Changes in tuberculous aerosol viability associated with drug therapy may provide insight into the basic biology of the mycobacterial cell wall. Similarly, the rapid changes in cough strength and frequency may suggest mechanisms in the pathophysiology of cough. Verifying the correlation between quantitative aerosol cultures and infectiousness using animal models may validate the use of the cough aerosol sampling system at the bedside. Data obtained from patients with tuberculosis may in turn validate the use of animal models of infection. This approach may open a new field of investigation of the host determinants of infectiousness, which could be extended to other respiratory infectious agents in the future. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HOST RESPONSE TO TB AND AIDS Principal Investigator & Institution: Rom, William N. Chief, Pulmonary and Critical Care Divis; Medicine; New York University School of Medicine 550 1St Ave New York, NY 10016 Timing: Fiscal Year 2001; Project Start 30-SEP-1997; Project End 31-AUG-2002 Summary: The recent tuberculosis (TB) epidemic in the United States has been fueled by several factors, including underfunded public health programs, overcrowding in urban homeless shelters and prisons, continuing immigration to the United States from countries with a high incidence of TB, and the HIV epidemic. The increased susceptibility to tuberculosis infection and disease among HIV-infected patients is directly related to impaired host immunity. In recent years, key components of the host
62 Tuberculosis
response to tuberculosis have been elucidated, and it now seems increasingly clear that a Th1-type T-lymphocyte response is associated with a good outcome in TB patients. In addition, there is increasing evidence that HIV-infected patients have impaired TH1 number and function, with a resultant deficiency of interferon-gamma (IFN-g), a key effector cytokine in host immunity in tuberculosis. This project proposes to study the role of T-helper cells in human tuberculosis, with a specific focus on the role of IFN-g in the pathogenesis of tuberculosis in patients with and without HIV infection. This project will study the role of Th1 cells in general and IFN-g in particular both at the clinical level as well as at the basic level so that we might understand both the regulation of gene expression of this cytokine as well as its interaction with other cytokines and inflammatory effector cells in the lung itself, both in HIV positive and negative patients. The specific aims are to: 1) modulate the Th phenotype in BAL cells and HIV-1 replication in active pulmonary tuberculosis by aerosol treatment with interferon-gamma; 2) investigate mechanisms by which IFN-gamma contributes to host defense against tuberculosis in HIV-positive and HIV-negative persons; and 3) analyze mechanisms of gene regulation effected by IFN-gamma treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HOST RESPONSES TO MYCOBACTERIUM INFECTION IN ZEBRAFISH Principal Investigator & Institution: Ramakrishnan, Lalita; Assistant Professor; Microbiology; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): Tuberculosis is the leading cause of death from infectious diseases worldwide, with increasing consequences due to the HIV epidemic. The existing vaccine, BCG, has marginal efficacy. Infection and disease are caused by the intracellular bacterial pathogen Mycobacterium tuberculosis. In the face of a complex immune response, the bacteria can persist indefinitely in granulomas, tight aggregates of highly differentiated macrophages and other immune cells. As with most infectious diseases, the impact of the different aspects of host immunity on tuberculous infection and disease are not well understood. To better understand the host responses to tuberculous infections, we will exploit the fact that Mycobacterium marinum, a close relative of M. tuberculosis is a natural pathogen of zebrafish, causing a tuberculosis-like disease. Zebrafish are genetically tractable vertebrates that are used as models of disease and development. We have exploited the optical transparency of the zebrafish embryo to visualize M. marinum infection of embryonic macrophages in real time. The infection parallels adult tuberculosis in many ways. We will use the zebrafish-M, marinum infection model to study the role of host immune genes in infection. We will use whole mount in situ hybridizations to determine which host immune markers thought to be important in tuberculosis, are expressed in the developing embryo. We will determine if their expression is changed during infection. We will inactivate these genes using morpholino technology and determine by real time visualization when and how they act in infection. We will determine their role for the different facets of infection, from early macrophage migration in response to M. marinum to granuloma formation. The ability to visualize infection in real time in zebrafish embryos with functional inactivation of individual host genes will allow us to study the role of the host immune system in unprecedented detail. The proposed experiments will inherently yield new information about the role of various immune genes in zebrafish development. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 63
•
Project Title: HTS FOR PROTEIN SPLICING INHIBITORS AS TB DRUGS Principal Investigator & Institution: Paulus, Henry; Director; Boston Biotechnology Corporation 64 Grove St Watertown, MA 02472 Timing: Fiscal Year 2003; Project Start 01-MAY-2003; Project End 30-APR-2004 Summary: (provided by applicant): One-third of the world' s population (2 billion people) are infected with Mycobacterium tuberculosis and 5-10% of these suffer active tuberculosis, leading to nearly 3 million deaths annually. An alarmingly growing number of patients in developed country are suffering from multidrug-resistant TB, which is essentially refractory to therapy by existing drugs. The mainline antituberculosis drugs need thus be supplemented by additional drugs against new targets, until those, too, succumb to resistance mechanisms. The aim of the proposed research is to discover drugs that inhibit the post-translational processing of the M. tuberculosis DnaB and RecA proteins by protein splicing. The DnaB and the RecA proteins play essential roles in DNA replication and DNA repair, respectively. Because in virulent strains of M. tuberculosis these proteins are synthesized as inactive precursors that need to be activated by protein splicing, the inteins that interrupt these proteins and promote the protein splicing reaction constitute anti-tuberculosis targets. This application focuses on developing in vitro fluorescent assays for DnaB and RecA protein splicing based on the activation of Green Fluorescent Protein (GFP) from inactive fusions with the DnaB or RecA intein, which can be adapted as a high-throughput screening system for protein splicing inhibitors. Inhibitors found with these screens will be for specificity and antibacterial activity using both in vitro and in vivo assay systems. Preference will be given to inhibitors which inhibit splicing of the DnaB as well as the RecA intein so as to interfere both with DNA replication and DNA repair. Because protein splicing occurs only in unicellular organism and in mycobacteria as the only pathogens, such inhibitors should be highly specific antimycobacterial agents with no effect on other bacteria associated with humans nor on the human host. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: HUMAN AND TUBERCULIN COA BIOSYNTHETIC ENZYME STRUCTURES Principal Investigator & Institution: Izard, Tina; St. Jude Children's Research Hospital Memphis, TN 381052794 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 29-FEB-2008 Summary: (provided by applicant): Coenzyme A (CoA) is the major acyl group carrier for all organisms and is essential for cell survival. In bacteria, the last two reactions of CoA biosynthesis are mediated by the enzymes phosphopantetheine adenylyltransferase (PPAT), which generates dephospho-CoA (dPCoA), and dephospho-CoA kinase (DPCK), which yields CoA. In contrast, in higher eukaryotes a bifunctional enzyme, CoA synthase, catalyzes both of these final reactions. The substrate of PPAT is rate-limiting and the enzyme is feedback regulated by CoA, indicating that PPAT is an excellent target for developing novel antibiotics. We have solved the crystal structures of PPAT from Escherichia coli, which exists as a hexamer, and of PPAT bound to its substrates and to its product dPCoA. These studies identified the residues involved in substrate/product binding and revealed an in-line displacement catalytic mechanism. Finally, our Preliminary Studies of the PPAT:CoA crystal structure revealed an unusual mechanism of feedback inhibition of PPAT by CoA. The structure of the monomeric DPCK enzyme (from Haemophilus influenzae) has recently been solved and suggests an induced-fit reaction mechanism typical of kinases. Collectively, these
64 Tuberculosis
structures form the foundation for the design of PPAT- and DPCK-specific inhibitors, an important issue in the context of treating drug-resistant bacteria, in particular tuberculosis. Like other bacteria, Mycobacterium tuberculosis requires PPAT and DPCK, and although the catalytic mechanisms of tuberculin PPAT and DPCK are likely identical to their homologs in other bacteria, there are significant differences predicted for the structures of these enzymes, especially DPCK. Recombinant M. tuberculosis PPAT and DPCK proteins have been produced and we have crystallized tuberculin PPAT. Experiments in Specific Aims #1 and #2 will determine the native and substratebound crystal structures of M. tuberculosis PPAT and DPCK. In addition, the structures of tuberculin PPAT bound to its product dPCoA, and to its inhibitor CoA will be solved. The design of PPAT- and DPCK-specific inhibitors requires that they not inhibit human CoA synthase. The monomeric nature, predicted structure, and coupled catalytic functions of CoA synthase indicate that regulation of this enzyme is unique, and a novel N-terminal domain may play a regulatory role. Experiments in Aim #3 will determine the native and substrate-bound crystal structures of human CoA synthase. The proposed crystallographic studies are essential for the development of novel inhibitors that selectively target M. tuberculosis PPAT and DPCK. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN TUBERCULOSIS
T
CELL
RESPONES
TO
MYCOBACTERIUM
Principal Investigator & Institution: Lewinsohn, David M. Assistant Professor; Medicine; Oregon Health & Science University Portland, OR 972393098 Timing: Fiscal Year 2001; Project Start 15-SEP-1998; Project End 31-AUG-2003 Summary: Tuberculosis is the leading single cause of infectious disease mortality worldwide. Immunity to tuberculosis depends upon the cellular immune system. Hence, developing an improved vaccine will require characterization of T cell antigens recognized early during the course of infection, and an understanding of the mechanisms by which T cells recognize and respond to Mtb infected cells. Two novel proteins (TbH9 and 38.1) from Mtb that are potent T cells antigens have recently been cloned and expressed in our laboratory. We have found that these proteins elicit vigorous T cell proliferation and interferon-gamma production from healthy PPD positive individuals, and that one of these proteins is preferentially expressed in cells infected with live Mtb. However, little is known about the response to these proteins in persons who have been recently infected or in those with active tuberculosis. Additionally, several lines of evidence, including the susceptibility of mice rendered deficient in beta2 microglobulin to infection with Mtb, have suggested an important role for CD8+ cytotoxic T lymphocytes (CTL) in immunity to tuberculosis. Using peripheral blood derived dendritic cells infected with Mtb, we have isolated human CD8+ CTL clones to Mtb. This is the first demonstration of human Mtb specific CD8+ T lymphocytes, and further characterization of these cells will be an important part of this proposal. This proposal rests upon two major hypotheses: 1) Protective T cell responses to Mtb arise early in the course of infection and are associated with the production of interferon-gamma (IFN-gamma), and 2) MHC class Ia restricted and non restricted CD8+ CTL that recognize Mtb infected cells are generated during the course of infection. The specific aims are: 1) To characterize human Mtb specific T cell responses in diseased and healthy infected individuals. 2) To characterize human CD8+ T cell responses to Mtb. The research methods for achieving these goals include a collaborative project with Seattle-King County Tuberculosis Clinic to study human T cell responses to recombinant Mtb antigens during the evolution of disease. In addition, the relative
Studies 65
contribution of MHC class Ia restricted and non-restricted CD8+ CTL will be evaluated in healthy PPD positive individuals. The mechanisms by which Mtb gain entry into the MHC class Ia will be explored using selective inhibition of antigen processing. The mechanisms of antigen processing and nature of the antigen or MHC class Ia nonrestricted clones will also be evaluated. Finally, mammalian expression vectors for the proteins TbH9 and Ag 85b will be constructed, and used to elicit antigen specific CD8+ CTL. The proposed studies will allow for greater understanding of T cell responses to tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: HUMAN TUBERCULOSIS
T
CELLS
ANTIGENS
OF
MYCOBACTERIUM
Principal Investigator & Institution: Reed, Steven G. Chief Scientific Officer; Infectious Disease Research Institute 1124 Columbia St, Ste 600 Seattle, WA 98104 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: (Adapted from the Applicant's Abstract): This proposal is aimed at identifying and characterizing T cell antigens of M. tuberculosis which may be important vaccine candidates. To identify novel Mtb antigens which may be relevant in protective immunity against tuberculosis we have used a variety of antigen discovery methods which emphasize expression cloning with anti-M. tuberculosis antisera and human T cells. Eight vaccine candidates (Mtb 8.4, Mtb 9.8, Mtb 9.9, Mtb 11, Mtb 19, Mtb 32, Mtb 39, Mtb 40) have so far been selected based on their ability to stimulate PBMC from donors infected with M. tuberculosis. These eight antigen genes will be evaluated as recombinant antigens or as naked DNA, alone or in combination, for immunogenicity and protection against tuberculosis in three animal models including cynomolgus monkeys, mice, and guinea pigs. These models will be used to assess T cell responses as well as protection. In addition, we will emphasize the use of human T cell expression cloning to identify other vaccine candidate antigens. These will be characterized in the in vitro and animal models as above. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOLOGICAL TUBERCULOSIS
BASIS
OF
SUSCEPTIBILITY
TO
Principal Investigator & Institution: Behar, Samuel M. Assistant Professor; Brigham and Women's Hospital 75 Francis Street Boston, MA 02115 Timing: Fiscal Year 2001; Project Start 30-SEP-1999; Project End 31-AUG-2004 Summary: The long term objectives of this project are to understand the immunological and genetic basis for susceptibility to tuberculosis. As the effectiveness of cellular immunity to Mycobacterium tuberculosis determines whether infection evolves into clinical disease, a better understanding of the immune response and the genes that govern it will facilitate a more rational approach to development and use of vaccines, drugs, and biological therapy. An aerosol route of inoculation will be used to infect intact mice that are either inherently resistant or susceptible to tuberculosis. The local immune response in the lung will be compared to the systemic response in the spleen using a variety of techniques including the quantitation of T cell subsets, intracellular cytokines staining, and RNAse protection assays in order to define immunological parameters that indicate a protective immune response. Other investigations will ascertain which genetic loci are critical for disease resistance. With this insight, these techniques will be applied to interventional models to determine how different
66 Tuberculosis
treatment strategies modify the immune response during primary infection (in the case of vaccines and biological treatments) or after subsequent rechallenge (in the case of chemotherapy). Finally, two different models that approximate the cell mediated defects observed in HIV/AIDS will be examined to determine how the immune response is altered to M. tuberculosis infection in the absence of CD4 plus T cells, and whether therapeutic interventions can beneficially augment the innate and adaptive immune responses under these conditions. The specific aims are as follows: Aim 1. Characterize the immunological differences between mouse strains that are either resistant or susceptible to infection with Mycobacterium tuberculosis after aerosol inoculation. Aim 2. Determine the genetic derangements that correlate with susceptibility and resistance. Aim 3. Identify how the immune response to tuberculosis changes as a consequence of therapeutic interventions in an animal model. Aim 4. Characterize the immune response to tuberculosis in mouse models that simulate the abnormalities of cell mediated immunity typical of HIV/AIDS patients. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOLOGICAL DIAGNOSIS OF TUBERCULOSIS Principal Investigator & Institution: Gennaro, Maria L. Associate Member; Public Health Research Institute 225 Warren St Newark, NJ 07103 Timing: Fiscal Year 2001; Project Start 30-SEP-1994; Project End 31-MAR-2003 Summary: (Adapted from the applicant's abstract): The increasing worldwide incidence of tuberculosis, which is the leading cause of death from a single infectious disease, and its frequent association with HIV-1 infection have rendered current laboratory diagnostic methods inadequate. Microscopic examination of sputum has low sensitivity, and culture techniques are too slow. DNA sequence amplification by PCR is sufficiently sensitive only in patients with multibacillary pulmonary TB. New diagnostic methods are urgently needed. The PI believes that serology presents an attractive approach. Serodiagnostic tests are simple, rapid, inexpensive and do not require the presence of mycobacteria in the clinical specimens. The present lack of a highly accurate immunoassay for TV is primary due to insufficient knowledge of the humoral immune response to TV and to a limited availability of purified mycobacterial antigens. During the current funding period, the PI developed a panel of eleven recombinant, highly purified antigens of M. tuberculosis and found a remarkable patient-to-patient variation in antigen recognition. The PI has also developed a strategy for multi-antigen-based serodiagnosis of TB. Antigens will be selected for a multi-antigen cocktail for diagnosis of active TB in the general population by identifying antigens that are highly seroactive and that are recognized by sera from patients with paucibacillary and multibacillary pulmonary TB. To minimize false positive results due to immune responses that are not associated with active TB, antigens for the cocktail will be chosen from those that are preferentially recognized by active TB patients rather than asymptomatic tuberculin reactors, BCG vaccines, and individuals with inactive TB. Cocktail development will be pursued by assessing the behavior of selected antigens when combined in solid phase. Peptides displaying immunodominant, M. tuberculosis complex-specific B cell epitopes on highly seroreactive proteins will be utilized to minimize antigen interference or loss of assay specificity that may be observed when antigens are combined. Special emphasis will be placed on development of diagnostic assays for TV in children and in HIV-1infected individuals. Because of the rapid progression from infection to active TB in children, antigens recognized by serum antibodies in pediatric TB may not be the same as those recognized by the adult populations. The PI will select antigens recognized by sera from children with TB to develop serodiagnostic assays specific for pediatric TB.
Studies 67
Another high risk group for rapid disease progression and high TB-associated mortality is the HIV-1-infected population. The PI's studies indicate that, although the overall antibody response is decreased in HIV+ TB, recognition os certain antigens of M. tuberculosis is unaltered in the presence of concomitant HIV-infection. Based on these findings, the PI proposed to develop serodiagnostic assays that meet the special needs of this population. The PI also anticipates that they will be able to identify early serological markers of TB infection in household contacts of patients with active TB. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IMMUNOSUPPRESSION IN MYCOBACTERIAL DISEASES Principal Investigator & Institution: Toossi, Zahra J. Associate Professor; Medicine; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106 Timing: Fiscal Year 2001; Project Start 01-JAN-1982; Project End 31-JUL-2002 Summary: The investigators' observations to date indicate a central immunomodulatory role for transforming growth factor beta (TGF-beta), a potent immunosuppressive molecule, in human tuberculosis. The sustained support of research at CWRU has delineated mechanisms that may explain the failure of expression of protective immunity during active tuberculosis, and the paradox of skin test anergy in a disease caused by an organism with adjuvant-like properties. M. tuberculosis, its PPD, and its cell wall antigens induce monocytes to production of TGF-beta. TGF-beta is present in tuberculous granulomas and is produced by mononuclear phagocytes of patients with tuberculosis. TGF-beta affects several events in T-cell activation, inhibits the cytokines important in development of a TH 1-like response (IFN-gamma, IL-12), and directly suppresses the TH 1 cytokines (IL-2, IFN-gamma). Further, TGF-beta may promote the expression, or synergize with other suppressive mediators (IL-10), thus amplifying immunosuppressive circuits in situ. A natural inhibitor of TGF-beta, decorin, binds and inactivates TGF-beta and may be clinically useful in diseases such as tuberculosis that are associated with excess TGF-beta activity. Previous observations and the preliminary data support the following hypothesis; the polysaccharide and protein antigens of virulent M. tuberculosis bias the cytokine profile of mononuclear phagocytes towards excess TGF-beta activity. The immunopathogenesis of active tuberculosis involves altered regulation of T-cell activation by TGF-beta which may lead to growth arrest and/or apoptosis of T-cells and an attenuated TH1 response. Down modulation of TGFbeta activity, for example, using the natural inhibitor decorin is expected to enhance such a TH1 response, and, therefore, may be useful as an adjunct to chemotherapy. Specific Aims are: 1. To examine the role of interaction of intact M. tuberculosis through its 30 kD antigen and ManLAM, with fibronectin and mannose receptors on monocytes in expression and activation of TGF-beta. 2. To examine the modulation by TGF-beta of early events in T-cell activation, the growth arrest and/or apoptosis of T-cells stimulated by M. tuberculosis and its products; and the role of TGF-beta in initiating immunosuppressive circuits involving IL-10. 3. To characterize the T-cell dysfunction of patients with active pulmonary tuberculosis, its relationship to TGF-beta and other suppressive cytokines (IL-10) and its reversal by inhibitors of TGF- beta. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: IMPACT OF TUBERCULOSIS OF HIV INFECTION IN UGANDA Principal Investigator & Institution: Whalen, Christopher C. Associate Professor; Epidemiology and Biostatistics; Case Western Reserve University 10900 Euclid Ave Cleveland, OH 44106
68 Tuberculosis
Timing: Fiscal Year 2001; Project Start 01-JUL-1992; Project End 31-AUG-2004 Summary: (Adapted from Investigator=s Abstract) The World Health Organization estimates that 10 million HIV-infected individuals will die of tuberculosis (TB) during the decade of the 1990's. Although HIV-infected patients with TB respond to effective antituberculous therapy, their prognosis remains poor. Early deaths are often attributable to TB, but later deaths result from complications of HIV infection other than tuberculosis. Recent epidemiologic observations indicate that TB reduces survival and increases the rate of opportunistic infections in HIV-infected patients. Mounting evidence from immunologic and virologic studies supports the concept of copathogenesis in which immune activation triggered by tuberculosis, and mediated by cytokines such as tumor necrosis factor-alpha (TNFa), stimulates viral replication, increases viral load, and accelerates HIV infection. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INDUCTION OF TH1 IMMUNITY IN TUBERCULOSIS Principal Investigator & Institution: Salgame, Padmini; Associate Professor; Microbiology and Immunology; Temple University 406 Usb, 083-45 Philadelphia, PA 19122 Timing: Fiscal Year 2003; Project Start 01-FEB-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Prevention of infectious diseases through vaccination remains a priority goal for scientists and public health officials. The high risk of developing multidrug-resistant Mycobacterium tuberculosis is a serious limitation to drug therapy, and consequently development of efficacious vaccines is critical for the successful eradication of tuberculosis. Vaccination against tuberculosis would rely on the immune system's ability to generate an appropriate protective response that can then be successfully garnered when the host is challenged with M. tuberculosis. Although we know that Th1 immunity is critical for protection against tuberculosis, yet the cells and mechanisms that are involved in generating a protective Th1 immunity are far from completely understood. In this proposal we combine two complementary approaches, a hypothesis-driven and low-through put approach and a global microarray analysis to ask mechanistic questions regarding how protective Th1 immunity to M. tuberculosis is generated. Therefore the central goal of this proposal is to examine the mechanism for the distinct cytokine response from dendritic cells and macrophages following M. tuberculois infection, and study its impact on the development of M. tuberculosis-reactive CD4 + Th1 cells in vivo: from naive to effector. Overall we expect to obtain from these studies an integrated appreciation of the dynamics of induction of Th1 immunity in tuberculosis. Successful completion of these studies will provide innovative strategies for vaccine development and also provide new modalities of modulating the immune response to shorten chemotherapy and/or overcome drug resistance. The specific aims that will address the goals of the proposal are: Aim 1. Corroborate the theory that signaling from TLRs is sufficient for IL-12 production from dendritic cells, and that macrophages require an additional signal to synergize with TLR signaling for IL-12 production. Aim 2. Examine the molecular basis for differential IL-12 regulation in M.tuberculosis stimulated dendritic cells and macrophages. Aim 3. Test the hypothesis that dendritic cells are critical for Th1 cell priming, and that macrophages are elemental for initiating the granulomatous response. Aim 4. Compare the reprogramming of the dendritic cell and macrophage transcriptome in response to M.tuberculosis alone and in response to M.tuberculosis and interferongamma. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 69
•
Project Title: INHIBITION TUBERCULOSIS
OF
MACROPHAGE
INNATE
IMMUNITY
IN
Principal Investigator & Institution: Kusner, David J. Associate Professor; Internal Medicine; University of Iowa Iowa City, IA 52242 Timing: Fiscal Year 2003; Project Start 15-AUG-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Tuberculosis (TB) is one of the world's greatest health problems, causing approximately 3 million deaths per year. Despite continuing increases in global morbidity and mortality, therapeutic and preventative options for TB remain severely limited. The central feature of TB pathogenesis is infection and intracellular survival of Mycobacterium tuberculosis (Mtb) within human macrophages. Following phagocytosis, Mtb evades the normally potent antimicrobial defenses of innate immunity by inhibiting the maturation of its phagosome to a microbicidal phagolysosome. The molecular mechanisms by which Mtb blocks phagosomal maturation and survives intracellularly are incompletely understood. The long-term goal of this project is to define the molecular mechanisms of tuberculous pathogenesis, to provide a foundation for improved therapies and vaccines. Recently, we demonstrated that live, virulent Mtb, but not killed Mtb, inhibit macrophage Ca2+signaling, and that this defect in host activation directly contributes to inhibition of phagosomal maturation and promotion of the bacilli's intracellular survival. Important gaps in our knowledge include: (1) the mycobacterial determinants responsible for inhibition of macrophage Ca2+-signaling, and (2) the macrophage targets of Mtbinduced inhibition during this critical phase of the host-pathogen interaction. The hypotheses are: (a) sphingosine kinase (SK) is a critical target of macrophage deactivation by live Mtb, and (b) inhibition of SK is causally related to defective Ca2+signaling, inhibition of phagosome maturation, and the survival of Mtb within human macrophages. We will investigate these hypotheses by pursuing the following Specific Aims: (1) Characterize the activation of macrophage SK during phagocytosis of killed Mtb and its role in Ca2+-signal transduction and phagosome maturation. (2) Determine whether inhibition of SK-mediatedCa2+-signaling by live Mtb is causally related to defective phagosome maturation and intracellular viability. In Aims 1 and 2, pharmacological, biochemical, and genetic approaches will be used to modulate specific signaling pathways. (3) Determine the component(s) of Mtb responsible for inhibition of macrophage SK- and Ca2+-mediated activation. A genetic approach of screening a transposon mutant library of Mtb and a biochemical approach of direct assessment of subcellular fractions of Mtb for effects on macrophage SK-andCa2+-mediated signal transduction will be undertaken. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITION M.TUBERCULOSIS
OF
MYOCOLIC
ACID
BIOSYNTHESIS--
Principal Investigator & Institution: Jacobs, William R. Investigator; Microbiology and Immunology; Yeshiva University 500 W 185Th St New York, NY 10033 Timing: Fiscal Year 2001; Project Start 01-JUL-1998; Project End 30-APR-2003 Summary: Tuberculosis and disseminated Mycobacterium avium cause significant morbidity and death in individuals with Human Immunodeficiency Virus (HIV) infection. Globally, tuberculosis is a leading cause of death for patients infected with HIV. The emergence of M. tuberculosis strains resistant to two or more anti-tuberculosis drugs have compromised control strategies. M. avium Complex (MAC) causes disseminated infection and increased mortality in up to 40 percent of patients with
70 Tuberculosis
AIDS. There is an urgent need to develop new, potent anti-mycobacterial drugs. Mycolic acids are integral and unique parts of the mycobacterial cell wall and the biosynthetic enzymes represent attractive targets for the development of novel drugs. Towards that goal, we are using a multi-disciplinary approach employing mycobacterial genetics, biochemistry, x-ray crystallography, molecular biology, organic chemistry and animal models to develop novel inhibitors. We have discovered a gene, named inhA, which was found to be a primary target to isoniazid (INH) and ethionamide (ETH). Point mutations within the structural gene, or overexpression of inhA confers INH- and ETHresistance in mycobacteria. Biochemical studies reveled that inhA encodes an NADHspecific enoyl-acyl carrier protein (ACP) reductase which prefers long chain fatty acids as substrates, consistent with its role in mycolic acid biosynthesis. The three dimensional structure of resistant and sensitive forms of InhA were determined. We demonstrated that INH is a pro-drug which, upon activation by a catalase-peroxidase forms a covalent adduct to NADH bound on the InhA enzyme. Armed with the knowledge of InhA structure and function, we have generated a series of long-chain fatty acid analog inhibitors that contain a triple bond between C2 and C3: the 2-alkynoic acids (KOAs). The KOAs inhibit the InhA enzyme and have activity against MAC, and against both INH- susceptible and INH-resistant M. tuberculosis. Furthermore, we have screened a combinatorial library of compounds against the InhA enzyme and identified two new classes of compounds with activity against InhA that inhibit M. tuberculosis and MAC growth. In this proposal, we intend to expand upon these successes and continue to elucidate the key targets of mycolic acid biosynthesis with the aim of developing novel drugs against M. tuberculosis and M. avium. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITION OF TUBERCULAR MYCOTHIOL PATHWAYS Principal Investigator & Institution: Knapp, Spencer A. Chemistry and Chemical Biology; Rutgers the St Univ of Nj New Brunswick Asb Iii New Brunswick, NJ 08901 Timing: Fiscal Year 2003; Project Start 15-APR-2003; Project End 31-MAR-2005 Summary: (provided by applicant): Drug-resistant tuberculosis now threatens a large portion of the earth's population, and the development of new treatments for tuberculosis infection has become a national and international priority. Mycobacterium tuberculosis depends on a low molecular weight thiol, "mycothiol," to maintain a reducing intracellular environment and to remove exogenous electrophilic agents. Disruption of the enzymatic pathways of mycothiol biosynthesis and/or mycothiolbased detoxification could leave M. tuberculosis vulnerable to drugs, oxygen, and other stress factors, and constitutes a new tactic for the control of tuberculosis. The objective of this project is to develop inhibitors of the mycothiol-related enzymes of M. tuberculosis, and eventually to design new and successful treatments for tuberculosis. Three enzymes will be targeted initially: mycothione reductase, mycothiol S-conjugate amidase, and inosityl GIcNAc deacetylase, although others, including a cysteine ligase and a cysteine transacetylase, could be added. This work will be guided by enzymatic assays conducted by collaborators using existing screens, and by preliminary results that already indicate that substantial structural simplification in designing mycothiol analogues is possible. First, the minimum substrate requirements for the M. tuberculosis enzymes will be defined. Then, inhibitors based on these minimum structures will be synthesized and evaluated. New methods for the synthesis of mycothiol-analogous compounds will be developed, and new ideas for enzyme inhibitor design will be explored. The most active compounds will be taken as leads for
Studies 71
further analogue development and for increasing the bioavailability, and metabolic stability in M. tuberculosis itself.
potency,
specificity,
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INHIBITORS OF SULFATE ASSIMILATION AS NEW THERAPY FOR TB Principal Investigator & Institution: Hemmerich, Stefan; Thios Biotechnology, Inc. 747 52Nd St Oakland, CA 94609 Timing: Fiscal Year 2003; Project Start 15-MAY-2003; Project End 14-NOV-2003 Summary: (provided by applicant): Mycobacterium tuberculosis (M. tuberculosis) is a major pathogen of global importance. Despite the availability of chemotherapy and the Bacille Calmette-Guerin vaccine, M. tuberculosis continues to claim more lives than any other single infectious agent. Recent years have seen increased incidence of tuberculosis in both developing and industrialized countries, the widespread emergence of drugresistant strains and a deadly synergy with the human immunodeficiency virus. The limitation of current therapy originates from the widespread occurrence of antibiotic resistant strains and also the requirement for prolonged and uninterrupted administration of antibiotics. Thus, new classes of antibiotics are desperately needed. Sulfur-containing metabolites, including the essential amino acids cysteine and methionine, and the virulence factors mycothiol and sulfolipid-1, are crucial for the infectivity of M. tuberculosis. Their biosynthesis involves the sulfate assimilation pathway, which has no counterpart in humans. Since the enzymes in this pathway comprise a central hub of metabolism and are unique to bacteria, we propose that these enzymes are prime targets for anti-mycobacterial therapy. This proposal focuses on 5'adenosinephosphosulfate (APS) reductase (CysH) as a target for small molecule drug development. In preliminary work, we have 1) confirmed the APS reductase activity of M. tuberculosis CysH using genetic complementation in E. coli, and 2) demonstrated that genetic deletion of CysH from a pathogenic strain of M. tuberculosis renders the mutant unable to establish infection in a mouse model of tuberculosis. In specific aim 1 of this proposal we shall screen a compound library for inhibitors of M. tuberculosis sulfate assimilation using an E. coli complementation assay. In specific aim 2 we shall set up cell-free homogenous assays for recombinant M. tuberculosis CysH, examine our leads from the primary screen for their ability to directly inhibit this enzyme, and optimize these leads through medicinal chemistry. In specific aim 3 the best compounds will be examined using in vitro susceptibility studies of clinical isolates of M. tuberculosis. In phase II of this study, the inhibitor leads from our feasibility study will be examined for bacteriostatic and bacteriocidic efficacy in mouse models of tuberculosis. The long-term objective of this study is to develop novel antibiotics for more effective treatment of human tuberculosis and other mycobacterial diseases. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: INNOVATIVE APPROACHES FOR TUBERCULOSIS CONTROL IN BRAZIL Principal Investigator & Institution: Lapa E Silva, Jose R.; Federal University of Rio De Janeiro Cidade Universitaria Rio De Janeiro, Timing: Fiscal Year 2002; Project Start 22-SEP-2002; Project End 21-SEP-2003 Summary: (provided by applicant): Tuberculosis is still an important cause of human suffering and economic loss in Brazil and beyond. A concerted effort to address all the questions related to TB control is needed, involving Universities and Health
72 Tuberculosis
Departments. The Millenium TB Network was organized in 2001 with the goal to generate new knowledge about the disease; to train highly qualified professionals with a critical view of the problem and to transfer the new information to the health system. For many years, leading American academic institutions working in Brazil recognized the importance of this initiative. The major goal of this proposal is to develop a competitive application for a Comprehensive ICOHRTA-AIDS/TB Cooperative Agreement linking Federal University of Rio de Janeiro and other collaborating sites in Brazil and Johns Hopkins University, Cornell University and UC Berkeley as collaborating sites in the U.S. The specific aims are 1) To establish a multilateral collaborative training program in tuberculosis control with investigators and physicians from Brazil and Johns Hopkins, Cornell, and Berkeley Universities.2) To establish a network system between the different institutions and individuals participating in the program in Brazil and USA in order to promote frequent consultation between the partners to define the type of didactic and laboratory training in health sciences pertinent to tuberculosis control. 3) To identify the needs in infra-structure, human rights protection, administration necessary to the establishment of a long-term term collaborative program on TB and AIDS/TB research. The major task of this new consortium will be to identify possible interactions between these partners, in order to guarantee efficiency in the actions. The goal will be to link separate projects, funded by several sources, into one multicenter and organized research and training program to address the TB problem at the national and, in the future, continental levels. During the planning year, projects that share similar objectives will be linked, needs at the collaborating sites, identified, and a common training and research agenda in TB will be developed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTERNET CONNECTION FOR 5 TUBERCULOSIS INSTITUTIONS Principal Investigator & Institution: Miller, Paula F. Assistant Regional Director; Project Hope 255 Carter Hall Ln Millwood, VA 22646 Timing: Fiscal Year 2002; Project Start 15-JAN-2002; Project End 31-AUG-2003 Summary: (provided by applicant): The goal of the Five Country Internet Access Project is to provide TB specialists, medical faculty, and medical students in the Central Asia Republics (CAR) - Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan with access to up-to-date medical information and resources, particularly those relating to Tuberculosis diagnosis and treatment that are readily available on the Internet. The specific objects of the projects are to: 1) Purchase equipment and service for connectivity for 6 library/learning centers; 2) Train 25 project personnel and 4500 users for the Internet; 3) Provide extended Internet access to over 10,000 medical professionals; 4) Establish a Tuberculosis materials database in each country through downloading, cataloging and initiating distribution of lists of materials available from library/learning centers in each country via e-mail; (5) Provide an Internet search center for materials on Tuberculosis for TB specialists, primary health care professionals, nurses and others located in 30 remote e-mail- connected TB pilot sites of countries of the CAR through submission of requests to the central library/learning center. The World Health Organization has identified the lack of training and updated knowledge of TB among Primary Health Care staff as one of several constraints hampering TB control in the Central Asia Republics. This Internet Access Project will build upon current TB diagnosis and treatment efforts currently being implemented by Project HOPE, the requesting organization, and strengthen capacity by improving exchange of information. The project will be initiated at the request and collaboration of the host
Studies 73
countries and is consistent with Project HOPE's vision and programming in the region. The projected plan for getting Internet access for the five TB institutes will begin with a consultant Internet specialist working with local Internet specialists and providing training of trainers specific to e-mail, the tuberculosis websites and provide the teaching methodologies to be Used in training at the TB institute sites. The consultant will assist with the preparation of an Internet Procedure Manual that outlines the use of Internet in a step-by-step format. Following the Training of Trainers (TOT), a two-page pamphlet in the local language will be written and printed by the local Internet specialist and may be given to each professional coming to the library/learning center to orient them how to use the Internet. The libraries/learning centers will be assisted by the Project HOPE office staff in each country to organize the connection of the phone line and modems and provide the training schedule for the staff. The local Internet specialist will go to each country to train the staff in the library learning center using the local language. Additionally, each site will be provided 750 pamphlets outlining procedure to use with medical staff requesting access to the Internet. Each library/learning center will keep a database of medical personnel accessing the Internet and report these statistics to the local HOPE office quarterly. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: INTRACELLULAR MACROPHAGES
INFECTION
OF
HUMAN
ALVEOLAR
Principal Investigator & Institution: Park, David R. Medicine; University of Washington Seattle, WA 98195 Timing: Fiscal Year 2001; Project Start 20-JUL-1997; Project End 30-JUN-2003 Summary: (Adapted from applicant's abstract) Legionella pneumophila and Mycobacterium tuberculosis, the etiologic agents of Legionnaires' disease and tuberculosis respectively, are facultative intra-cellular pathogens which parasitize human alveolar macrophages and blood monocytes recruited to the site of lung infection. An effective host response to these infections depends on cell-mediated immunity, and cytokine networks modulate this response. The overall hypothesis driving this proposal is that L. pneumophia and M. tuberculosis subvert the human alveolar macrophage cytokine response to facilitate their own survival by inducing permissive host cytokines which disarm the protective antimicrobial mechanisms of the phagocyte. The specific aims are: 1) to define the role of cytokine activation of human alveolar macrophages in determining the tolerance or elimination of intracellular infection by L. pneumophila and M. tuberculosis; 2) to determine whether apoptosis of infected alveolar macrophages diminishes the viability of intra-cellular L. pneumophila and M. tuberculosis; 3) to develop and use a virulent L. pneumophila strain transduced with the A victoria green fluorescent protein gene to co-localize intracellular bacteria and specific components of the human alveolar macrophage host response in infected cells. The experimental approach to the specific aims will use an established in vitro model in which human alveolar macrophages are infected with L. pneumophila or M. tuberculosis. Effects of cytokines on intracellular growth will be measured using selected combinations of recombinant cytokines and blocking antibodies. Specific interactions signaling cytokine induction by live bacteria and cell wall glycolipids will be assessed by blocking complement receptors, CD14, and LBP. Macrophage apoptosis will be assessed by cellular morphology, Annexin V binding, and by DNA fragmentation assays, and associated changes in bacterial viability will be quantitated. Individual cell response by infected cells will be assessed by flow cytometry and fluorescent microscopy co-localization of green fluorescent protein expressing bacterial
74 Tuberculosis
strains with selected markers of host defense. These studies will provide important insights into the human host responses to L. pneumophila and M. tuberculosis infections. A thorough understanding of these responses will be necessary for the development of rational immunotherapeutic approaches to the treatment of Legionnaires' disease and tuberculosis, which will be increasingly important for the treatment of immunocompromised patients and infections with drug-resistant strains. (End of Abstract) Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: IRON TUBERCULOSIS
REGULATION
&
VIRULENCE--MYCOBACTERIUM
Principal Investigator & Institution: Manabe, Yukari C. Medicine; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-AUG-1999; Project End 31-JUL-2004 Summary: The candidate is completing a three year infectious disease fellowship and has devoted the last 2 years to basic science research in tuberculosis. In particular, the candidate is interested in studying gene regulation in tuberculosis to elucidate virulence genes and protein antigens which may make important drug and vaccine targets. Through the research conducted under this grant, the candidate would like to establish herself as a junior faculty member at an academic medical institution and continue to pursue tuberculosis disease pathogenesis using molecular biologic techniques. In collaboration with Dr. John Murphy, a leader in iron-dependent regulons in diphtheria, and Dr. Richard Silver, who has developed a reproducible macrophage model of tuberculosis infection, the candidate will have the collaborative resources necessary for the successful completion of this project. The sponsor, Dr. William Bishai, has wellestablished expertise in mycobacterial gene regulation and tuberculosis disease pathogenesis. To complement her research, the candidate will attend approximately 3 hours per week of infectious disease and TB-related conferences. She also plans to take courses in molecular biology, tuberculosis, vaccine development, and immunology in the School of Medicine and the School of Public Health and Hygiene. Fueled by antibiotic resistance and HIV infection, the global burden of tuberculosis infection is staggering. The elucidation of virulence mechanisms and protein antigens for new antimicrobials and vaccines has moved to the forefront. Iron is an essential nutrient for the survival of most organisms and has played a central role in the virulence of multiple important infectious disease pathogens. Using the corynebacterial, iron- dependent DtxR regulon as a model, the candidate will study the mycobacterial homologue, ideR and its regulon. Preliminary results have shown that an iron-independent, corynebacterial DtxR mutant hyperrepressor attenuates Mycobacterium tuberculosis virulence in a murine model. A similar mutant of the mycobacterial ideR has been constructed and will be tested in vitro using a gel-shift assay, and in vivo in a murine and macrophage models. Taking advantage of the DtxR/IdeR "iron box", a palindromic DNA binding sequence present in all DtxR-regulated genes, other genes of interest have been identified in silico and will be examined. Elucidation of this iron-dependent IdeR regulon may lead to the identification of virulence determinants, and novel antigens for vaccines and therapeutics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies 75
•
Project Title: RESISTANCE
KATG
PEROXIDASE
IN
ISONIAZID
ACTIVATION
AND
Principal Investigator & Institution: Owen, Whyte G.; Mayo Clinic Rochester 200 1St St Sw Rochester, MN 55905 Timing: Fiscal Year 2002; Project Start 01-MAY-2002; Project End 30-APR-2006 Summary: (Adapted from the Applicant's Abstract): Tuberculosis is one of the leading causes of death worldwide from an infectious disease. Isoniazid is a front line antibiotic used in the treatment of tuberculosis. The Mycobacterium tuberculosis heme catalase/peroxidase KatG is responsible for activating isoniazid to a reactive biocidal species. Antibiotic resistance to isoniazid is a growing concern and can occur by deletions or point mutations in the katG gene. One of these, a serine-to-threonine substitution at position 315, KatG(S315T) is found in about 50 percent of clinical isolates resistant to isoniazid. Our research seeks to understand the mechanism of isoniazid activation and molecular basis for drug resistance caused by the S315T and other point mutations in KatG using biochemical, genetic, and spectroscopic techniques. KatG will be purified from recombinant and native sources and the activities and spectroscopic properties compared. Besides a catalase/peroxidase activity, KatG can also catalyze several other reactions including Mn2+ peroxidase, P450-like oxygenase, and peroxynitritase activities. Which of these or possibly other redox reactions are responsible for isoniazid oxidation and activation will be tested using wild-type and mutant KatG proteins to investigate the mechanism of activation. Genetic methods investigating the role of superoxide in isoniazid activation are proposed. Optical, EPR, NMR, and resonance Raman spectroscopies are revealing subtle differences in the heme active site of wild-type KatG and KatG(S315T). These spectroscopic techniques will be applied to various forms of wild-type and mutant enzymes in order to elucidate the molecular basis for reactivity toward isoniazid and the reduced rate of isoniazid oxidation by KatG(S315T). NMR relaxation measurements and x-ray crystallography will be used to map the isoniazid binding site on both enzymes to determine whether subtle differences in distance and/or orientation are responsible for the reduced turnover of drug by the mutant enzyme. Steady-state and rapid kinetic techniques will follow ligand-binding rates to the heme iron and the formation and decay of reactive intermediates in the catalytic cycle for both wild-type KatG and KatG(S3 1ST) to determine whether the S3 1ST mutation affects one of the steps in the catalytic cycle. EPR spectroscopy and spin-traps are being used to trap reactive intermediates. The stable products formed in this reaction are being characterized by mass spectrometry to reveal chemical information about the nature of intermediates in the reaction of isoniazid oxidation by KatG. Site directed mutagenesis of residues also implicated in isoniazid resistance other than S3 15 will be generated and the effects on enzyme activities and spectroscopic properties examined to determine structural information about the mutant enzymes. Analogs of isoniazid will be used as additional biochemical and spectroscopic probes of the reaction mechanism and molecular basis for drug resistance. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: LOSS OF OXYR IN M TUBERCULOSIS Principal Investigator & Institution: Deretic, Vojo P. Professor; Molecular Genetics & Microbiol; University of New Mexico Albuquerque Controller's Office Albuquerque, NM 87131 Timing: Fiscal Year 2001; Project Start 01-APR-1998; Project End 31-MAR-2003
76 Tuberculosis
Summary: (Adapted from the applicant's abstract): M. tuberculosis is a natural mutant in the putative central regulator of oxidative stress response, oxyR. All M. tuberculosis strains investigated to date have nearly identical lesions in oxyR, and the elimination of oxyR function may have coincided with or directly participated in the evolution of M. tuberculosis into the potent contemporary human pathogen. The loss of oxyR has a dual significance for M. tuberculosis pathogenesis and treatment of tuberculosis. First, this surprising phenomenon reflects the complexity of host-parasite interactions and its continuing analyses are expected to reveal strategies used by M. tuberculosis for survival in the host. Second, the loss of oxyR and the associated dysfunction of oxidative stress responses most likely contribute to the exceptional sensitivity of M. tuberculosis to isonicotinic acid hydrazide (INH). The goals of this proposal are: (i) to delineate the effects of the loss of oxyR on M. tuberculosis response to reactive oxygen and nitrogen intermediates. This will be accomplished by identifying genes and functions affected by the loss of oxyR, analyzing alternative modes of their regulation, and characterizing M. tuberculosis response to reactive oxygen and nitrogen; (ii) to determine whether and how oxyR inactivation and the resulting dysfunction of oxidative stress responses contribute to the exceptional sensitivity of M. tuberculosis to INH. This will be examined by complementation of the defect in M. tuberculosis using a functional mycobacterial oxyR, by inactivation of oxyR in model mycobacteria, and by determination of the effects that such modifications have on INH sensitivity in vitro and in vivo; (iii) to investigate the role of the loss of oxyR in M. tuberculosis virulence and pathogenesis using mouse bone marrow derived macrophages and human monocytes, and models of tuberculosis in mice and guinea pigs. In addition to conventional analyses of M. tuberculosis survival and histopathology, GFP-based technologies developed in the PI's laboratory will be employed to monitor mycobacterial localization, and potential tissue- and infection stage-specific expression of oxidative stress response genes (e.g. ahpC). These experiments will delineate the effects that the loss of oxyR has on host-pathogen interactions in tuberculosis. The proposed studies are expected to improve understanding of the elusive virulence attributes of M. tuberculosis, and may help explain, at least in part, its high sensitivity to the front-line antituberculosis agent INH. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: M TB SURVIVAL REGULATORY GENES Principal Investigator & Institution: Bishai, William R. Associate Professor; Molecular Microbiol and Immun; Johns Hopkins University 3400 N Charles St Baltimore, MD 21218 Timing: Fiscal Year 2001; Project Start 01-APR-1997; Project End 31-MAR-2003 Summary: (Adapted from the applicant's abstract): This is a revised application in which the PI proposes to analyze an alternate sigma factor of Mycobacterium tuberculosis which may be involved in the intracellular survival of the tubercle bacilli. The PI points out that the ability of M. tuberculosis to adapt to a variety of environmental conditions is an important feature of its pathogenicity. Many bacteria use alternate sigma factors for RNA polymerase to upregulate response genes specific for a needed adaptation. Using degenerate PCR, the PI has identified an alternate sigma factor from M. tuberculosis which he has called SigF. M. tuberculosis SigF is homologous to the SigF and SigB proteins of Bacillus subtilis, which are involved in regulation of sporulation and general stress response gene expression, respectively. Not only does M. tuberculosis SigF have homology with B. subtilis SigF and SigB, but it is preceded by an antisigma and a possible anti-antisigma homologue, just as are the B. subtilis sigma
Studies 77
factors. In vitro (i.e., broth-grown cultures), the expression of the M. tuberculosis SigF is upregulated by stress conditions and entry into stationary phase. In vivo, its expression increases 10-fold upon entry into murine macrophages. Hence, the PI hypothesizes that the M. tuberculosis SigF may govern an intracellular survival regulon. In this application, the PI proposes to determine (i) the in vitro and in vivo phenotypes of an M. tuberculosis sigF mutant, (ii) how SigF is regulated (i.e., is an antisigma partner switching mechanism involved?), and (iii) the identities of SigF-dependent genes. The PI anticipates that understanding how M. tuberculosis adapts for intracellular survival may lead to novel drug and vaccine targets for tuberculosis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: M DESIGN/EVALUATION
TUBERCULOSIS
CTL
EPITOPES:
VACCINE
Principal Investigator & Institution: Clayberger, Carol A. Associate Professor; Cardiovascular Surgery; Stanford University Stanford, CA 94305 Timing: Fiscal Year 2003; Project Start 15-FEB-2003; Project End 31-JAN-2008 Summary: (provided by applicant): Tuberculosis (TB) is the leading cause of death from a single infectious agent (Mycobacterium tuberculosis (Mtb)), causing approximately 3,000,000 deaths each year. Although TB can be effectively treated with a combination of antibiotics, drug resistant Mtb strains have recently emerged which are classified as Category C biological agents. Thus, it is widely felt that the long term control of TB will require the development of a more effective vaccine. Mycobacterium bovis Bacille Calmette-Guerin (BCG), the current anti-TB vaccine, is quite variable in its ability to protect against TB but is effective against tuberculosis meningitis, suggesting that for the foreseeable future, new TB vaccines will be given as an adjuvant or boost to BCG. Thus, understanding the immune response to both Mtb and BCG is critical for the development of an improved vaccine for TB. An increasing body of evidence indicates that both CD4+ and CD8+ T lymphocytes are critical to a protective immune response against Mtb. However, little is known about the antigens targeted by protective immune responses against Mtb in humans. Such information is required for the rational development and clinical evaluation of new, more effective TB vaccines. We propose here to characterize the human CD4+ and CD8+ T cell response to a panel of Mtb antigens in order to identify correlates with protective immunity. Antigens to be tested include proteins as well as peptide epit